#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Structural and functional brain biomarkers of clinical response to rTMS of medication-resistant auditory hallucinations in schizophrenia patients: study protocol for a randomized sham-controlled double-blind clinical trial Background The potential of non-invasive repetitive transcranial magnetic stimulation (rTMS) to improve auditory verbal hallucinations (AVH) in schizophrenia patients has been increasingly explored over the past decade.
1-1	0-10	Structural	_
1-2	11-14	and	_
1-3	15-25	functional	_
1-4	26-31	brain	_
1-5	32-42	biomarkers	_
1-6	43-45	of	_
1-7	46-54	clinical	_
1-8	55-63	response	_
1-9	64-66	to	_
1-10	67-71	rTMS	_
1-11	72-74	of	_
1-12	75-95	medication-resistant	_
1-13	96-104	auditory	_
1-14	105-119	hallucinations	_
1-15	120-122	in	_
1-16	123-136	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-17	137-145	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-18	146-147	:	_
1-19	148-153	study	_
1-20	154-162	protocol	_
1-21	163-166	for	_
1-22	167-168	a	_
1-23	169-179	randomized	_
1-24	180-195	sham-controlled	_
1-25	196-208	double-blind	_
1-26	209-217	clinical	_
1-27	218-223	trial	_
1-28	224-234	Background	_
1-29	235-238	The	_
1-30	239-248	potential	_
1-31	249-251	of	_
1-32	252-264	non-invasive	_
1-33	265-275	repetitive	_
1-34	276-288	transcranial	_
1-35	289-297	magnetic	_
1-36	298-309	stimulation	_
1-37	310-311	(	_
1-38	312-316	rTMS	_
1-39	317-318	)	_
1-40	319-321	to	_
1-41	322-329	improve	_
1-42	330-338	auditory	_
1-43	339-345	verbal	_
1-44	346-360	hallucinations	_
1-45	361-362	(	_
1-46	363-366	AVH	_
1-47	367-368	)	http://maven.renci.org/NeuroBridge/neurobridge#Thing
1-48	369-371	in	_
1-49	372-385	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-50	386-394	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-51	395-398	has	_
1-52	399-403	been	_
1-53	404-416	increasingly	_
1-54	417-425	explored	_
1-55	426-430	over	_
1-56	431-434	the	_
1-57	435-439	past	_
1-58	440-446	decade	_
1-59	447-448	.	_

Text=Despite highly promising results, high inter-individual variability of clinical response and ineffective outcomes in a significant number of patients underscored the need to identify factors associated with the clinical response to rTMS.
2-1	449-456	Despite	_
2-2	457-463	highly	_
2-3	464-473	promising	_
2-4	474-481	results	_
2-5	482-483	,	_
2-6	484-488	high	_
2-7	489-505	inter-individual	_
2-8	506-517	variability	_
2-9	518-520	of	_
2-10	521-529	clinical	_
2-11	530-538	response	_
2-12	539-542	and	_
2-13	543-554	ineffective	_
2-14	555-563	outcomes	_
2-15	564-566	in	_
2-16	567-568	a	_
2-17	569-580	significant	_
2-18	581-587	number	_
2-19	588-590	of	_
2-20	591-599	patients	_
2-21	600-611	underscored	_
2-22	612-615	the	_
2-23	616-620	need	_
2-24	621-623	to	_
2-25	624-632	identify	_
2-26	633-640	factors	_
2-27	641-651	associated	_
2-28	652-656	with	_
2-29	657-660	the	_
2-30	661-669	clinical	_
2-31	670-678	response	_
2-32	679-681	to	_
2-33	682-686	rTMS	_
2-34	687-688	.	_

Text=It should help improve the efficacy of rTMS in patients with medication-resistant AVH, and allow a better understanding of its neural impact.
3-1	689-691	It	_
3-2	692-698	should	_
3-3	699-703	help	_
3-4	704-711	improve	_
3-5	712-715	the	_
3-6	716-724	efficacy	_
3-7	725-727	of	_
3-8	728-732	rTMS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
3-9	733-735	in	_
3-10	736-744	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-11	745-749	with	_
3-12	750-770	medication-resistant	_
3-13	771-774	AVH	http://maven.renci.org/NeuroBridge/neurobridge#Thing
3-14	775-776	,	_
3-15	777-780	and	_
3-16	781-786	allow	_
3-17	787-788	a	_
3-18	789-795	better	_
3-19	796-809	understanding	_
3-20	810-812	of	_
3-21	813-816	its	_
3-22	817-823	neural	_
3-23	824-830	impact	_
3-24	831-832	.	_

Text=Here, we describe an exploratory study protocol which aims to identify structural and functional brain biomarkers associated with clinical response after an rTMS treatment for medication-resistant AVH in schizophrenia.
4-1	833-837	Here	_
4-2	838-839	,	_
4-3	840-842	we	_
4-4	843-851	describe	_
4-5	852-854	an	_
4-6	855-866	exploratory	_
4-7	867-872	study	_
4-8	873-881	protocol	_
4-9	882-887	which	_
4-10	888-892	aims	_
4-11	893-895	to	_
4-12	896-904	identify	_
4-13	905-915	structural	_
4-14	916-919	and	_
4-15	920-930	functional	_
4-16	931-936	brain	_
4-17	937-947	biomarkers	_
4-18	948-958	associated	_
4-19	959-963	with	_
4-20	964-972	clinical	_
4-21	973-981	response	_
4-22	982-987	after	_
4-23	988-990	an	_
4-24	991-995	rTMS	_
4-25	996-1005	treatment	_
4-26	1006-1009	for	_
4-27	1010-1030	medication-resistant	_
4-28	1031-1034	AVH	_
4-29	1035-1037	in	_
4-30	1038-1051	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-31	1052-1053	.	_

Text=Methods Forty-five schizophrenia patients with medication-resistant AVH will be enrolled in a double-blind randomized sham-controlled monocentric clinical trial.
5-1	1054-1061	Methods	_
5-2	1062-1072	Forty-five	_
5-3	1073-1086	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-4	1087-1095	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-5	1096-1100	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-6	1101-1121	medication-resistant	http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus
5-7	1122-1125	AVH	http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus
5-8	1126-1130	will	_
5-9	1131-1133	be	_
5-10	1134-1142	enrolled	_
5-11	1143-1145	in	_
5-12	1146-1147	a	_
5-13	1148-1160	double-blind	_
5-14	1161-1171	randomized	_
5-15	1172-1187	sham-controlled	_
5-16	1188-1199	monocentric	_
5-17	1200-1208	clinical	_
5-18	1209-1214	trial	_
5-19	1215-1216	.	_

Text=Patients will be assigned to a regime of 20 sessions of active or sham 1 Hz rTMS delivered twice a day, 5 days a week for 2 weeks over the left temporo-parietal junction.
6-1	1217-1225	Patients	_
6-2	1226-1230	will	_
6-3	1231-1233	be	_
6-4	1234-1242	assigned	_
6-5	1243-1245	to	_
6-6	1246-1247	a	_
6-7	1248-1254	regime	_
6-8	1255-1257	of	_
6-9	1258-1260	20	_
6-10	1261-1269	sessions	_
6-11	1270-1272	of	_
6-12	1273-1279	active	_
6-13	1280-1282	or	_
6-14	1283-1287	sham	_
6-15	1288-1289	1	_
6-16	1290-1292	Hz	_
6-17	1293-1297	rTMS	_
6-18	1298-1307	delivered	_
6-19	1308-1313	twice	_
6-20	1314-1315	a	_
6-21	1316-1319	day	_
6-22	1320-1321	,	_
6-23	1322-1323	5	_
6-24	1324-1328	days	_
6-25	1329-1330	a	_
6-26	1331-1335	week	_
6-27	1336-1339	for	_
6-28	1340-1341	2	_
6-29	1342-1347	weeks	_
6-30	1348-1352	over	_
6-31	1353-1356	the	_
6-32	1357-1361	left	_
6-33	1362-1378	temporo-parietal	_
6-34	1379-1387	junction	_
6-35	1388-1389	.	_

Text=Response will be assessed after rTMS and patients will be classified in responders or non-responders to treatment.
7-1	1390-1398	Response	_
7-2	1399-1403	will	_
7-3	1404-1406	be	_
7-4	1407-1415	assessed	_
7-5	1416-1421	after	_
7-6	1422-1426	rTMS	_
7-7	1427-1430	and	_
7-8	1431-1439	patients	_
7-9	1440-1444	will	_
7-10	1445-1447	be	_
7-11	1448-1458	classified	_
7-12	1459-1461	in	_
7-13	1462-1472	responders	_
7-14	1473-1475	or	_
7-15	1476-1490	non-responders	_
7-16	1491-1493	to	_
7-17	1494-1503	treatment	_
7-18	1504-1505	.	_

Text=Magnetic resonance imaging (MRI) sessions including diffusion weighted imaging and resting-state functional MRI sequences will be recorded before the onset of the rTMS treatment and 3 days following its discontinuation.
8-1	1506-1514	Magnetic	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
8-2	1515-1524	resonance	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
8-3	1525-1532	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
8-4	1533-1534	(	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
8-5	1535-1538	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
8-6	1539-1540	)	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
8-7	1541-1549	sessions	_
8-8	1550-1559	including	_
8-9	1560-1569	diffusion	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
8-10	1570-1578	weighted	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
8-11	1579-1586	imaging	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
8-12	1587-1590	and	_
8-13	1591-1604	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-14	1605-1615	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-15	1616-1619	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-16	1620-1629	sequences	_
8-17	1630-1634	will	_
8-18	1635-1637	be	_
8-19	1638-1646	recorded	_
8-20	1647-1653	before	_
8-21	1654-1657	the	_
8-22	1658-1663	onset	_
8-23	1664-1666	of	_
8-24	1667-1670	the	_
8-25	1671-1675	rTMS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
8-26	1676-1685	treatment	_
8-27	1686-1689	and	_
8-28	1690-1691	3	_
8-29	1692-1696	days	_
8-30	1697-1706	following	_
8-31	1707-1710	its	_
8-32	1711-1726	discontinuation	_
8-33	1727-1728	.	_

Text=The primary outcome measure is difference in fractional anisotropy between responder and non-responder patients at baseline.
9-1	1729-1732	The	_
9-2	1733-1740	primary	_
9-3	1741-1748	outcome	_
9-4	1749-1756	measure	_
9-5	1757-1759	is	_
9-6	1760-1770	difference	_
9-7	1771-1773	in	_
9-8	1774-1784	fractional	_
9-9	1785-1795	anisotropy	_
9-10	1796-1803	between	_
9-11	1804-1813	responder	_
9-12	1814-1817	and	_
9-13	1818-1831	non-responder	_
9-14	1832-1840	patients	_
9-15	1841-1843	at	_
9-16	1844-1852	baseline	_
9-17	1853-1854	.	_

Text=Differences in resting-state functional MRI data at baseline will be also investigated between responder and non-responder groups.
10-1	1855-1866	Differences	_
10-2	1867-1869	in	_
10-3	1870-1883	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
10-4	1884-1894	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
10-5	1895-1898	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
10-6	1899-1903	data	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
10-7	1904-1906	at	_
10-8	1907-1915	baseline	_
10-9	1916-1920	will	_
10-10	1921-1923	be	_
10-11	1924-1928	also	_
10-12	1929-1941	investigated	_
10-13	1942-1949	between	_
10-14	1950-1959	responder	_
10-15	1960-1963	and	_
10-16	1964-1977	non-responder	_
10-17	1978-1984	groups	_
10-18	1985-1986	.	_

Text=Clinical, neuropsychological, neurophysiological, and blood serum BDNF assessments will be performed at baseline, 3 days, 1 month, and 3 months following rTMS.
11-1	1987-1995	Clinical	_
11-2	1996-1997	,	_
11-3	1998-2016	neuropsychological	_
11-4	2017-2018	,	_
11-5	2019-2037	neurophysiological	_
11-6	2038-2039	,	_
11-7	2040-2043	and	_
11-8	2044-2049	blood	_
11-9	2050-2055	serum	_
11-10	2056-2060	BDNF	_
11-11	2061-2072	assessments	_
11-12	2073-2077	will	_
11-13	2078-2080	be	_
11-14	2081-2090	performed	_
11-15	2091-2093	at	_
11-16	2094-2102	baseline	_
11-17	2103-2104	,	_
11-18	2105-2106	3	_
11-19	2107-2111	days	_
11-20	2112-2113	,	_
11-21	2114-2115	1	_
11-22	2116-2121	month	_
11-23	2122-2123	,	_
11-24	2124-2127	and	_
11-25	2128-2129	3	_
11-26	2130-2136	months	_
11-27	2137-2146	following	_
11-28	2147-2151	rTMS	_
11-29	2152-2153	.	_

Text=Discussion The aim of this research project is to identify and assess the biomarker value of MRI-based structural and functional biomarkers predicting clinical response to rTMS for AVH in schizophrenia patients.
12-1	2154-2164	Discussion	_
12-2	2165-2168	The	_
12-3	2169-2172	aim	_
12-4	2173-2175	of	_
12-5	2176-2180	this	_
12-6	2181-2189	research	_
12-7	2190-2197	project	_
12-8	2198-2200	is	_
12-9	2201-2203	to	_
12-10	2204-2212	identify	_
12-11	2213-2216	and	_
12-12	2217-2223	assess	_
12-13	2224-2227	the	_
12-14	2228-2237	biomarker	_
12-15	2238-2243	value	_
12-16	2244-2246	of	_
12-17	2247-2256	MRI-based	http://maven.renci.org/NeuroBridge/neurobridge#EcologicalStudy
12-18	2257-2267	structural	_
12-19	2268-2271	and	_
12-20	2272-2282	functional	_
12-21	2283-2293	biomarkers	_
12-22	2294-2304	predicting	_
12-23	2305-2313	clinical	_
12-24	2314-2322	response	_
12-25	2323-2325	to	_
12-26	2326-2330	rTMS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
12-27	2331-2334	for	_
12-28	2335-2338	AVH	http://maven.renci.org/NeuroBridge/neurobridge#Thing
12-29	2339-2341	in	_
12-30	2342-2355	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-31	2356-2364	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-32	2365-2366	.	_

Text=The outcome of the trial should improve patient care by offering them a novel suitable therapy and deepen our understanding on how rTMS may impact AVH and develop more effective therapies adapted to individual patient needs.
13-1	2367-2370	The	_
13-2	2371-2378	outcome	_
13-3	2379-2381	of	_
13-4	2382-2385	the	_
13-5	2386-2391	trial	_
13-6	2392-2398	should	_
13-7	2399-2406	improve	_
13-8	2407-2414	patient	_
13-9	2415-2419	care	_
13-10	2420-2422	by	_
13-11	2423-2431	offering	_
13-12	2432-2436	them	_
13-13	2437-2438	a	_
13-14	2439-2444	novel	_
13-15	2445-2453	suitable	_
13-16	2454-2461	therapy	_
13-17	2462-2465	and	_
13-18	2466-2472	deepen	_
13-19	2473-2476	our	_
13-20	2477-2490	understanding	_
13-21	2491-2493	on	_
13-22	2494-2497	how	_
13-23	2498-2502	rTMS	_
13-24	2503-2506	may	_
13-25	2507-2513	impact	_
13-26	2514-2517	AVH	_
13-27	2518-2521	and	_
13-28	2522-2529	develop	_
13-29	2530-2534	more	_
13-30	2535-2544	effective	_
13-31	2545-2554	therapies	_
13-32	2555-2562	adapted	_
13-33	2563-2565	to	_
13-34	2566-2576	individual	_
13-35	2577-2584	patient	_
13-36	2585-2590	needs	_
13-37	2591-2592	.	_

Text=Trial registration ClinicalTrials.gov, NCT02755623.
14-1	2593-2598	Trial	_
14-2	2599-2611	registration	_
14-3	2612-2630	ClinicalTrials.gov	_
14-4	2631-2632	,	_
14-5	2633-2644	NCT02755623	_
14-6	2645-2646	.	_

Text=Registered on 22 April 2016.
15-1	2647-2657	Registered	_
15-2	2658-2660	on	_
15-3	2661-2663	22	_
15-4	2664-2669	April	_
15-5	2670-2674	2016	_
15-6	2675-2676	.	_

Text=Electronic supplementary material The online version of this article (10.1186/s13063-019-3311-x) contains supplementary material, which is available to authorized users.
16-1	2677-2687	Electronic	_
16-2	2688-2701	supplementary	_
16-3	2702-2710	material	_
16-4	2711-2714	The	_
16-5	2715-2721	online	_
16-6	2722-2729	version	_
16-7	2730-2732	of	_
16-8	2733-2737	this	_
16-9	2738-2745	article	_
16-10	2746-2747	(	_
16-11	2748-2773	10.1186/s13063-019-3311-x	_
16-12	2774-2775	)	_
16-13	2776-2784	contains	_
16-14	2785-2798	supplementary	_
16-15	2799-2807	material	_
16-16	2808-2809	,	_
16-17	2810-2815	which	_
16-18	2816-2818	is	_
16-19	2819-2828	available	_
16-20	2829-2831	to	_
16-21	2832-2842	authorized	_
16-22	2843-2848	users	_
16-23	2849-2850	.	_

Text=Methods/design Study design This is a randomized, sham-controlled double-blind, monocentric study.
17-1	2851-2865	Methods/design	http://maven.renci.org/NeuroBridge/neurobridge#StudyDesign
17-2	2866-2871	Study	_
17-3	2872-2878	design	_
17-4	2879-2883	This	_
17-5	2884-2886	is	_
17-6	2887-2888	a	_
17-7	2889-2899	randomized	_
17-8	2900-2901	,	_
17-9	2902-2917	sham-controlled	_
17-10	2918-2930	double-blind	_
17-11	2931-2932	,	_
17-12	2933-2944	monocentric	_
17-13	2945-2950	study	_
17-14	2951-2952	.	_

Text=Patients will be randomly assigned to one of two arms, either active rTMS or sham rTMS applied to the left TPJ of each patient.
18-1	2953-2961	Patients	_
18-2	2962-2966	will	_
18-3	2967-2969	be	_
18-4	2970-2978	randomly	_
18-5	2979-2987	assigned	_
18-6	2988-2990	to	_
18-7	2991-2994	one	_
18-8	2995-2997	of	_
18-9	2998-3001	two	_
18-10	3002-3006	arms	_
18-11	3007-3008	,	_
18-12	3009-3015	either	_
18-13	3016-3022	active	_
18-14	3023-3027	rTMS	_
18-15	3028-3030	or	_
18-16	3031-3035	sham	_
18-17	3036-3040	rTMS	_
18-18	3041-3048	applied	_
18-19	3049-3051	to	_
18-20	3052-3055	the	_
18-21	3056-3060	left	_
18-22	3061-3064	TPJ	_
18-23	3065-3067	of	_
18-24	3068-3072	each	_
18-25	3073-3080	patient	_
18-26	3081-3082	.	_

Text=Twenty sessions of rTMS treatment will be administered daily (from Monday to Friday, weekends off) at a frequency of 1 Hz for a period of 2 weeks.
19-1	3083-3089	Twenty	_
19-2	3090-3098	sessions	_
19-3	3099-3101	of	_
19-4	3102-3106	rTMS	http://maven.renci.org/NeuroBridge/neurobridge#TreatmentResponseProgressScale
19-5	3107-3116	treatment	http://maven.renci.org/NeuroBridge/neurobridge#TreatmentResponseProgressScale
19-6	3117-3121	will	_
19-7	3122-3124	be	_
19-8	3125-3137	administered	_
19-9	3138-3143	daily	_
19-10	3144-3145	(	_
19-11	3146-3150	from	_
19-12	3151-3157	Monday	_
19-13	3158-3160	to	_
19-14	3161-3167	Friday	_
19-15	3168-3169	,	_
19-16	3170-3178	weekends	_
19-17	3179-3182	off	_
19-18	3183-3184	)	_
19-19	3185-3187	at	_
19-20	3188-3189	a	_
19-21	3190-3199	frequency	_
19-22	3200-3202	of	_
19-23	3203-3204	1	_
19-24	3205-3207	Hz	_
19-25	3208-3211	for	_
19-26	3212-3213	a	_
19-27	3214-3220	period	_
19-28	3221-3223	of	_
19-29	3224-3225	2	_
19-30	3226-3231	weeks	_
19-31	3232-3233	.	_

Text=Clinical, neuropsychological, neurophysiological, and biological evaluations will be carried out before regime onset (W0), on the week following the end of rTMS treatment (W3), and at 1 (W7) and 3 months (W15) after the termination of rTMS treatment.
20-1	3234-3242	Clinical	_
20-2	3243-3244	,	_
20-3	3245-3263	neuropsychological	_
20-4	3264-3265	,	_
20-5	3266-3284	neurophysiological	_
20-6	3285-3286	,	_
20-7	3287-3290	and	_
20-8	3291-3301	biological	_
20-9	3302-3313	evaluations	_
20-10	3314-3318	will	_
20-11	3319-3321	be	_
20-12	3322-3329	carried	_
20-13	3330-3333	out	_
20-14	3334-3340	before	_
20-15	3341-3347	regime	_
20-16	3348-3353	onset	_
20-17	3354-3355	(	_
20-18	3356-3358	W0	_
20-19	3359-3360	)	_
20-20	3361-3362	,	_
20-21	3363-3365	on	_
20-22	3366-3369	the	_
20-23	3370-3374	week	_
20-24	3375-3384	following	_
20-25	3385-3388	the	_
20-26	3389-3392	end	_
20-27	3393-3395	of	_
20-28	3396-3400	rTMS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
20-29	3401-3410	treatment	_
20-30	3411-3412	(	_
20-31	3413-3415	W3	_
20-32	3416-3417	)	_
20-33	3418-3419	,	_
20-34	3420-3423	and	_
20-35	3424-3426	at	_
20-36	3427-3428	1	_
20-37	3429-3430	(	_
20-38	3431-3433	W7	_
20-39	3434-3435	)	_
20-40	3436-3439	and	_
20-41	3440-3441	3	_
20-42	3442-3448	months	_
20-43	3449-3450	(	_
20-44	3451-3454	W15	_
20-45	3455-3456	)	_
20-46	3457-3462	after	_
20-47	3463-3466	the	_
20-48	3467-3478	termination	_
20-49	3479-3481	of	_
20-50	3482-3486	rTMS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
20-51	3487-3496	treatment	_
20-52	3497-3498	.	_

Text=MRI sequences will be recorded at W0 and W3.
21-1	3499-3502	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
21-2	3503-3512	sequences	_
21-3	3513-3517	will	_
21-4	3518-3520	be	_
21-5	3521-3529	recorded	_
21-6	3530-3532	at	_
21-7	3533-3535	W0	_
21-8	3536-3539	and	_
21-9	3540-3542	W3	_
21-10	3543-3544	.	_

Text=The first MRI acquisition will be recorded on the Friday of W0 (3 days before rTMS treatment) and the second on the Monday of W3 (3 days after rTMS treatment).
22-1	3545-3548	The	_
22-2	3549-3554	first	_
22-3	3555-3558	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
22-4	3559-3570	acquisition	_
22-5	3571-3575	will	_
22-6	3576-3578	be	_
22-7	3579-3587	recorded	_
22-8	3588-3590	on	_
22-9	3591-3594	the	_
22-10	3595-3601	Friday	_
22-11	3602-3604	of	_
22-12	3605-3607	W0	_
22-13	3608-3609	(	_
22-14	3610-3611	3	_
22-15	3612-3616	days	_
22-16	3617-3623	before	_
22-17	3624-3628	rTMS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
22-18	3629-3638	treatment	_
22-19	3639-3640	)	_
22-20	3641-3644	and	_
22-21	3645-3648	the	_
22-22	3649-3655	second	_
22-23	3656-3658	on	_
22-24	3659-3662	the	_
22-25	3663-3669	Monday	_
22-26	3670-3672	of	_
22-27	3673-3675	W3	_
22-28	3676-3677	(	_
22-29	3678-3679	3	_
22-30	3680-3684	days	_
22-31	3685-3690	after	_
22-32	3691-3695	rTMS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
22-33	3696-3705	treatment	_
22-34	3706-3707	)	_
22-35	3708-3709	.	_

Text=Figures 1 and 2 show the experimental design.
23-1	3710-3717	Figures	_
23-2	3718-3719	1	_
23-3	3720-3723	and	_
23-4	3724-3725	2	_
23-5	3726-3730	show	_
23-6	3731-3734	the	_
23-7	3735-3747	experimental	_
23-8	3748-3754	design	_
23-9	3755-3756	.	_

Text=The protocol study follows the SPIRIT recommendations.
24-1	3757-3760	The	_
24-2	3761-3769	protocol	_
24-3	3770-3775	study	_
24-4	3776-3783	follows	_
24-5	3784-3787	the	_
24-6	3788-3794	SPIRIT	_
24-7	3795-3810	recommendations	_
24-8	3811-3812	.	_

Text=For the SPIRIT checklist see Additional file 1.
25-1	3813-3816	For	_
25-2	3817-3820	the	_
25-3	3821-3827	SPIRIT	_
25-4	3828-3837	checklist	_
25-5	3838-3841	see	_
25-6	3842-3852	Additional	_
25-7	3853-3857	file	_
25-8	3858-3859	1	_
25-9	3860-3861	.	_

Text=Study setting This trial will be conducted by the Unité de Recherche Clinique of the Etablissement Public de Santé Ville-Evrard (Neuilly-sur-Marne, France).
26-1	3862-3867	Study	_
26-2	3868-3875	setting	_
26-3	3876-3880	This	_
26-4	3881-3886	trial	_
26-5	3887-3891	will	_
26-6	3892-3894	be	_
26-7	3895-3904	conducted	_
26-8	3905-3907	by	_
26-9	3908-3911	the	_
26-10	3912-3917	Unité	_
26-11	3918-3920	de	_
26-12	3921-3930	Recherche	_
26-13	3931-3939	Clinique	_
26-14	3940-3942	of	_
26-15	3943-3946	the	_
26-16	3947-3960	Etablissement	_
26-17	3961-3967	Public	_
26-18	3968-3970	de	_
26-19	3971-3976	Santé	_
26-20	3977-3989	Ville-Evrard	_
26-21	3990-3991	(	_
26-22	3992-4009	Neuilly-sur-Marne	_
26-23	4010-4011	,	_
26-24	4012-4018	France	_
26-25	4019-4020	)	_
26-26	4021-4022	.	_

Text=All assessments and rTMS interventions will be performed at the Unité de Recherche Clinique of the Établissement Public de Santé Ville-Evrard.
27-1	4023-4026	All	_
27-2	4027-4038	assessments	_
27-3	4039-4042	and	_
27-4	4043-4047	rTMS	_
27-5	4048-4061	interventions	_
27-6	4062-4066	will	_
27-7	4067-4069	be	_
27-8	4070-4079	performed	_
27-9	4080-4082	at	_
27-10	4083-4086	the	_
27-11	4087-4092	Unité	_
27-12	4093-4095	de	_
27-13	4096-4105	Recherche	_
27-14	4106-4114	Clinique	_
27-15	4115-4117	of	_
27-16	4118-4121	the	_
27-17	4122-4135	Établissement	_
27-18	4136-4142	Public	_
27-19	4143-4145	de	_
27-20	4146-4151	Santé	_
27-21	4152-4164	Ville-Evrard	_
27-22	4165-4166	.	_

Text=The MRI acquisitions will be performed at the Center for Neuroimaging Research at the Institut du Cerveau et de la Moelle Epinière (Paris, France).
28-1	4167-4170	The	_
28-2	4171-4174	MRI	_
28-3	4175-4187	acquisitions	_
28-4	4188-4192	will	_
28-5	4193-4195	be	_
28-6	4196-4205	performed	_
28-7	4206-4208	at	_
28-8	4209-4212	the	_
28-9	4213-4219	Center	_
28-10	4220-4223	for	_
28-11	4224-4236	Neuroimaging	_
28-12	4237-4245	Research	_
28-13	4246-4248	at	_
28-14	4249-4252	the	_
28-15	4253-4261	Institut	_
28-16	4262-4264	du	_
28-17	4265-4272	Cerveau	_
28-18	4273-4275	et	_
28-19	4276-4278	de	_
28-20	4279-4281	la	_
28-21	4282-4288	Moelle	_
28-22	4289-4297	Epinière	_
28-23	4298-4299	(	_
28-24	4300-4305	Paris	_
28-25	4306-4307	,	_
28-26	4308-4314	France	_
28-27	4315-4316	)	_
28-28	4317-4318	.	_

Text=Participants Recruitment Participants will be enrolled through psychiatric services of the Établissement Public de Santé Ville-Evrard, hospitals of the region Ile-de-France (within and around Paris, France) and referral by medical practitioners or therapists.
29-1	4319-4331	Participants	_
29-2	4332-4343	Recruitment	_
29-3	4344-4356	Participants	_
29-4	4357-4361	will	_
29-5	4362-4364	be	_
29-6	4365-4373	enrolled	_
29-7	4374-4381	through	_
29-8	4382-4393	psychiatric	_
29-9	4394-4402	services	_
29-10	4403-4405	of	_
29-11	4406-4409	the	_
29-12	4410-4423	Établissement	_
29-13	4424-4430	Public	_
29-14	4431-4433	de	_
29-15	4434-4439	Santé	_
29-16	4440-4452	Ville-Evrard	_
29-17	4453-4454	,	_
29-18	4455-4464	hospitals	_
29-19	4465-4467	of	_
29-20	4468-4471	the	_
29-21	4472-4478	region	_
29-22	4479-4492	Ile-de-France	_
29-23	4493-4494	(	_
29-24	4495-4501	within	_
29-25	4502-4505	and	_
29-26	4506-4512	around	_
29-27	4513-4518	Paris	_
29-28	4519-4520	,	_
29-29	4521-4527	France	_
29-30	4528-4529	)	_
29-31	4530-4533	and	_
29-32	4534-4542	referral	_
29-33	4543-4545	by	_
29-34	4546-4553	medical	_
29-35	4554-4567	practitioners	_
29-36	4568-4570	or	_
29-37	4571-4581	therapists	_
29-38	4582-4583	.	_

Text=The choice of rTMS treatment for schizophrenia patients will be decided by their clinician consultant.
30-1	4584-4587	The	_
30-2	4588-4594	choice	_
30-3	4595-4597	of	_
30-4	4598-4602	rTMS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
30-5	4603-4612	treatment	_
30-6	4613-4616	for	_
30-7	4617-4630	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
30-8	4631-4639	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
30-9	4640-4644	will	_
30-10	4645-4647	be	_
30-11	4648-4655	decided	_
30-12	4656-4658	by	_
30-13	4659-4664	their	_
30-14	4665-4674	clinician	_
30-15	4675-4685	consultant	_
30-16	4686-4687	.	_

Text=Following verification of the eligibility criteria by researchers, patients wishing to participate in the protocol will be included in the study.
31-1	4688-4697	Following	_
31-2	4698-4710	verification	_
31-3	4711-4713	of	_
31-4	4714-4717	the	_
31-5	4718-4729	eligibility	_
31-6	4730-4738	criteria	_
31-7	4739-4741	by	_
31-8	4742-4753	researchers	_
31-9	4754-4755	,	_
31-10	4756-4764	patients	_
31-11	4765-4772	wishing	_
31-12	4773-4775	to	_
31-13	4776-4787	participate	_
31-14	4788-4790	in	_
31-15	4791-4794	the	_
31-16	4795-4803	protocol	_
31-17	4804-4808	will	_
31-18	4809-4811	be	_
31-19	4812-4820	included	_
31-20	4821-4823	in	_
31-21	4824-4827	the	_
31-22	4828-4833	study	_
31-23	4834-4835	.	_

Text=Inclusion criteria Patients will have to be diagnosed with schizophrenia according to DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, 5th edition) criteria, suffer from medication-resistant AVH, demonstrate clinical stability for at least 3 months, be aged between 18 and 65 years old, and be right-handed.
32-1	4836-4845	Inclusion	_
32-2	4846-4854	criteria	_
32-3	4855-4863	Patients	_
32-4	4864-4868	will	_
32-5	4869-4873	have	_
32-6	4874-4876	to	_
32-7	4877-4879	be	_
32-8	4880-4889	diagnosed	_
32-9	4890-4894	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
32-10	4895-4908	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
32-11	4909-4918	according	_
32-12	4919-4921	to	_
32-13	4922-4927	DSM-5	_
32-14	4928-4929	(	_
32-15	4930-4940	Diagnostic	_
32-16	4941-4944	and	_
32-17	4945-4956	Statistical	_
32-18	4957-4963	Manual	_
32-19	4964-4966	of	_
32-20	4967-4973	Mental	_
32-21	4974-4983	Disorders	_
32-22	4984-4985	,	_
32-23	4986-4989	5th	_
32-24	4990-4997	edition	_
32-25	4998-4999	)	_
32-26	5000-5008	criteria	_
32-27	5009-5010	,	_
32-28	5011-5017	suffer	_
32-29	5018-5022	from	_
32-30	5023-5043	medication-resistant	_
32-31	5044-5047	AVH	http://maven.renci.org/NeuroBridge/neurobridge#Thing
32-32	5048-5049	,	_
32-33	5050-5061	demonstrate	_
32-34	5062-5070	clinical	_
32-35	5071-5080	stability	_
32-36	5081-5084	for	_
32-37	5085-5087	at	_
32-38	5088-5093	least	_
32-39	5094-5095	3	_
32-40	5096-5102	months	_
32-41	5103-5104	,	_
32-42	5105-5107	be	_
32-43	5108-5112	aged	_
32-44	5113-5120	between	_
32-45	5121-5123	18	_
32-46	5124-5127	and	_
32-47	5128-5130	65	_
32-48	5131-5136	years	_
32-49	5137-5140	old	_
32-50	5141-5142	,	_
32-51	5143-5146	and	_
32-52	5147-5149	be	_
32-53	5150-5162	right-handed	_
32-54	5163-5164	.	_

Text=Medication refractoriness is defined as a failure of treatment with two different antipsychotic drugs, of which at least one is considered atypical.
33-1	5165-5175	Medication	_
33-2	5176-5190	refractoriness	_
33-3	5191-5193	is	_
33-4	5194-5201	defined	_
33-5	5202-5204	as	_
33-6	5205-5206	a	_
33-7	5207-5214	failure	_
33-8	5215-5217	of	_
33-9	5218-5227	treatment	_
33-10	5228-5232	with	_
33-11	5233-5236	two	_
33-12	5237-5246	different	_
33-13	5247-5260	antipsychotic	_
33-14	5261-5266	drugs	_
33-15	5267-5268	,	_
33-16	5269-5271	of	_
33-17	5272-5277	which	_
33-18	5278-5280	at	_
33-19	5281-5286	least	_
33-20	5287-5290	one	_
33-21	5291-5293	is	_
33-22	5294-5304	considered	_
33-23	5305-5313	atypical	_
33-24	5314-5315	.	_

Text=Patients and their physicians will be strongly instructed not to modify the pharmacological treatment right before or throughout participation in the study.
34-1	5316-5324	Patients	_
34-2	5325-5328	and	_
34-3	5329-5334	their	_
34-4	5335-5345	physicians	_
34-5	5346-5350	will	_
34-6	5351-5353	be	_
34-7	5354-5362	strongly	_
34-8	5363-5373	instructed	_
34-9	5374-5377	not	_
34-10	5378-5380	to	_
34-11	5381-5387	modify	_
34-12	5388-5391	the	_
34-13	5392-5407	pharmacological	_
34-14	5408-5417	treatment	_
34-15	5418-5423	right	_
34-16	5424-5430	before	_
34-17	5431-5433	or	_
34-18	5434-5444	throughout	_
34-19	5445-5458	participation	_
34-20	5459-5461	in	_
34-21	5462-5465	the	_
34-22	5466-5471	study	_
34-23	5472-5473	.	_

Text=Additionally, patients will have to have sufficient knowledge of the French language.
35-1	5474-5486	Additionally	_
35-2	5487-5488	,	_
35-3	5489-5497	patients	_
35-4	5498-5502	will	_
35-5	5503-5507	have	_
35-6	5508-5510	to	_
35-7	5511-5515	have	_
35-8	5516-5526	sufficient	_
35-9	5527-5536	knowledge	_
35-10	5537-5539	of	_
35-11	5540-5543	the	_
35-12	5544-5550	French	_
35-13	5551-5559	language	_
35-14	5560-5561	.	_

Text=All participants of the study will be asked to sign an informed consent form.
36-1	5562-5565	All	_
36-2	5566-5578	participants	_
36-3	5579-5581	of	_
36-4	5582-5585	the	_
36-5	5586-5591	study	_
36-6	5592-5596	will	_
36-7	5597-5599	be	_
36-8	5600-5605	asked	_
36-9	5606-5608	to	_
36-10	5609-5613	sign	_
36-11	5614-5616	an	_
36-12	5617-5625	informed	_
36-13	5626-5633	consent	_
36-14	5634-5638	form	_
36-15	5639-5640	.	_

Text=Non-inclusion criteria Patients presenting with at least one of the following criteria are not to be enrolled in the study: (1) major psychiatric disorders other than schizophrenia according to DSM-5 criteria; (2) indulging in an addiction (alcohol, psychoactive substances) over the last 12 months; (3) having received rTMS treatment in the last 12 months; (4) participating in a concurrent research protocol; (5) a history of seizures; (6) having any contraindication for rTMS (patient with epilepsy, brain surgery and/or head trauma in the past, use of cardiac pacemaker, or surgical staples on the scalp); (7) having potential contraindications to MRI, e.g.
37-1	5641-5654	Non-inclusion	_
37-2	5655-5663	criteria	_
37-3	5664-5672	Patients	_
37-4	5673-5683	presenting	_
37-5	5684-5688	with	_
37-6	5689-5691	at	_
37-7	5692-5697	least	_
37-8	5698-5701	one	_
37-9	5702-5704	of	_
37-10	5705-5708	the	_
37-11	5709-5718	following	_
37-12	5719-5727	criteria	_
37-13	5728-5731	are	_
37-14	5732-5735	not	_
37-15	5736-5738	to	_
37-16	5739-5741	be	_
37-17	5742-5750	enrolled	_
37-18	5751-5753	in	_
37-19	5754-5757	the	_
37-20	5758-5763	study	_
37-21	5764-5765	:	_
37-22	5766-5767	(	_
37-23	5768-5769	1	_
37-24	5770-5771	)	_
37-25	5772-5777	major	_
37-26	5778-5789	psychiatric	_
37-27	5790-5799	disorders	_
37-28	5800-5805	other	_
37-29	5806-5810	than	_
37-30	5811-5824	schizophrenia	_
37-31	5825-5834	according	_
37-32	5835-5837	to	_
37-33	5838-5843	DSM-5	_
37-34	5844-5852	criteria	_
37-35	5853-5854	;	_
37-36	5855-5856	(	_
37-37	5857-5858	2	_
37-38	5859-5860	)	_
37-39	5861-5870	indulging	_
37-40	5871-5873	in	_
37-41	5874-5876	an	_
37-42	5877-5886	addiction	_
37-43	5887-5888	(	_
37-44	5889-5896	alcohol	_
37-45	5897-5898	,	_
37-46	5899-5911	psychoactive	_
37-47	5912-5922	substances	_
37-48	5923-5924	)	_
37-49	5925-5929	over	_
37-50	5930-5933	the	_
37-51	5934-5938	last	_
37-52	5939-5941	12	_
37-53	5942-5948	months	_
37-54	5949-5950	;	_
37-55	5951-5952	(	_
37-56	5953-5954	3	_
37-57	5955-5956	)	_
37-58	5957-5963	having	_
37-59	5964-5972	received	_
37-60	5973-5977	rTMS	_
37-61	5978-5987	treatment	_
37-62	5988-5990	in	_
37-63	5991-5994	the	_
37-64	5995-5999	last	_
37-65	6000-6002	12	_
37-66	6003-6009	months	_
37-67	6010-6011	;	_
37-68	6012-6013	(	_
37-69	6014-6015	4	_
37-70	6016-6017	)	_
37-71	6018-6031	participating	_
37-72	6032-6034	in	_
37-73	6035-6036	a	_
37-74	6037-6047	concurrent	_
37-75	6048-6056	research	_
37-76	6057-6065	protocol	_
37-77	6066-6067	;	_
37-78	6068-6069	(	_
37-79	6070-6071	5	_
37-80	6072-6073	)	_
37-81	6074-6075	a	_
37-82	6076-6083	history	_
37-83	6084-6086	of	_
37-84	6087-6095	seizures	_
37-85	6096-6097	;	_
37-86	6098-6099	(	_
37-87	6100-6101	6	_
37-88	6102-6103	)	_
37-89	6104-6110	having	_
37-90	6111-6114	any	_
37-91	6115-6131	contraindication	_
37-92	6132-6135	for	_
37-93	6136-6140	rTMS	_
37-94	6141-6142	(	_
37-95	6143-6150	patient	_
37-96	6151-6155	with	_
37-97	6156-6164	epilepsy	_
37-98	6165-6166	,	_
37-99	6167-6172	brain	_
37-100	6173-6180	surgery	_
37-101	6181-6187	and/or	_
37-102	6188-6192	head	_
37-103	6193-6199	trauma	_
37-104	6200-6202	in	_
37-105	6203-6206	the	_
37-106	6207-6211	past	_
37-107	6212-6213	,	_
37-108	6214-6217	use	_
37-109	6218-6220	of	_
37-110	6221-6228	cardiac	_
37-111	6229-6238	pacemaker	_
37-112	6239-6240	,	_
37-113	6241-6243	or	_
37-114	6244-6252	surgical	_
37-115	6253-6260	staples	_
37-116	6261-6263	on	_
37-117	6264-6267	the	_
37-118	6268-6273	scalp	_
37-119	6274-6275	)	_
37-120	6276-6277	;	_
37-121	6278-6279	(	_
37-122	6280-6281	7	_
37-123	6282-6283	)	_
37-124	6284-6290	having	_
37-125	6291-6300	potential	_
37-126	6301-6318	contraindications	_
37-127	6319-6321	to	_
37-128	6322-6325	MRI	_
37-129	6326-6327	,	_
37-130	6328-6331	e.g	_
37-131	6332-6333	.	_

Text=pregnancy or lactating (a negative pregnancy test will be required if the patient is a female in reproductive years who does not use contraception), use of a cardiac pacemaker or surgical staples, patients suffering a neurological disorder, head trauma or claustrophobia; (8) patients with severe cardiovascular disease; (9) patients with medication which could decrease the epileptic threshold (bupropion, methadone, and theophylline); and (10) patients placed in psychiatric care either by the state or a third party.
38-1	6334-6343	pregnancy	_
38-2	6344-6346	or	_
38-3	6347-6356	lactating	_
38-4	6357-6358	(	_
38-5	6359-6360	a	_
38-6	6361-6369	negative	_
38-7	6370-6379	pregnancy	_
38-8	6380-6384	test	_
38-9	6385-6389	will	_
38-10	6390-6392	be	_
38-11	6393-6401	required	_
38-12	6402-6404	if	_
38-13	6405-6408	the	_
38-14	6409-6416	patient	_
38-15	6417-6419	is	_
38-16	6420-6421	a	_
38-17	6422-6428	female	_
38-18	6429-6431	in	_
38-19	6432-6444	reproductive	_
38-20	6445-6450	years	_
38-21	6451-6454	who	_
38-22	6455-6459	does	_
38-23	6460-6463	not	_
38-24	6464-6467	use	_
38-25	6468-6481	contraception	_
38-26	6482-6483	)	_
38-27	6484-6485	,	_
38-28	6486-6489	use	_
38-29	6490-6492	of	_
38-30	6493-6494	a	_
38-31	6495-6502	cardiac	_
38-32	6503-6512	pacemaker	_
38-33	6513-6515	or	_
38-34	6516-6524	surgical	_
38-35	6525-6532	staples	_
38-36	6533-6534	,	_
38-37	6535-6543	patients	_
38-38	6544-6553	suffering	_
38-39	6554-6555	a	_
38-40	6556-6568	neurological	_
38-41	6569-6577	disorder	_
38-42	6578-6579	,	_
38-43	6580-6584	head	_
38-44	6585-6591	trauma	_
38-45	6592-6594	or	_
38-46	6595-6609	claustrophobia	_
38-47	6610-6611	;	_
38-48	6612-6613	(	_
38-49	6614-6615	8	_
38-50	6616-6617	)	_
38-51	6618-6626	patients	_
38-52	6627-6631	with	_
38-53	6632-6638	severe	_
38-54	6639-6653	cardiovascular	_
38-55	6654-6661	disease	_
38-56	6662-6663	;	_
38-57	6664-6665	(	_
38-58	6666-6667	9	_
38-59	6668-6669	)	_
38-60	6670-6678	patients	_
38-61	6679-6683	with	_
38-62	6684-6694	medication	_
38-63	6695-6700	which	_
38-64	6701-6706	could	_
38-65	6707-6715	decrease	_
38-66	6716-6719	the	_
38-67	6720-6729	epileptic	_
38-68	6730-6739	threshold	_
38-69	6740-6741	(	_
38-70	6742-6751	bupropion	_
38-71	6752-6753	,	_
38-72	6754-6763	methadone	_
38-73	6764-6765	,	_
38-74	6766-6769	and	_
38-75	6770-6782	theophylline	_
38-76	6783-6784	)	_
38-77	6785-6786	;	_
38-78	6787-6790	and	_
38-79	6791-6792	(	_
38-80	6793-6795	10	_
38-81	6796-6797	)	_
38-82	6798-6806	patients	_
38-83	6807-6813	placed	_
38-84	6814-6816	in	_
38-85	6817-6828	psychiatric	_
38-86	6829-6833	care	_
38-87	6834-6840	either	_
38-88	6841-6843	by	_
38-89	6844-6847	the	_
38-90	6848-6853	state	_
38-91	6854-6856	or	_
38-92	6857-6858	a	_
38-93	6859-6864	third	_
38-94	6865-6870	party	_
38-95	6871-6872	.	_

Text=Exit criteria Patients will be withdrawn from the trial if (1) they simply wish to stop participation; (2) they could not undergo the first MRI session; (3) they did not complete the rTMS sessions; and (4) if they suffered from worsening symptoms.
39-1	6873-6877	Exit	_
39-2	6878-6886	criteria	_
39-3	6887-6895	Patients	_
39-4	6896-6900	will	_
39-5	6901-6903	be	_
39-6	6904-6913	withdrawn	_
39-7	6914-6918	from	_
39-8	6919-6922	the	_
39-9	6923-6928	trial	_
39-10	6929-6931	if	_
39-11	6932-6933	(	_
39-12	6934-6935	1	_
39-13	6936-6937	)	_
39-14	6938-6942	they	_
39-15	6943-6949	simply	_
39-16	6950-6954	wish	_
39-17	6955-6957	to	_
39-18	6958-6962	stop	_
39-19	6963-6976	participation	_
39-20	6977-6978	;	_
39-21	6979-6980	(	_
39-22	6981-6982	2	_
39-23	6983-6984	)	_
39-24	6985-6989	they	_
39-25	6990-6995	could	_
39-26	6996-6999	not	_
39-27	7000-7007	undergo	_
39-28	7008-7011	the	_
39-29	7012-7017	first	_
39-30	7018-7021	MRI	_
39-31	7022-7029	session	_
39-32	7030-7031	;	_
39-33	7032-7033	(	_
39-34	7034-7035	3	_
39-35	7036-7037	)	_
39-36	7038-7042	they	_
39-37	7043-7046	did	_
39-38	7047-7050	not	_
39-39	7051-7059	complete	_
39-40	7060-7063	the	_
39-41	7064-7068	rTMS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
39-42	7069-7077	sessions	_
39-43	7078-7079	;	_
39-44	7080-7083	and	_
39-45	7084-7085	(	_
39-46	7086-7087	4	_
39-47	7088-7089	)	_
39-48	7090-7092	if	_
39-49	7093-7097	they	_
39-50	7098-7106	suffered	_
39-51	7107-7111	from	_
39-52	7112-7121	worsening	_
39-53	7122-7130	symptoms	_
39-54	7131-7132	.	_

Text=Randomization and blinding The study plans to include a total of 45 patients with schizophrenia randomized into two groups, namely an active rTMS group comprising 35 patients (78% of the total sample) and a sham rTMS group of 10 patients (22%).
40-1	7133-7146	Randomization	_
40-2	7147-7150	and	_
40-3	7151-7159	blinding	_
40-4	7160-7163	The	_
40-5	7164-7169	study	_
40-6	7170-7175	plans	_
40-7	7176-7178	to	_
40-8	7179-7186	include	_
40-9	7187-7188	a	_
40-10	7189-7194	total	_
40-11	7195-7197	of	_
40-12	7198-7200	45	_
40-13	7201-7209	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
40-14	7210-7214	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
40-15	7215-7228	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
40-16	7229-7239	randomized	_
40-17	7240-7244	into	_
40-18	7245-7248	two	_
40-19	7249-7255	groups	_
40-20	7256-7257	,	_
40-21	7258-7264	namely	_
40-22	7265-7267	an	_
40-23	7268-7274	active	_
40-24	7275-7279	rTMS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
40-25	7280-7285	group	_
40-26	7286-7296	comprising	_
40-27	7297-7299	35	_
40-28	7300-7308	patients	_
40-29	7309-7310	(	_
40-30	7311-7313	78	_
40-31	7314-7315	%	_
40-32	7316-7318	of	_
40-33	7319-7322	the	_
40-34	7323-7328	total	_
40-35	7329-7335	sample	_
40-36	7336-7337	)	_
40-37	7338-7341	and	_
40-38	7342-7343	a	_
40-39	7344-7348	sham	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
40-40	7349-7353	rTMS	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
40-41	7354-7359	group	_
40-42	7360-7362	of	_
40-43	7363-7365	10	_
40-44	7366-7374	patients	_
40-45	7375-7376	(	_
40-46	7377-7379	22	_
40-47	7380-7381	%	_
40-48	7382-7383	)	_
40-49	7384-7385	.	_

Text=We will use computer generated blocked-randomization with stratification on gender to get an equal number of males and females on each group.
41-1	7386-7388	We	_
41-2	7389-7393	will	_
41-3	7394-7397	use	_
41-4	7398-7406	computer	_
41-5	7407-7416	generated	_
41-6	7417-7438	blocked-randomization	_
41-7	7439-7443	with	_
41-8	7444-7458	stratification	_
41-9	7459-7461	on	_
41-10	7462-7468	gender	_
41-11	7469-7471	to	_
41-12	7472-7475	get	_
41-13	7476-7478	an	_
41-14	7479-7484	equal	_
41-15	7485-7491	number	_
41-16	7492-7494	of	_
41-17	7495-7500	males	_
41-18	7501-7504	and	_
41-19	7505-7512	females	_
41-20	7513-7515	on	_
41-21	7516-7520	each	_
41-22	7521-7526	group	_
41-23	7527-7528	.	_

Text=The randomization will be carried out in five blocks of nine participants.
42-1	7529-7532	The	_
42-2	7533-7546	randomization	_
42-3	7547-7551	will	_
42-4	7552-7554	be	_
42-5	7555-7562	carried	_
42-6	7563-7566	out	_
42-7	7567-7569	in	_
42-8	7570-7574	five	_
42-9	7575-7581	blocks	_
42-10	7582-7584	of	_
42-11	7585-7589	nine	_
42-12	7590-7602	participants	_
42-13	7603-7604	.	_

Text=Each block will consist of seven patients in the active rTMS group and two patients in the sham rTMS group.
43-1	7605-7609	Each	_
43-2	7610-7615	block	_
43-3	7616-7620	will	_
43-4	7621-7628	consist	_
43-5	7629-7631	of	_
43-6	7632-7637	seven	_
43-7	7638-7646	patients	_
43-8	7647-7649	in	_
43-9	7650-7653	the	_
43-10	7654-7660	active	http://maven.renci.org/NeuroBridge/neurobridge#Activity
43-11	7661-7665	rTMS	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
43-12	7666-7671	group	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
43-13	7672-7675	and	_
43-14	7676-7679	two	_
43-15	7680-7688	patients	_
43-16	7689-7691	in	_
43-17	7692-7695	the	_
43-18	7696-7700	sham	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
43-19	7701-7705	rTMS	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
43-20	7706-7711	group	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
43-21	7712-7713	.	_

Text=Each patient will be randomized during the baseline period by VM.
44-1	7714-7718	Each	_
44-2	7719-7726	patient	_
44-3	7727-7731	will	_
44-4	7732-7734	be	_
44-5	7735-7745	randomized	_
44-6	7746-7752	during	_
44-7	7753-7756	the	_
44-8	7757-7765	baseline	_
44-9	7766-7772	period	_
44-10	7773-7775	by	_
44-11	7776-7778	VM	_
44-12	7779-7780	.	_

Text=In order to eliminate measurement bias, no member of the trial will be aware of the group in which each patient is randomized to, with the exception of the caregiver performing the rTMS treatment sessions.
45-1	7781-7783	In	_
45-2	7784-7789	order	_
45-3	7790-7792	to	_
45-4	7793-7802	eliminate	_
45-5	7803-7814	measurement	_
45-6	7815-7819	bias	_
45-7	7820-7821	,	_
45-8	7822-7824	no	_
45-9	7825-7831	member	_
45-10	7832-7834	of	_
45-11	7835-7838	the	_
45-12	7839-7844	trial	_
45-13	7845-7849	will	_
45-14	7850-7852	be	_
45-15	7853-7858	aware	_
45-16	7859-7861	of	_
45-17	7862-7865	the	_
45-18	7866-7871	group	_
45-19	7872-7874	in	_
45-20	7875-7880	which	_
45-21	7881-7885	each	_
45-22	7886-7893	patient	_
45-23	7894-7896	is	_
45-24	7897-7907	randomized	_
45-25	7908-7910	to	_
45-26	7911-7912	,	_
45-27	7913-7917	with	_
45-28	7918-7921	the	_
45-29	7922-7931	exception	_
45-30	7932-7934	of	_
45-31	7935-7938	the	_
45-32	7939-7948	caregiver	_
45-33	7949-7959	performing	_
45-34	7960-7963	the	_
45-35	7964-7968	rTMS	_
45-36	7969-7978	treatment	_
45-37	7979-7987	sessions	_
45-38	7988-7989	.	_

Text=At the end of the rTMS treatment (W3), the medical evaluator will debrief with patients on their participation in the protocol and document if they felt they had been assigned to and therefore received an active or sham rTMS treatment.
46-1	7990-7992	At	_
46-2	7993-7996	the	_
46-3	7997-8000	end	_
46-4	8001-8003	of	_
46-5	8004-8007	the	_
46-6	8008-8012	rTMS	_
46-7	8013-8022	treatment	_
46-8	8023-8024	(	_
46-9	8025-8027	W3	_
46-10	8028-8029	)	_
46-11	8030-8031	,	_
46-12	8032-8035	the	_
46-13	8036-8043	medical	_
46-14	8044-8053	evaluator	_
46-15	8054-8058	will	_
46-16	8059-8066	debrief	_
46-17	8067-8071	with	_
46-18	8072-8080	patients	_
46-19	8081-8083	on	_
46-20	8084-8089	their	_
46-21	8090-8103	participation	_
46-22	8104-8106	in	_
46-23	8107-8110	the	_
46-24	8111-8119	protocol	_
46-25	8120-8123	and	_
46-26	8124-8132	document	_
46-27	8133-8135	if	_
46-28	8136-8140	they	_
46-29	8141-8145	felt	_
46-30	8146-8150	they	_
46-31	8151-8154	had	_
46-32	8155-8159	been	_
46-33	8160-8168	assigned	_
46-34	8169-8171	to	_
46-35	8172-8175	and	_
46-36	8176-8185	therefore	_
46-37	8186-8194	received	_
46-38	8195-8197	an	_
46-39	8198-8204	active	_
46-40	8205-8207	or	_
46-41	8208-8212	sham	_
46-42	8213-8217	rTMS	_
46-43	8218-8227	treatment	_
46-44	8228-8229	.	_

Text=Interventions Active rTMS protocol Sessions of rTMS treatment will be carried out with a standard 70 mm figure-of-eight coil (Active Air Film coil, Magstim, Wales, UK), attached to a Magstim Rapid2 Stimulator (Magstim, Wales, UK).
47-1	8230-8243	Interventions	_
47-2	8244-8250	Active	_
47-3	8251-8255	rTMS	_
47-4	8256-8264	protocol	_
47-5	8265-8273	Sessions	_
47-6	8274-8276	of	_
47-7	8277-8281	rTMS	_
47-8	8282-8291	treatment	_
47-9	8292-8296	will	_
47-10	8297-8299	be	_
47-11	8300-8307	carried	_
47-12	8308-8311	out	_
47-13	8312-8316	with	_
47-14	8317-8318	a	_
47-15	8319-8327	standard	_
47-16	8328-8330	70	_
47-17	8331-8333	mm	_
47-18	8334-8349	figure-of-eight	_
47-19	8350-8354	coil	_
47-20	8355-8356	(	_
47-21	8357-8363	Active	_
47-22	8364-8367	Air	_
47-23	8368-8372	Film	_
47-24	8373-8377	coil	_
47-25	8378-8379	,	_
47-26	8380-8387	Magstim	_
47-27	8388-8389	,	_
47-28	8390-8395	Wales	_
47-29	8396-8397	,	_
47-30	8398-8400	UK	_
47-31	8401-8402	)	_
47-32	8403-8404	,	_
47-33	8405-8413	attached	_
47-34	8414-8416	to	_
47-35	8417-8418	a	_
47-36	8419-8426	Magstim	_
47-37	8427-8433	Rapid2	_
47-38	8434-8444	Stimulator	_
47-39	8445-8446	(	_
47-40	8447-8454	Magstim	_
47-41	8455-8456	,	_
47-42	8457-8462	Wales	_
47-43	8463-8464	,	_
47-44	8465-8467	UK	_
47-45	8468-8469	)	_
47-46	8470-8471	.	_

Text=Participants will be randomly allocated to either the active rTMS (n = 35 patients) or to the sham rTMS (n = 10) groups.
48-1	8472-8484	Participants	_
48-2	8485-8489	will	_
48-3	8490-8492	be	_
48-4	8493-8501	randomly	_
48-5	8502-8511	allocated	_
48-6	8512-8514	to	_
48-7	8515-8521	either	_
48-8	8522-8525	the	_
48-9	8526-8532	active	_
48-10	8533-8537	rTMS	_
48-11	8538-8539	(	_
48-12	8540-8541	n	_
48-13	8542-8543	=	_
48-14	8544-8546	35	_
48-15	8547-8555	patients	_
48-16	8556-8557	)	_
48-17	8558-8560	or	_
48-18	8561-8563	to	_
48-19	8564-8567	the	_
48-20	8568-8572	sham	_
48-21	8573-8577	rTMS	_
48-22	8578-8579	(	_
48-23	8580-8581	n	_
48-24	8582-8583	=	_
48-25	8584-8586	10	_
48-26	8587-8588	)	_
48-27	8589-8595	groups	_
48-28	8596-8597	.	_

Text=For both groups, the treatment will be administered in two consecutive sessions of rTMS, each delivered for 20 min and interleaved by a stimulation-free 1 h interval.
49-1	8598-8601	For	_
49-2	8602-8606	both	_
49-3	8607-8613	groups	_
49-4	8614-8615	,	_
49-5	8616-8619	the	_
49-6	8620-8629	treatment	_
49-7	8630-8634	will	_
49-8	8635-8637	be	_
49-9	8638-8650	administered	_
49-10	8651-8653	in	_
49-11	8654-8657	two	_
49-12	8658-8669	consecutive	_
49-13	8670-8678	sessions	_
49-14	8679-8681	of	_
49-15	8682-8686	rTMS	_
49-16	8687-8688	,	_
49-17	8689-8693	each	_
49-18	8694-8703	delivered	_
49-19	8704-8707	for	_
49-20	8708-8710	20	_
49-21	8711-8714	min	_
49-22	8715-8718	and	_
49-23	8719-8730	interleaved	_
49-24	8731-8733	by	_
49-25	8734-8735	a	_
49-26	8736-8752	stimulation-free	_
49-27	8753-8754	1	_
49-28	8755-8756	h	_
49-29	8757-8765	interval	_
49-30	8766-8767	.	_

Text=All patients will receive twice-daily rTMS sessions over a period of 2 weeks (from Monday to Friday, weekends off), and therefore accrue a total of 20 rTMS stimulation sessions.
50-1	8768-8771	All	_
50-2	8772-8780	patients	_
50-3	8781-8785	will	_
50-4	8786-8793	receive	_
50-5	8794-8805	twice-daily	_
50-6	8806-8810	rTMS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
50-7	8811-8819	sessions	_
50-8	8820-8824	over	_
50-9	8825-8826	a	_
50-10	8827-8833	period	_
50-11	8834-8836	of	_
50-12	8837-8838	2	_
50-13	8839-8844	weeks	_
50-14	8845-8846	(	_
50-15	8847-8851	from	_
50-16	8852-8858	Monday	_
50-17	8859-8861	to	_
50-18	8862-8868	Friday	_
50-19	8869-8870	,	_
50-20	8871-8879	weekends	_
50-21	8880-8883	off	_
50-22	8884-8885	)	_
50-23	8886-8887	,	_
50-24	8888-8891	and	_
50-25	8892-8901	therefore	_
50-26	8902-8908	accrue	_
50-27	8909-8910	a	_
50-28	8911-8916	total	_
50-29	8917-8919	of	_
50-30	8920-8922	20	_
50-31	8923-8927	rTMS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
50-32	8928-8939	stimulation	_
50-33	8940-8948	sessions	_
50-34	8949-8950	.	_

Text=The rTMS parameters that will be used are a frequency of 1 Hz (1 pulse per second), an intensity of 100% of the motor threshold (MT), and 1200 continuous pulses per session (thus 2400 pulses per day and 24,000 pulses in total for the whole treatment).
51-1	8951-8954	The	_
51-2	8955-8959	rTMS	_
51-3	8960-8970	parameters	_
51-4	8971-8975	that	_
51-5	8976-8980	will	_
51-6	8981-8983	be	_
51-7	8984-8988	used	_
51-8	8989-8992	are	_
51-9	8993-8994	a	_
51-10	8995-9004	frequency	_
51-11	9005-9007	of	_
51-12	9008-9009	1	_
51-13	9010-9012	Hz	_
51-14	9013-9014	(	_
51-15	9015-9016	1	_
51-16	9017-9022	pulse	_
51-17	9023-9026	per	_
51-18	9027-9033	second	_
51-19	9034-9035	)	_
51-20	9036-9037	,	_
51-21	9038-9040	an	_
51-22	9041-9050	intensity	_
51-23	9051-9053	of	_
51-24	9054-9057	100	_
51-25	9058-9059	%	_
51-26	9060-9062	of	_
51-27	9063-9066	the	_
51-28	9067-9072	motor	_
51-29	9073-9082	threshold	_
51-30	9083-9084	(	_
51-31	9085-9087	MT	_
51-32	9088-9089	)	_
51-33	9090-9091	,	_
51-34	9092-9095	and	_
51-35	9096-9100	1200	_
51-36	9101-9111	continuous	_
51-37	9112-9118	pulses	_
51-38	9119-9122	per	_
51-39	9123-9130	session	_
51-40	9131-9132	(	_
51-41	9133-9137	thus	_
51-42	9138-9142	2400	_
51-43	9143-9149	pulses	_
51-44	9150-9153	per	_
51-45	9154-9157	day	_
51-46	9158-9161	and	_
51-47	9162-9168	24,000	_
51-48	9169-9175	pulses	_
51-49	9176-9178	in	_
51-50	9179-9184	total	_
51-51	9185-9188	for	_
51-52	9189-9192	the	_
51-53	9193-9198	whole	_
51-54	9199-9208	treatment	_
51-55	9209-9210	)	_
51-56	9211-9212	.	_

Text=The MT is defined as the minimal TMS intensity required to elicit motor evoked potentials (MEPs) measured with electromyographic (EMG) surface electrodes placed on the first dorsal interosseous hand muscle, of at least 50 μV peak-to-peak amplitude, at rest, in 5 out of 10 consecutive trials.
52-1	9213-9216	The	_
52-2	9217-9219	MT	_
52-3	9220-9222	is	_
52-4	9223-9230	defined	_
52-5	9231-9233	as	_
52-6	9234-9237	the	_
52-7	9238-9245	minimal	_
52-8	9246-9249	TMS	_
52-9	9250-9259	intensity	_
52-10	9260-9268	required	_
52-11	9269-9271	to	_
52-12	9272-9278	elicit	_
52-13	9279-9284	motor	_
52-14	9285-9291	evoked	_
52-15	9292-9302	potentials	_
52-16	9303-9304	(	_
52-17	9305-9309	MEPs	_
52-18	9310-9311	)	_
52-19	9312-9320	measured	_
52-20	9321-9325	with	_
52-21	9326-9343	electromyographic	_
52-22	9344-9345	(	_
52-23	9346-9349	EMG	_
52-24	9350-9351	)	_
52-25	9352-9359	surface	_
52-26	9360-9370	electrodes	_
52-27	9371-9377	placed	_
52-28	9378-9380	on	_
52-29	9381-9384	the	_
52-30	9385-9390	first	_
52-31	9391-9397	dorsal	_
52-32	9398-9410	interosseous	_
52-33	9411-9415	hand	_
52-34	9416-9422	muscle	_
52-35	9423-9424	,	_
52-36	9425-9427	of	_
52-37	9428-9430	at	_
52-38	9431-9436	least	_
52-39	9437-9439	50	_
52-40	9440-9442	μV	_
52-41	9443-9455	peak-to-peak	_
52-42	9456-9465	amplitude	_
52-43	9466-9467	,	_
52-44	9468-9470	at	_
52-45	9471-9475	rest	_
52-46	9476-9477	,	_
52-47	9478-9480	in	_
52-48	9481-9482	5	_
52-49	9483-9486	out	_
52-50	9487-9489	of	_
52-51	9490-9492	10	_
52-52	9493-9504	consecutive	_
52-53	9505-9511	trials	_
52-54	9512-9513	.	_

Text=The rTMS coil will be applied over the left TPJ, which will be targeted using established spatial coordinates for the Wernicke ’ s area in the left TPJ (Montreal Neurological Institute (MNI) coordinates: x = − 69, y = − 41, z = 11).
53-1	9514-9517	The	_
53-2	9518-9522	rTMS	_
53-3	9523-9527	coil	_
53-4	9528-9532	will	_
53-5	9533-9535	be	_
53-6	9536-9543	applied	_
53-7	9544-9548	over	_
53-8	9549-9552	the	_
53-9	9553-9557	left	_
53-10	9558-9561	TPJ	_
53-11	9562-9563	,	_
53-12	9564-9569	which	_
53-13	9570-9574	will	_
53-14	9575-9577	be	_
53-15	9578-9586	targeted	_
53-16	9587-9592	using	_
53-17	9593-9604	established	_
53-18	9605-9612	spatial	_
53-19	9613-9624	coordinates	_
53-20	9625-9628	for	_
53-21	9629-9632	the	_
53-22	9633-9641	Wernicke	_
53-23	9642-9643	’	_
53-24	9644-9645	s	_
53-25	9646-9650	area	_
53-26	9651-9653	in	_
53-27	9654-9657	the	_
53-28	9658-9662	left	_
53-29	9663-9666	TPJ	_
53-30	9667-9668	(	_
53-31	9669-9677	Montreal	_
53-32	9678-9690	Neurological	_
53-33	9691-9700	Institute	_
53-34	9701-9702	(	_
53-35	9703-9706	MNI	_
53-36	9707-9708	)	_
53-37	9709-9720	coordinates	_
53-38	9721-9722	:	_
53-39	9723-9724	x	_
53-40	9725-9726	=	_
53-41	9727-9728	−	_
53-42	9729-9731	69	_
53-43	9732-9733	,	_
53-44	9734-9735	y	_
53-45	9736-9737	=	_
53-46	9738-9739	−	_
53-47	9740-9742	41	_
53-48	9743-9744	,	_
53-49	9745-9746	z	_
53-50	9747-9748	=	_
53-51	9749-9751	11	_
53-52	9752-9753	)	_
53-53	9754-9755	.	_

Text=This brain area will be labeled on a 3D rendering of the patient ’ s individual T1 MRI sequence on each patient.
54-1	9756-9760	This	_
54-2	9761-9766	brain	_
54-3	9767-9771	area	_
54-4	9772-9776	will	_
54-5	9777-9779	be	_
54-6	9780-9787	labeled	_
54-7	9788-9790	on	_
54-8	9791-9792	a	_
54-9	9793-9795	3D	_
54-10	9796-9805	rendering	_
54-11	9806-9808	of	_
54-12	9809-9812	the	_
54-13	9813-9820	patient	_
54-14	9821-9822	’	_
54-15	9823-9824	s	_
54-16	9825-9835	individual	_
54-17	9836-9838	T1	_
54-18	9839-9842	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
54-19	9843-9851	sequence	_
54-20	9852-9854	on	_
54-21	9855-9859	each	_
54-22	9860-9867	patient	_
54-23	9868-9869	.	_

Text=The TMS coil will be positioned tangential to the scalp location overlying the left TPJ using an MRI-based frameless stereotactic neuronavigation system (Brainsight, Rogue Research Inc., Montreal, Canada) (Fig.
55-1	9870-9873	The	_
55-2	9874-9877	TMS	_
55-3	9878-9882	coil	_
55-4	9883-9887	will	_
55-5	9888-9890	be	_
55-6	9891-9901	positioned	_
55-7	9902-9912	tangential	_
55-8	9913-9915	to	_
55-9	9916-9919	the	_
55-10	9920-9925	scalp	_
55-11	9926-9934	location	_
55-12	9935-9944	overlying	_
55-13	9945-9948	the	_
55-14	9949-9953	left	_
55-15	9954-9957	TPJ	_
55-16	9958-9963	using	_
55-17	9964-9966	an	_
55-18	9967-9976	MRI-based	http://maven.renci.org/NeuroBridge/neurobridge#EcologicalStudy
55-19	9977-9986	frameless	_
55-20	9987-9999	stereotactic	_
55-21	10000-10015	neuronavigation	_
55-22	10016-10022	system	_
55-23	10023-10024	(	_
55-24	10025-10035	Brainsight	_
55-25	10036-10037	,	_
55-26	10038-10043	Rogue	_
55-27	10044-10052	Research	_
55-28	10053-10057	Inc.	_
55-29	10058-10059	,	_
55-30	10060-10068	Montreal	_
55-31	10069-10070	,	_
55-32	10071-10077	Canada	_
55-33	10078-10079	)	_
55-34	10080-10081	(	_
55-35	10082-10085	Fig	_
55-36	10086-10087	.	_

Text=3).
56-1	10088-10089	3	_
56-2	10090-10091	)	_
56-3	10092-10093	.	_

Text=Sham rTMS protocol The sham TMS treatment condition will be strictly identical to the active treatment condition thanks to the use of a sham TMS coil (Sham Air Film coil, Magstim, Wales, UK).
57-1	10094-10098	Sham	_
57-2	10099-10103	rTMS	_
57-3	10104-10112	protocol	_
57-4	10113-10116	The	_
57-5	10117-10121	sham	_
57-6	10122-10125	TMS	_
57-7	10126-10135	treatment	_
57-8	10136-10145	condition	_
57-9	10146-10150	will	_
57-10	10151-10153	be	_
57-11	10154-10162	strictly	_
57-12	10163-10172	identical	_
57-13	10173-10175	to	_
57-14	10176-10179	the	_
57-15	10180-10186	active	_
57-16	10187-10196	treatment	_
57-17	10197-10206	condition	_
57-18	10207-10213	thanks	_
57-19	10214-10216	to	_
57-20	10217-10220	the	_
57-21	10221-10224	use	_
57-22	10225-10227	of	_
57-23	10228-10229	a	_
57-24	10230-10234	sham	_
57-25	10235-10238	TMS	_
57-26	10239-10243	coil	_
57-27	10244-10245	(	_
57-28	10246-10250	Sham	_
57-29	10251-10254	Air	_
57-30	10255-10259	Film	_
57-31	10260-10264	coil	_
57-32	10265-10266	,	_
57-33	10267-10274	Magstim	_
57-34	10275-10276	,	_
57-35	10277-10282	Wales	_
57-36	10283-10284	,	_
57-37	10285-10287	UK	_
57-38	10288-10289	)	_
57-39	10290-10291	.	_

Text=The sham rTMS coil is indistinguishable in terms of general appearance and shape from an active coil, and able to emulate periodic noise and scalp tactile sensations similar to those produced during the active TMS session for rTMS naïve patients or even experienced healthy subjects.
58-1	10292-10295	The	_
58-2	10296-10300	sham	_
58-3	10301-10305	rTMS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
58-4	10306-10310	coil	_
58-5	10311-10313	is	_
58-6	10314-10331	indistinguishable	_
58-7	10332-10334	in	_
58-8	10335-10340	terms	_
58-9	10341-10343	of	_
58-10	10344-10351	general	_
58-11	10352-10362	appearance	_
58-12	10363-10366	and	_
58-13	10367-10372	shape	_
58-14	10373-10377	from	_
58-15	10378-10380	an	_
58-16	10381-10387	active	_
58-17	10388-10392	coil	_
58-18	10393-10394	,	_
58-19	10395-10398	and	_
58-20	10399-10403	able	_
58-21	10404-10406	to	_
58-22	10407-10414	emulate	_
58-23	10415-10423	periodic	_
58-24	10424-10429	noise	_
58-25	10430-10433	and	_
58-26	10434-10439	scalp	_
58-27	10440-10447	tactile	_
58-28	10448-10458	sensations	_
58-29	10459-10466	similar	_
58-30	10467-10469	to	_
58-31	10470-10475	those	_
58-32	10476-10484	produced	_
58-33	10485-10491	during	_
58-34	10492-10495	the	_
58-35	10496-10502	active	_
58-36	10503-10506	TMS	_
58-37	10507-10514	session	_
58-38	10515-10518	for	_
58-39	10519-10523	rTMS	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
58-40	10524-10529	naïve	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
58-41	10530-10538	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
58-42	10539-10541	or	_
58-43	10542-10546	even	_
58-44	10547-10558	experienced	_
58-45	10559-10566	healthy	_
58-46	10567-10575	subjects	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
58-47	10576-10577	.	_

Text=Moreover, this coil has a magnetic shield that reduces the diffusion of the magnetic field under its surface, stimulating only scalp skin receptors or superficial muscles, without inducing any significant physiological transcranial effect on the brain.
59-1	10578-10586	Moreover	_
59-2	10587-10588	,	_
59-3	10589-10593	this	_
59-4	10594-10598	coil	_
59-5	10599-10602	has	_
59-6	10603-10604	a	_
59-7	10605-10613	magnetic	_
59-8	10614-10620	shield	_
59-9	10621-10625	that	_
59-10	10626-10633	reduces	_
59-11	10634-10637	the	_
59-12	10638-10647	diffusion	_
59-13	10648-10650	of	_
59-14	10651-10654	the	_
59-15	10655-10663	magnetic	_
59-16	10664-10669	field	_
59-17	10670-10675	under	_
59-18	10676-10679	its	_
59-19	10680-10687	surface	_
59-20	10688-10689	,	_
59-21	10690-10701	stimulating	_
59-22	10702-10706	only	_
59-23	10707-10712	scalp	_
59-24	10713-10717	skin	_
59-25	10718-10727	receptors	_
59-26	10728-10730	or	_
59-27	10731-10742	superficial	_
59-28	10743-10750	muscles	_
59-29	10751-10752	,	_
59-30	10753-10760	without	_
59-31	10761-10769	inducing	_
59-32	10770-10773	any	_
59-33	10774-10785	significant	_
59-34	10786-10799	physiological	_
59-35	10800-10812	transcranial	_
59-36	10813-10819	effect	_
59-37	10820-10822	on	_
59-38	10823-10826	the	_
59-39	10827-10832	brain	_
59-40	10833-10834	.	_

Text=The two rTMS conditions will be performed in parallel in separate subsets of patients; therefore, patients and evaluators will not be able to differentiate between active and sham stimulation.
60-1	10835-10838	The	_
60-2	10839-10842	two	_
60-3	10843-10847	rTMS	_
60-4	10848-10858	conditions	_
60-5	10859-10863	will	_
60-6	10864-10866	be	_
60-7	10867-10876	performed	_
60-8	10877-10879	in	_
60-9	10880-10888	parallel	_
60-10	10889-10891	in	_
60-11	10892-10900	separate	_
60-12	10901-10908	subsets	_
60-13	10909-10911	of	_
60-14	10912-10920	patients	_
60-15	10921-10922	;	_
60-16	10923-10932	therefore	_
60-17	10933-10934	,	_
60-18	10935-10943	patients	_
60-19	10944-10947	and	_
60-20	10948-10958	evaluators	_
60-21	10959-10963	will	_
60-22	10964-10967	not	_
60-23	10968-10970	be	_
60-24	10971-10975	able	_
60-25	10976-10978	to	_
60-26	10979-10992	differentiate	_
60-27	10993-11000	between	_
60-28	11001-11007	active	_
60-29	11008-11011	and	_
60-30	11012-11016	sham	_
60-31	11017-11028	stimulation	_
60-32	11029-11030	.	_

Text=Imaging acquisition Before and after the TMS therapy, MRI scans will be obtained in all participants on a 3 Tesla scanner (Siemens Healthcare, Erlangen, Germany).
61-1	11031-11038	Imaging	_
61-2	11039-11050	acquisition	_
61-3	11051-11057	Before	_
61-4	11058-11061	and	_
61-5	11062-11067	after	_
61-6	11068-11071	the	_
61-7	11072-11075	TMS	http://maven.renci.org/NeuroBridge/neurobridge#Intervention
61-8	11076-11083	therapy	http://maven.renci.org/NeuroBridge/neurobridge#Intervention
61-9	11084-11085	,	_
61-10	11086-11089	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
61-11	11090-11095	scans	_
61-12	11096-11100	will	_
61-13	11101-11103	be	_
61-14	11104-11112	obtained	_
61-15	11113-11115	in	_
61-16	11116-11119	all	_
61-17	11120-11132	participants	_
61-18	11133-11135	on	_
61-19	11136-11137	a	_
61-20	11138-11139	3	_
61-21	11140-11145	Tesla	_
61-22	11146-11153	scanner	_
61-23	11154-11155	(	_
61-24	11156-11163	Siemens	_
61-25	11164-11174	Healthcare	_
61-26	11175-11176	,	_
61-27	11177-11185	Erlangen	_
61-28	11186-11187	,	_
61-29	11188-11195	Germany	_
61-30	11196-11197	)	_
61-31	11198-11199	.	_

Text=To characterize brain structure and navigate the rTMS coil location, we will record three-dimensional, high-resolution, isovoxel, T1-weighted brain volumes acquired with the following parameters: 256 × 240 × 176 matrix size with 176 contiguous slices, field of view (FOV) = 256 mm, 1 mm isotropic resolution, sagittal slice orientation, repetition time (TR) = 2300 ms, and echo time (TE) = 2.98 ms. To characterize the structural connectivity, diffusion-weighted images (DWIs) will be obtained using a DWI sequence (104 × 104 × 84 matrix size with 60 contiguous slices, FOV = 208 mm, 2 mm isotropic resolution, transversal slice orientation, flip angle = 90°, TR = 3800 ms, TE = 86 ms).
62-1	11200-11202	To	_
62-2	11203-11215	characterize	_
62-3	11216-11221	brain	_
62-4	11222-11231	structure	_
62-5	11232-11235	and	_
62-6	11236-11244	navigate	_
62-7	11245-11248	the	_
62-8	11249-11253	rTMS	_
62-9	11254-11258	coil	_
62-10	11259-11267	location	_
62-11	11268-11269	,	_
62-12	11270-11272	we	_
62-13	11273-11277	will	_
62-14	11278-11284	record	_
62-15	11285-11302	three-dimensional	_
62-16	11303-11304	,	_
62-17	11305-11320	high-resolution	_
62-18	11321-11322	,	_
62-19	11323-11331	isovoxel	_
62-20	11332-11333	,	_
62-21	11334-11345	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
62-22	11346-11351	brain	_
62-23	11352-11359	volumes	_
62-24	11360-11368	acquired	_
62-25	11369-11373	with	_
62-26	11374-11377	the	_
62-27	11378-11387	following	_
62-28	11388-11398	parameters	_
62-29	11399-11400	:	_
62-30	11401-11404	256	_
62-31	11405-11406	×	_
62-32	11407-11410	240	_
62-33	11411-11412	×	_
62-34	11413-11416	176	_
62-35	11417-11423	matrix	_
62-36	11424-11428	size	_
62-37	11429-11433	with	_
62-38	11434-11437	176	_
62-39	11438-11448	contiguous	_
62-40	11449-11455	slices	_
62-41	11456-11457	,	_
62-42	11458-11463	field	_
62-43	11464-11466	of	_
62-44	11467-11471	view	_
62-45	11472-11473	(	_
62-46	11474-11477	FOV	_
62-47	11478-11479	)	_
62-48	11480-11481	=	_
62-49	11482-11485	256	_
62-50	11486-11488	mm	_
62-51	11489-11490	,	_
62-52	11491-11492	1	_
62-53	11493-11495	mm	_
62-54	11496-11505	isotropic	_
62-55	11506-11516	resolution	_
62-56	11517-11518	,	_
62-57	11519-11527	sagittal	_
62-58	11528-11533	slice	_
62-59	11534-11545	orientation	_
62-60	11546-11547	,	_
62-61	11548-11558	repetition	_
62-62	11559-11563	time	_
62-63	11564-11565	(	_
62-64	11566-11568	TR	_
62-65	11569-11570	)	_
62-66	11571-11572	=	_
62-67	11573-11577	2300	_
62-68	11578-11580	ms	_
62-69	11581-11582	,	_
62-70	11583-11586	and	_
62-71	11587-11591	echo	_
62-72	11592-11596	time	_
62-73	11597-11598	(	_
62-74	11599-11601	TE	_
62-75	11602-11603	)	_
62-76	11604-11605	=	_
62-77	11606-11610	2.98	_
62-78	11611-11614	ms.	_
62-79	11615-11617	To	_
62-80	11618-11630	characterize	_
62-81	11631-11634	the	_
62-82	11635-11645	structural	_
62-83	11646-11658	connectivity	_
62-84	11659-11660	,	_
62-85	11661-11679	diffusion-weighted	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
62-86	11680-11686	images	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
62-87	11687-11688	(	_
62-88	11689-11693	DWIs	_
62-89	11694-11695	)	_
62-90	11696-11700	will	_
62-91	11701-11703	be	_
62-92	11704-11712	obtained	_
62-93	11713-11718	using	_
62-94	11719-11720	a	_
62-95	11721-11724	DWI	_
62-96	11725-11733	sequence	_
62-97	11734-11735	(	_
62-98	11736-11739	104	_
62-99	11740-11741	×	_
62-100	11742-11745	104	_
62-101	11746-11747	×	_
62-102	11748-11750	84	_
62-103	11751-11757	matrix	_
62-104	11758-11762	size	_
62-105	11763-11767	with	_
62-106	11768-11770	60	_
62-107	11771-11781	contiguous	_
62-108	11782-11788	slices	_
62-109	11789-11790	,	_
62-110	11791-11794	FOV	_
62-111	11795-11796	=	_
62-112	11797-11800	208	_
62-113	11801-11803	mm	_
62-114	11804-11805	,	_
62-115	11806-11807	2	_
62-116	11808-11810	mm	_
62-117	11811-11820	isotropic	_
62-118	11821-11831	resolution	_
62-119	11832-11833	,	_
62-120	11834-11845	transversal	_
62-121	11846-11851	slice	_
62-122	11852-11863	orientation	_
62-123	11864-11865	,	_
62-124	11866-11870	flip	_
62-125	11871-11876	angle	_
62-126	11877-11878	=	_
62-127	11879-11882	90°	_
62-128	11883-11884	,	_
62-129	11885-11887	TR	_
62-130	11888-11889	=	_
62-131	11890-11894	3800	_
62-132	11895-11897	ms	_
62-133	11898-11899	,	_
62-134	11900-11902	TE	_
62-135	11903-11904	=	_
62-136	11905-11907	86	_
62-137	11908-11910	ms	_
62-138	11911-11912	)	_
62-139	11913-11914	.	_

Text=The encoding protocol will include 64 different non-collinear directions (gradient factor b = 1500 s/mm2) and one image without diffusion weighting used as the reference volume (b = 0 s/mm2, b0 image).
63-1	11915-11918	The	_
63-2	11919-11927	encoding	_
63-3	11928-11936	protocol	_
63-4	11937-11941	will	_
63-5	11942-11949	include	_
63-6	11950-11952	64	_
63-7	11953-11962	different	_
63-8	11963-11976	non-collinear	_
63-9	11977-11987	directions	_
63-10	11988-11989	(	_
63-11	11990-11998	gradient	_
63-12	11999-12005	factor	_
63-13	12006-12007	b	_
63-14	12008-12009	=	_
63-15	12010-12014	1500	_
63-16	12015-12020	s/mm2	_
63-17	12021-12022	)	_
63-18	12023-12026	and	_
63-19	12027-12030	one	_
63-20	12031-12036	image	_
63-21	12037-12044	without	_
63-22	12045-12054	diffusion	_
63-23	12055-12064	weighting	_
63-24	12065-12069	used	_
63-25	12070-12072	as	_
63-26	12073-12076	the	_
63-27	12077-12086	reference	_
63-28	12087-12093	volume	_
63-29	12094-12095	(	_
63-30	12096-12097	b	_
63-31	12098-12099	=	_
63-32	12100-12101	0	_
63-33	12102-12107	s/mm2	_
63-34	12108-12109	,	_
63-35	12110-12112	b0	_
63-36	12113-12118	image	_
63-37	12119-12120	)	_
63-38	12121-12122	.	_

Text=To characterize functional connectivity (resting-state functional MRI or rs-fMRI), we will record T2 * -weighted MRI sequence applied with an echo-planar gradient (192 × 192 × 162 matrix size with 45 contiguous slices, FOV = 192 mm, 3 mm isotropic resolution, 20% interslice gap, transversal and coronal slice orientation, flip angle = 80°, TR = 2500 ms, TE = 30 ms) when subjects are resting while keeping their eyes closed.
64-1	12123-12125	To	_
64-2	12126-12138	characterize	_
64-3	12139-12149	functional	_
64-4	12150-12162	connectivity	_
64-5	12163-12164	(	_
64-6	12165-12178	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
64-7	12179-12189	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
64-8	12190-12193	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
64-9	12194-12196	or	_
64-10	12197-12204	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
64-11	12205-12206	)	_
64-12	12207-12208	,	_
64-13	12209-12211	we	_
64-14	12212-12216	will	_
64-15	12217-12223	record	_
64-16	12224-12226	T2	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
64-17	12227-12228	*	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
64-18	12229-12238	-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
64-19	12239-12242	MRI	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
64-20	12243-12251	sequence	_
64-21	12252-12259	applied	_
64-22	12260-12264	with	_
64-23	12265-12267	an	_
64-24	12268-12279	echo-planar	_
64-25	12280-12288	gradient	_
64-26	12289-12290	(	_
64-27	12291-12294	192	_
64-28	12295-12296	×	_
64-29	12297-12300	192	_
64-30	12301-12302	×	_
64-31	12303-12306	162	_
64-32	12307-12313	matrix	_
64-33	12314-12318	size	_
64-34	12319-12323	with	_
64-35	12324-12326	45	_
64-36	12327-12337	contiguous	_
64-37	12338-12344	slices	_
64-38	12345-12346	,	_
64-39	12347-12350	FOV	_
64-40	12351-12352	=	_
64-41	12353-12356	192	_
64-42	12357-12359	mm	_
64-43	12360-12361	,	_
64-44	12362-12363	3	_
64-45	12364-12366	mm	_
64-46	12367-12376	isotropic	_
64-47	12377-12387	resolution	_
64-48	12388-12389	,	_
64-49	12390-12392	20	_
64-50	12393-12394	%	_
64-51	12395-12405	interslice	_
64-52	12406-12409	gap	_
64-53	12410-12411	,	_
64-54	12412-12423	transversal	_
64-55	12424-12427	and	_
64-56	12428-12435	coronal	_
64-57	12436-12441	slice	_
64-58	12442-12453	orientation	_
64-59	12454-12455	,	_
64-60	12456-12460	flip	_
64-61	12461-12466	angle	_
64-62	12467-12468	=	_
64-63	12469-12472	80°	_
64-64	12473-12474	,	_
64-65	12475-12477	TR	_
64-66	12478-12479	=	_
64-67	12480-12484	2500	_
64-68	12485-12487	ms	_
64-69	12488-12489	,	_
64-70	12490-12492	TE	_
64-71	12493-12494	=	_
64-72	12495-12497	30	_
64-73	12498-12500	ms	_
64-74	12501-12502	)	_
64-75	12503-12507	when	_
64-76	12508-12516	subjects	_
64-77	12517-12520	are	_
64-78	12521-12528	resting	_
64-79	12529-12534	while	_
64-80	12535-12542	keeping	_
64-81	12543-12548	their	_
64-82	12549-12553	eyes	_
64-83	12554-12560	closed	_
64-84	12561-12562	.	_

Text=Patients are instructed to relax, remain still, and not to fall asleep.
65-1	12563-12571	Patients	_
65-2	12572-12575	are	_
65-3	12576-12586	instructed	_
65-4	12587-12589	to	_
65-5	12590-12595	relax	_
65-6	12596-12597	,	_
65-7	12598-12604	remain	_
65-8	12605-12610	still	_
65-9	12611-12612	,	_
65-10	12613-12616	and	_
65-11	12617-12620	not	_
65-12	12621-12623	to	_
65-13	12624-12628	fall	_
65-14	12629-12635	asleep	_
65-15	12636-12637	.	_

Text=After each MRI scan, we will also debrief with patients to investigate and document whether patients experienced hallucinations during the MRI sessions, and if so, in which sensory modalities and during which MRI sequences those might have occurred.
66-1	12638-12643	After	_
66-2	12644-12648	each	_
66-3	12649-12652	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
66-4	12653-12657	scan	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
66-5	12658-12659	,	_
66-6	12660-12662	we	_
66-7	12663-12667	will	_
66-8	12668-12672	also	_
66-9	12673-12680	debrief	_
66-10	12681-12685	with	_
66-11	12686-12694	patients	_
66-12	12695-12697	to	_
66-13	12698-12709	investigate	_
66-14	12710-12713	and	_
66-15	12714-12722	document	_
66-16	12723-12730	whether	_
66-17	12731-12739	patients	_
66-18	12740-12751	experienced	_
66-19	12752-12766	hallucinations	_
66-20	12767-12773	during	_
66-21	12774-12777	the	_
66-22	12778-12781	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
66-23	12782-12790	sessions	_
66-24	12791-12792	,	_
66-25	12793-12796	and	_
66-26	12797-12799	if	_
66-27	12800-12802	so	_
66-28	12803-12804	,	_
66-29	12805-12807	in	_
66-30	12808-12813	which	_
66-31	12814-12821	sensory	_
66-32	12822-12832	modalities	_
66-33	12833-12836	and	_
66-34	12837-12843	during	_
66-35	12844-12849	which	_
66-36	12850-12853	MRI	_
66-37	12854-12863	sequences	_
66-38	12864-12869	those	_
66-39	12870-12875	might	_
66-40	12876-12880	have	_
66-41	12881-12889	occurred	_
66-42	12890-12891	.	_

Text=Outcome measures Primary outcome measures Our primary aim is to identify brain connectivity differences between patients ‘ responders ’ and ‘ non-responders ’ to rTMS treatment.
67-1	12892-12899	Outcome	_
67-2	12900-12908	measures	_
67-3	12909-12916	Primary	_
67-4	12917-12924	outcome	_
67-5	12925-12933	measures	_
67-6	12934-12937	Our	_
67-7	12938-12945	primary	_
67-8	12946-12949	aim	_
67-9	12950-12952	is	_
67-10	12953-12955	to	_
67-11	12956-12964	identify	_
67-12	12965-12970	brain	_
67-13	12971-12983	connectivity	_
67-14	12984-12995	differences	_
67-15	12996-13003	between	_
67-16	13004-13012	patients	_
67-17	13013-13014	‘	_
67-18	13015-13025	responders	_
67-19	13026-13027	’	_
67-20	13028-13031	and	_
67-21	13032-13033	‘	_
67-22	13034-13048	non-responders	_
67-23	13049-13050	’	_
67-24	13051-13053	to	_
67-25	13054-13058	rTMS	_
67-26	13059-13068	treatment	_
67-27	13069-13070	.	_

Text=To cluster patients as ‘ responders ’ or ‘ non-responders ’, the clinical response to rTMS will be defined as a decrease of 50% or more in the HCS from baseline (W0) at the end of the active rTMS stimulation (W3).
68-1	13071-13073	To	_
68-2	13074-13081	cluster	_
68-3	13082-13090	patients	_
68-4	13091-13093	as	_
68-5	13094-13095	‘	_
68-6	13096-13106	responders	_
68-7	13107-13108	’	_
68-8	13109-13111	or	_
68-9	13112-13113	‘	_
68-10	13114-13128	non-responders	_
68-11	13129-13130	’	_
68-12	13131-13132	,	_
68-13	13133-13136	the	_
68-14	13137-13145	clinical	_
68-15	13146-13154	response	_
68-16	13155-13157	to	_
68-17	13158-13162	rTMS	_
68-18	13163-13167	will	_
68-19	13168-13170	be	_
68-20	13171-13178	defined	_
68-21	13179-13181	as	_
68-22	13182-13183	a	_
68-23	13184-13192	decrease	_
68-24	13193-13195	of	_
68-25	13196-13198	50	_
68-26	13199-13200	%	_
68-27	13201-13203	or	_
68-28	13204-13208	more	_
68-29	13209-13211	in	_
68-30	13212-13215	the	_
68-31	13216-13219	HCS	_
68-32	13220-13224	from	_
68-33	13225-13233	baseline	_
68-34	13234-13235	(	_
68-35	13236-13238	W0	_
68-36	13239-13240	)	_
68-37	13241-13243	at	_
68-38	13244-13247	the	_
68-39	13248-13251	end	_
68-40	13252-13254	of	_
68-41	13255-13258	the	_
68-42	13259-13265	active	_
68-43	13266-13270	rTMS	_
68-44	13271-13282	stimulation	_
68-45	13283-13284	(	_
68-46	13285-13287	W3	_
68-47	13288-13289	)	_
68-48	13290-13291	.	_

Text=This definition is similar to that employed in previous studies.
69-1	13292-13296	This	_
69-2	13297-13307	definition	_
69-3	13308-13310	is	_
69-4	13311-13318	similar	_
69-5	13319-13321	to	_
69-6	13322-13326	that	_
69-7	13327-13335	employed	_
69-8	13336-13338	in	_
69-9	13339-13347	previous	_
69-10	13348-13355	studies	_
69-11	13356-13357	.	_

Text=The HCS is described in the Clinical assessments section in the Secondary outcome measures paragraph and will allow analysis of the dataset in search of biomarkers associated with rTMS response, in particular structural and functional connectivity biomarkers.
70-1	13358-13361	The	_
70-2	13362-13365	HCS	_
70-3	13366-13368	is	_
70-4	13369-13378	described	_
70-5	13379-13381	in	_
70-6	13382-13385	the	_
70-7	13386-13394	Clinical	_
70-8	13395-13406	assessments	_
70-9	13407-13414	section	_
70-10	13415-13417	in	_
70-11	13418-13421	the	_
70-12	13422-13431	Secondary	_
70-13	13432-13439	outcome	_
70-14	13440-13448	measures	_
70-15	13449-13458	paragraph	_
70-16	13459-13462	and	_
70-17	13463-13467	will	_
70-18	13468-13473	allow	_
70-19	13474-13482	analysis	_
70-20	13483-13485	of	_
70-21	13486-13489	the	_
70-22	13490-13497	dataset	_
70-23	13498-13500	in	_
70-24	13501-13507	search	_
70-25	13508-13510	of	_
70-26	13511-13521	biomarkers	_
70-27	13522-13532	associated	_
70-28	13533-13537	with	_
70-29	13538-13542	rTMS	_
70-30	13543-13551	response	_
70-31	13552-13553	,	_
70-32	13554-13556	in	_
70-33	13557-13567	particular	_
70-34	13568-13578	structural	_
70-35	13579-13582	and	_
70-36	13583-13593	functional	_
70-37	13594-13606	connectivity	_
70-38	13607-13617	biomarkers	_
70-39	13618-13619	.	_

Text=To identify structural connectivity biomarkers to rTMS therapeutic response, we will compare DWI datasets, acquired at baseline, between ‘ responder ’ and ‘ non-responder ’ patients to rTMS.
71-1	13620-13622	To	_
71-2	13623-13631	identify	_
71-3	13632-13642	structural	_
71-4	13643-13655	connectivity	_
71-5	13656-13666	biomarkers	_
71-6	13667-13669	to	_
71-7	13670-13674	rTMS	_
71-8	13675-13686	therapeutic	_
71-9	13687-13695	response	_
71-10	13696-13697	,	_
71-11	13698-13700	we	_
71-12	13701-13705	will	_
71-13	13706-13713	compare	_
71-14	13714-13717	DWI	_
71-15	13718-13726	datasets	_
71-16	13727-13728	,	_
71-17	13729-13737	acquired	_
71-18	13738-13740	at	_
71-19	13741-13749	baseline	_
71-20	13750-13751	,	_
71-21	13752-13759	between	_
71-22	13760-13761	‘	_
71-23	13762-13771	responder	_
71-24	13772-13773	’	_
71-25	13774-13777	and	_
71-26	13778-13779	‘	_
71-27	13780-13793	non-responder	_
71-28	13794-13795	’	_
71-29	13796-13804	patients	_
71-30	13805-13807	to	_
71-31	13808-13812	rTMS	_
71-32	13813-13814	.	_

Text=More precisely, we will consider fractional anisotropy (FA) levels along tracts of interest that will be reconstructed from probabilistic tractography algorithms.
72-1	13815-13819	More	_
72-2	13820-13829	precisely	_
72-3	13830-13831	,	_
72-4	13832-13834	we	_
72-5	13835-13839	will	_
72-6	13840-13848	consider	_
72-7	13849-13859	fractional	_
72-8	13860-13870	anisotropy	_
72-9	13871-13872	(	_
72-10	13873-13875	FA	_
72-11	13876-13877	)	_
72-12	13878-13884	levels	_
72-13	13885-13890	along	_
72-14	13891-13897	tracts	_
72-15	13898-13900	of	_
72-16	13901-13909	interest	_
72-17	13910-13914	that	_
72-18	13915-13919	will	_
72-19	13920-13922	be	_
72-20	13923-13936	reconstructed	_
72-21	13937-13941	from	_
72-22	13942-13955	probabilistic	_
72-23	13956-13968	tractography	_
72-24	13969-13979	algorithms	_
72-25	13980-13981	.	_

Text=FA levels will be obtained at several equidistant points along the tract of interest.
73-1	13982-13984	FA	_
73-2	13985-13991	levels	_
73-3	13992-13996	will	_
73-4	13997-13999	be	_
73-5	14000-14008	obtained	_
73-6	14009-14011	at	_
73-7	14012-14019	several	_
73-8	14020-14031	equidistant	_
73-9	14032-14038	points	_
73-10	14039-14044	along	_
73-11	14045-14048	the	_
73-12	14049-14054	tract	_
73-13	14055-14057	of	_
73-14	14058-14066	interest	_
73-15	14067-14068	.	_

Text=This procedure will allow evaluation of the existence of global or focal (close to the stimulation site) white matter integrity alterations between ‘ responders ’ and ‘ non-responders ’.
74-1	14069-14073	This	_
74-2	14074-14083	procedure	_
74-3	14084-14088	will	_
74-4	14089-14094	allow	_
74-5	14095-14105	evaluation	_
74-6	14106-14108	of	_
74-7	14109-14112	the	_
74-8	14113-14122	existence	_
74-9	14123-14125	of	_
74-10	14126-14132	global	_
74-11	14133-14135	or	_
74-12	14136-14141	focal	_
74-13	14142-14143	(	_
74-14	14144-14149	close	_
74-15	14150-14152	to	_
74-16	14153-14156	the	_
74-17	14157-14168	stimulation	_
74-18	14169-14173	site	_
74-19	14174-14175	)	_
74-20	14176-14181	white	_
74-21	14182-14188	matter	_
74-22	14189-14198	integrity	_
74-23	14199-14210	alterations	_
74-24	14211-14218	between	_
74-25	14219-14220	‘	_
74-26	14221-14231	responders	_
74-27	14232-14233	’	_
74-28	14234-14237	and	_
74-29	14238-14239	‘	_
74-30	14240-14254	non-responders	_
74-31	14255-14256	’	_
74-32	14257-14258	.	_

Text=Tracts of interest will include the fasciculi that are involved in the language network (connections between TPJ and Broca areas, so called the arcuate fasciculi on each hemisphere, and transcallosal connections between the TPJ or Broca areas), and those that are part of the DMN (connections between the superior parietal cortex and prefrontal areas within each hemisphere; transcallosal connections between superior parietal cortex or prefrontal areas).
75-1	14259-14265	Tracts	_
75-2	14266-14268	of	_
75-3	14269-14277	interest	_
75-4	14278-14282	will	_
75-5	14283-14290	include	_
75-6	14291-14294	the	_
75-7	14295-14304	fasciculi	_
75-8	14305-14309	that	_
75-9	14310-14313	are	_
75-10	14314-14322	involved	_
75-11	14323-14325	in	_
75-12	14326-14329	the	_
75-13	14330-14338	language	_
75-14	14339-14346	network	_
75-15	14347-14348	(	_
75-16	14349-14360	connections	_
75-17	14361-14368	between	_
75-18	14369-14372	TPJ	_
75-19	14373-14376	and	_
75-20	14377-14382	Broca	_
75-21	14383-14388	areas	_
75-22	14389-14390	,	_
75-23	14391-14393	so	_
75-24	14394-14400	called	_
75-25	14401-14404	the	_
75-26	14405-14412	arcuate	_
75-27	14413-14422	fasciculi	_
75-28	14423-14425	on	_
75-29	14426-14430	each	_
75-30	14431-14441	hemisphere	_
75-31	14442-14443	,	_
75-32	14444-14447	and	_
75-33	14448-14461	transcallosal	_
75-34	14462-14473	connections	_
75-35	14474-14481	between	_
75-36	14482-14485	the	_
75-37	14486-14489	TPJ	_
75-38	14490-14492	or	_
75-39	14493-14498	Broca	_
75-40	14499-14504	areas	_
75-41	14505-14506	)	_
75-42	14507-14508	,	_
75-43	14509-14512	and	_
75-44	14513-14518	those	_
75-45	14519-14523	that	_
75-46	14524-14527	are	_
75-47	14528-14532	part	_
75-48	14533-14535	of	_
75-49	14536-14539	the	_
75-50	14540-14543	DMN	_
75-51	14544-14545	(	_
75-52	14546-14557	connections	_
75-53	14558-14565	between	_
75-54	14566-14569	the	_
75-55	14570-14578	superior	_
75-56	14579-14587	parietal	_
75-57	14588-14594	cortex	_
75-58	14595-14598	and	_
75-59	14599-14609	prefrontal	_
75-60	14610-14615	areas	_
75-61	14616-14622	within	_
75-62	14623-14627	each	_
75-63	14628-14638	hemisphere	_
75-64	14639-14640	;	_
75-65	14641-14654	transcallosal	_
75-66	14655-14666	connections	_
75-67	14667-14674	between	_
75-68	14675-14683	superior	_
75-69	14684-14692	parietal	_
75-70	14693-14699	cortex	_
75-71	14700-14702	or	_
75-72	14703-14713	prefrontal	_
75-73	14714-14719	areas	_
75-74	14720-14721	)	_
75-75	14722-14723	.	_

Text=FA values along each tract will be obtained at baseline (W0) and after rTMS treatment (W3) for ‘ responders ’ and ‘ non-responders ’.
76-1	14724-14726	FA	_
76-2	14727-14733	values	_
76-3	14734-14739	along	_
76-4	14740-14744	each	_
76-5	14745-14750	tract	_
76-6	14751-14755	will	_
76-7	14756-14758	be	_
76-8	14759-14767	obtained	_
76-9	14768-14770	at	_
76-10	14771-14779	baseline	_
76-11	14780-14781	(	_
76-12	14782-14784	W0	_
76-13	14785-14786	)	_
76-14	14787-14790	and	_
76-15	14791-14796	after	_
76-16	14797-14801	rTMS	_
76-17	14802-14811	treatment	_
76-18	14812-14813	(	_
76-19	14814-14816	W3	_
76-20	14817-14818	)	_
76-21	14819-14822	for	_
76-22	14823-14824	‘	_
76-23	14825-14835	responders	_
76-24	14836-14837	’	_
76-25	14838-14841	and	_
76-26	14842-14843	‘	_
76-27	14844-14858	non-responders	_
76-28	14859-14860	’	_
76-29	14861-14862	.	_

Text=To identify functional connectivity biomarkers to rTMS response, we will compare functional volumes, obtained at baseline and at rest, between ‘ responders ’ and ‘ non-responders ’.
77-1	14863-14865	To	_
77-2	14866-14874	identify	_
77-3	14875-14885	functional	_
77-4	14886-14898	connectivity	_
77-5	14899-14909	biomarkers	_
77-6	14910-14912	to	_
77-7	14913-14917	rTMS	_
77-8	14918-14926	response	_
77-9	14927-14928	,	_
77-10	14929-14931	we	_
77-11	14932-14936	will	_
77-12	14937-14944	compare	_
77-13	14945-14955	functional	_
77-14	14956-14963	volumes	_
77-15	14964-14965	,	_
77-16	14966-14974	obtained	_
77-17	14975-14977	at	_
77-18	14978-14986	baseline	_
77-19	14987-14990	and	_
77-20	14991-14993	at	_
77-21	14994-14998	rest	_
77-22	14999-15000	,	_
77-23	15001-15008	between	_
77-24	15009-15010	‘	_
77-25	15011-15021	responders	_
77-26	15022-15023	’	_
77-27	15024-15027	and	_
77-28	15028-15029	‘	_
77-29	15030-15044	non-responders	_
77-30	15045-15046	’	_
77-31	15047-15048	.	_

Text=We will consider the connectivity strength between areas of networks of interest.
78-1	15049-15051	We	_
78-2	15052-15056	will	_
78-3	15057-15065	consider	_
78-4	15066-15069	the	_
78-5	15070-15082	connectivity	_
78-6	15083-15091	strength	_
78-7	15092-15099	between	_
78-8	15100-15105	areas	_
78-9	15106-15108	of	_
78-10	15109-15117	networks	_
78-11	15118-15120	of	_
78-12	15121-15129	interest	_
78-13	15130-15131	.	_

Text=Connectivity strength is the degree of dependence between the time courses of two areas (measured with a Pearson coefficient or using dynamic causal modeling (DCM)).
79-1	15132-15144	Connectivity	_
79-2	15145-15153	strength	_
79-3	15154-15156	is	_
79-4	15157-15160	the	_
79-5	15161-15167	degree	_
79-6	15168-15170	of	_
79-7	15171-15181	dependence	_
79-8	15182-15189	between	_
79-9	15190-15193	the	_
79-10	15194-15198	time	_
79-11	15199-15206	courses	_
79-12	15207-15209	of	_
79-13	15210-15213	two	_
79-14	15214-15219	areas	_
79-15	15220-15221	(	_
79-16	15222-15230	measured	_
79-17	15231-15235	with	_
79-18	15236-15237	a	_
79-19	15238-15245	Pearson	_
79-20	15246-15257	coefficient	_
79-21	15258-15260	or	_
79-22	15261-15266	using	_
79-23	15267-15274	dynamic	_
79-24	15275-15281	causal	_
79-25	15282-15290	modeling	_
79-26	15291-15292	(	_
79-27	15293-15296	DCM	_
79-28	15297-15298	)	_
79-29	15299-15300	)	_
79-30	15301-15302	.	_

Text=The networks of interest will include the DMN (bilateral anterior cingulate cortex, bilateral prefrontal areas, bilateral superior parietal areas, bilateral precuneus) and the language network (bilateral TPJ, Broca areas).
80-1	15303-15306	The	_
80-2	15307-15315	networks	_
80-3	15316-15318	of	_
80-4	15319-15327	interest	_
80-5	15328-15332	will	_
80-6	15333-15340	include	_
80-7	15341-15344	the	_
80-8	15345-15348	DMN	_
80-9	15349-15350	(	_
80-10	15351-15360	bilateral	_
80-11	15361-15369	anterior	_
80-12	15370-15379	cingulate	_
80-13	15380-15386	cortex	_
80-14	15387-15388	,	_
80-15	15389-15398	bilateral	_
80-16	15399-15409	prefrontal	_
80-17	15410-15415	areas	_
80-18	15416-15417	,	_
80-19	15418-15427	bilateral	_
80-20	15428-15436	superior	_
80-21	15437-15445	parietal	_
80-22	15446-15451	areas	_
80-23	15452-15453	,	_
80-24	15454-15463	bilateral	_
80-25	15464-15473	precuneus	_
80-26	15474-15475	)	_
80-27	15476-15479	and	_
80-28	15480-15483	the	_
80-29	15484-15492	language	_
80-30	15493-15500	network	_
80-31	15501-15502	(	_
80-32	15503-15512	bilateral	_
80-33	15513-15516	TPJ	_
80-34	15517-15518	,	_
80-35	15519-15524	Broca	_
80-36	15525-15530	areas	_
80-37	15531-15532	)	_
80-38	15533-15534	.	_

Text=Connectivity strength between areas of these two networks will be obtained at baseline (W0) and after rTMS treatment (W3) in ‘ responders ’ and ‘ non-responders ’.
81-1	15535-15547	Connectivity	_
81-2	15548-15556	strength	_
81-3	15557-15564	between	_
81-4	15565-15570	areas	_
81-5	15571-15573	of	_
81-6	15574-15579	these	_
81-7	15580-15583	two	_
81-8	15584-15592	networks	_
81-9	15593-15597	will	_
81-10	15598-15600	be	_
81-11	15601-15609	obtained	_
81-12	15610-15612	at	_
81-13	15613-15621	baseline	_
81-14	15622-15623	(	_
81-15	15624-15626	W0	_
81-16	15627-15628	)	_
81-17	15629-15632	and	_
81-18	15633-15638	after	_
81-19	15639-15643	rTMS	_
81-20	15644-15653	treatment	_
81-21	15654-15655	(	_
81-22	15656-15658	W3	_
81-23	15659-15660	)	_
81-24	15661-15663	in	_
81-25	15664-15665	‘	_
81-26	15666-15676	responders	_
81-27	15677-15678	’	_
81-28	15679-15682	and	_
81-29	15683-15684	‘	_
81-30	15685-15699	non-responders	_
81-31	15700-15701	’	_
81-32	15702-15703	.	_

Text=Secondary outcome measures Sociodemographic and clinical data For each participant, sociodemographic information (age, sex, educational level, marital status, main activity) and clinical data (onset of schizophrenia, number of hospitalizations, dosage of antipsychotic medication, drug consumption such as tobacco, alcohol and cannabis, history of neurostimulation treatment) will be registered in the patient ’ s case report form (CRF).
82-1	15704-15713	Secondary	_
82-2	15714-15721	outcome	_
82-3	15722-15730	measures	_
82-4	15731-15747	Sociodemographic	_
82-5	15748-15751	and	_
82-6	15752-15760	clinical	_
82-7	15761-15765	data	_
82-8	15766-15769	For	_
82-9	15770-15774	each	_
82-10	15775-15786	participant	_
82-11	15787-15788	,	_
82-12	15789-15805	sociodemographic	_
82-13	15806-15817	information	_
82-14	15818-15819	(	_
82-15	15820-15823	age	_
82-16	15824-15825	,	_
82-17	15826-15829	sex	_
82-18	15830-15831	,	_
82-19	15832-15843	educational	_
82-20	15844-15849	level	_
82-21	15850-15851	,	_
82-22	15852-15859	marital	_
82-23	15860-15866	status	_
82-24	15867-15868	,	_
82-25	15869-15873	main	_
82-26	15874-15882	activity	_
82-27	15883-15884	)	_
82-28	15885-15888	and	_
82-29	15889-15897	clinical	_
82-30	15898-15902	data	_
82-31	15903-15904	(	_
82-32	15905-15910	onset	_
82-33	15911-15913	of	_
82-34	15914-15927	schizophrenia	_
82-35	15928-15929	,	_
82-36	15930-15936	number	_
82-37	15937-15939	of	_
82-38	15940-15956	hospitalizations	_
82-39	15957-15958	,	_
82-40	15959-15965	dosage	_
82-41	15966-15968	of	_
82-42	15969-15982	antipsychotic	_
82-43	15983-15993	medication	_
82-44	15994-15995	,	_
82-45	15996-16000	drug	_
82-46	16001-16012	consumption	_
82-47	16013-16017	such	_
82-48	16018-16020	as	_
82-49	16021-16028	tobacco	_
82-50	16029-16030	,	_
82-51	16031-16038	alcohol	_
82-52	16039-16042	and	_
82-53	16043-16051	cannabis	_
82-54	16052-16053	,	_
82-55	16054-16061	history	_
82-56	16062-16064	of	_
82-57	16065-16081	neurostimulation	_
82-58	16082-16091	treatment	_
82-59	16092-16093	)	_
82-60	16094-16098	will	_
82-61	16099-16101	be	_
82-62	16102-16112	registered	_
82-63	16113-16115	in	_
82-64	16116-16119	the	_
82-65	16120-16127	patient	_
82-66	16128-16129	’	_
82-67	16130-16131	s	_
82-68	16132-16136	case	_
82-69	16137-16143	report	_
82-70	16144-16148	form	_
82-71	16149-16150	(	_
82-72	16151-16154	CRF	_
82-73	16155-16156	)	_
82-74	16157-16158	.	_

Text=Note that the pharmacological treatment is recorded at baseline for each patient and any change will be recorded in the patient ’ s CRF by the psychiatrist in charge.
83-1	16159-16163	Note	_
83-2	16164-16168	that	_
83-3	16169-16172	the	_
83-4	16173-16188	pharmacological	_
83-5	16189-16198	treatment	_
83-6	16199-16201	is	_
83-7	16202-16210	recorded	_
83-8	16211-16213	at	_
83-9	16214-16222	baseline	_
83-10	16223-16226	for	_
83-11	16227-16231	each	_
83-12	16232-16239	patient	_
83-13	16240-16243	and	_
83-14	16244-16247	any	_
83-15	16248-16254	change	_
83-16	16255-16259	will	_
83-17	16260-16262	be	_
83-18	16263-16271	recorded	_
83-19	16272-16274	in	_
83-20	16275-16278	the	_
83-21	16279-16286	patient	_
83-22	16287-16288	’	_
83-23	16289-16290	s	_
83-24	16291-16294	CRF	_
83-25	16295-16297	by	_
83-26	16298-16301	the	_
83-27	16302-16314	psychiatrist	_
83-28	16315-16317	in	_
83-29	16318-16324	charge	_
83-30	16325-16326	.	_

Text=The Edinburgh handedness inventory will be used to ensure that all patients are right-handed.
84-1	16327-16330	The	_
84-2	16331-16340	Edinburgh	_
84-3	16341-16351	handedness	_
84-4	16352-16361	inventory	_
84-5	16362-16366	will	_
84-6	16367-16369	be	_
84-7	16370-16374	used	_
84-8	16375-16377	to	_
84-9	16378-16384	ensure	_
84-10	16385-16389	that	_
84-11	16390-16393	all	_
84-12	16394-16402	patients	_
84-13	16403-16406	are	_
84-14	16407-16419	right-handed	_
84-15	16420-16421	.	_

Text=Clinical assessments The Auditory Hallucinations Rating Scale (AHRS) is widely used to assess the presence and severity of AVH across seven items investigating frequency, level of reality, loudness, number of voices, length of the content, level of distraction, and distress.
85-1	16422-16430	Clinical	_
85-2	16431-16442	assessments	_
85-3	16443-16446	The	_
85-4	16447-16455	Auditory	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale
85-5	16456-16470	Hallucinations	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale
85-6	16471-16477	Rating	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale
85-7	16478-16483	Scale	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale
85-8	16484-16485	(	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale
85-9	16486-16490	AHRS	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale
85-10	16491-16492	)	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale
85-11	16493-16495	is	_
85-12	16496-16502	widely	_
85-13	16503-16507	used	_
85-14	16508-16510	to	_
85-15	16511-16517	assess	_
85-16	16518-16521	the	_
85-17	16522-16530	presence	_
85-18	16531-16534	and	_
85-19	16535-16543	severity	_
85-20	16544-16546	of	_
85-21	16547-16550	AVH	http://maven.renci.org/NeuroBridge/neurobridge#Thing
85-22	16551-16557	across	_
85-23	16558-16563	seven	_
85-24	16564-16569	items	_
85-25	16570-16583	investigating	_
85-26	16584-16593	frequency	_
85-27	16594-16595	,	_
85-28	16596-16601	level	_
85-29	16602-16604	of	_
85-30	16605-16612	reality	_
85-31	16613-16614	,	_
85-32	16615-16623	loudness	_
85-33	16624-16625	,	_
85-34	16626-16632	number	_
85-35	16633-16635	of	_
85-36	16636-16642	voices	_
85-37	16643-16644	,	_
85-38	16645-16651	length	_
85-39	16652-16654	of	_
85-40	16655-16658	the	_
85-41	16659-16666	content	_
85-42	16667-16668	,	_
85-43	16669-16674	level	_
85-44	16675-16677	of	_
85-45	16678-16689	distraction	_
85-46	16690-16691	,	_
85-47	16692-16695	and	_
85-48	16696-16704	distress	_
85-49	16705-16706	.	_

Text=The HCS is linked to the AHRS and evaluates the percentage of AVH change.
86-1	16707-16710	The	_
86-2	16711-16714	HCS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
86-3	16715-16717	is	_
86-4	16718-16724	linked	_
86-5	16725-16727	to	_
86-6	16728-16731	the	_
86-7	16732-16736	AHRS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
86-8	16737-16740	and	_
86-9	16741-16750	evaluates	_
86-10	16751-16754	the	_
86-11	16755-16765	percentage	_
86-12	16766-16768	of	_
86-13	16769-16772	AVH	_
86-14	16773-16779	change	_
86-15	16780-16781	.	_

Text=On a scale from 0 to 20, a default score of 10 will be attributed to a narrative description of the patient AVH prior to the rTMS sessions (baseline, W0).
87-1	16782-16784	On	_
87-2	16785-16786	a	_
87-3	16787-16792	scale	_
87-4	16793-16797	from	_
87-5	16798-16799	0	_
87-6	16800-16802	to	_
87-7	16803-16805	20	_
87-8	16806-16807	,	_
87-9	16808-16809	a	_
87-10	16810-16817	default	_
87-11	16818-16823	score	_
87-12	16824-16826	of	_
87-13	16827-16829	10	_
87-14	16830-16834	will	_
87-15	16835-16837	be	_
87-16	16838-16848	attributed	_
87-17	16849-16851	to	_
87-18	16852-16853	a	_
87-19	16854-16863	narrative	_
87-20	16864-16875	description	_
87-21	16876-16878	of	_
87-22	16879-16882	the	_
87-23	16883-16890	patient	_
87-24	16891-16894	AVH	_
87-25	16895-16900	prior	_
87-26	16901-16903	to	_
87-27	16904-16907	the	_
87-28	16908-16912	rTMS	_
87-29	16913-16921	sessions	_
87-30	16922-16923	(	_
87-31	16924-16932	baseline	_
87-32	16933-16934	,	_
87-33	16935-16937	W0	_
87-34	16938-16939	)	_
87-35	16940-16941	.	_

Text=For the re-assessment of the AVH following rTMS treatment, scores will be evaluated again, and ascribed lower values (with 0 corresponding to total absence of AVH) if AVH severity decreases, whereas a higher score will be ascribed if AVH severity is worse (with 20 indicating twice the severity of AVH compared to baseline).
88-1	16942-16945	For	_
88-2	16946-16949	the	_
88-3	16950-16963	re-assessment	_
88-4	16964-16966	of	_
88-5	16967-16970	the	_
88-6	16971-16974	AVH	_
88-7	16975-16984	following	_
88-8	16985-16989	rTMS	_
88-9	16990-16999	treatment	_
88-10	17000-17001	,	_
88-11	17002-17008	scores	_
88-12	17009-17013	will	_
88-13	17014-17016	be	_
88-14	17017-17026	evaluated	_
88-15	17027-17032	again	_
88-16	17033-17034	,	_
88-17	17035-17038	and	_
88-18	17039-17047	ascribed	_
88-19	17048-17053	lower	_
88-20	17054-17060	values	_
88-21	17061-17062	(	_
88-22	17063-17067	with	_
88-23	17068-17069	0	_
88-24	17070-17083	corresponding	_
88-25	17084-17086	to	_
88-26	17087-17092	total	_
88-27	17093-17100	absence	_
88-28	17101-17103	of	_
88-29	17104-17107	AVH	_
88-30	17108-17109	)	_
88-31	17110-17112	if	_
88-32	17113-17116	AVH	_
88-33	17117-17125	severity	_
88-34	17126-17135	decreases	_
88-35	17136-17137	,	_
88-36	17138-17145	whereas	_
88-37	17146-17147	a	_
88-38	17148-17154	higher	_
88-39	17155-17160	score	_
88-40	17161-17165	will	_
88-41	17166-17168	be	_
88-42	17169-17177	ascribed	_
88-43	17178-17180	if	_
88-44	17181-17184	AVH	_
88-45	17185-17193	severity	_
88-46	17194-17196	is	_
88-47	17197-17202	worse	_
88-48	17203-17204	(	_
88-49	17205-17209	with	_
88-50	17210-17212	20	_
88-51	17213-17223	indicating	_
88-52	17224-17229	twice	_
88-53	17230-17233	the	_
88-54	17234-17242	severity	_
88-55	17243-17245	of	_
88-56	17246-17249	AVH	_
88-57	17250-17258	compared	_
88-58	17259-17261	to	_
88-59	17262-17270	baseline	_
88-60	17271-17272	)	_
88-61	17273-17274	.	_

Text=The scoring system of the HCS allows estimation of a percentage of AVH change after rTMS treatment.
89-1	17275-17278	The	_
89-2	17279-17286	scoring	_
89-3	17287-17293	system	_
89-4	17294-17296	of	_
89-5	17297-17300	the	_
89-6	17301-17304	HCS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
89-7	17305-17311	allows	_
89-8	17312-17322	estimation	_
89-9	17323-17325	of	_
89-10	17326-17327	a	_
89-11	17328-17338	percentage	_
89-12	17339-17341	of	_
89-13	17342-17345	AVH	_
89-14	17346-17352	change	_
89-15	17353-17358	after	_
89-16	17359-17363	rTMS	_
89-17	17364-17373	treatment	_
89-18	17374-17375	.	_

Text=A score of 5 or less ascribed by the medical evaluator at W3 indicates a decrease of 50% or more of AVH.
90-1	17376-17377	A	_
90-2	17378-17383	score	_
90-3	17384-17386	of	_
90-4	17387-17388	5	_
90-5	17389-17391	or	_
90-6	17392-17396	less	_
90-7	17397-17405	ascribed	_
90-8	17406-17408	by	_
90-9	17409-17412	the	_
90-10	17413-17420	medical	_
90-11	17421-17430	evaluator	_
90-12	17431-17433	at	_
90-13	17434-17436	W3	_
90-14	17437-17446	indicates	_
90-15	17447-17448	a	_
90-16	17449-17457	decrease	_
90-17	17458-17460	of	_
90-18	17461-17463	50	_
90-19	17464-17465	%	_
90-20	17466-17468	or	_
90-21	17469-17473	more	_
90-22	17474-17476	of	_
90-23	17477-17480	AVH	_
90-24	17481-17482	.	_

Text=In this case, the patient will be considered a ‘ responder ’.
91-1	17483-17485	In	_
91-2	17486-17490	this	_
91-3	17491-17495	case	_
91-4	17496-17497	,	_
91-5	17498-17501	the	_
91-6	17502-17509	patient	_
91-7	17510-17514	will	_
91-8	17515-17517	be	_
91-9	17518-17528	considered	_
91-10	17529-17530	a	_
91-11	17531-17532	‘	_
91-12	17533-17542	responder	_
91-13	17543-17544	’	_
91-14	17545-17546	.	_

Text=Otherwise, the patient will be considered a ‘ non-responder ’.
92-1	17547-17556	Otherwise	_
92-2	17557-17558	,	_
92-3	17559-17562	the	_
92-4	17563-17570	patient	_
92-5	17571-17575	will	_
92-6	17576-17578	be	_
92-7	17579-17589	considered	_
92-8	17590-17591	a	_
92-9	17592-17593	‘	_
92-10	17594-17607	non-responder	_
92-11	17608-17609	’	_
92-12	17610-17611	.	_

Text=The AHRS and HCS will be employed to assess the severity of AVH and the efficacy of rTMS therapy.
93-1	17612-17615	The	_
93-2	17616-17620	AHRS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
93-3	17621-17624	and	_
93-4	17625-17628	HCS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
93-5	17629-17633	will	_
93-6	17634-17636	be	_
93-7	17637-17645	employed	_
93-8	17646-17648	to	_
93-9	17649-17655	assess	_
93-10	17656-17659	the	_
93-11	17660-17668	severity	_
93-12	17669-17671	of	_
93-13	17672-17675	AVH	http://maven.renci.org/NeuroBridge/neurobridge#Thing
93-14	17676-17679	and	_
93-15	17680-17683	the	_
93-16	17684-17692	efficacy	_
93-17	17693-17695	of	_
93-18	17696-17700	rTMS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
93-19	17701-17708	therapy	_
93-20	17709-17710	.	_

Text=AHRS and HCS will be recorded at each time point of this study (W0, W3, W7, and W15).
94-1	17711-17715	AHRS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
94-2	17716-17719	and	_
94-3	17720-17723	HCS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
94-4	17724-17728	will	_
94-5	17729-17731	be	_
94-6	17732-17740	recorded	_
94-7	17741-17743	at	_
94-8	17744-17748	each	_
94-9	17749-17753	time	_
94-10	17754-17759	point	_
94-11	17760-17762	of	_
94-12	17763-17767	this	_
94-13	17768-17773	study	_
94-14	17774-17775	(	_
94-15	17776-17778	W0	_
94-16	17779-17780	,	_
94-17	17781-17783	W3	_
94-18	17784-17785	,	_
94-19	17786-17788	W7	_
94-20	17789-17790	,	_
94-21	17791-17794	and	_
94-22	17795-17798	W15	_
94-23	17799-17800	)	_
94-24	17801-17802	.	_

Text=The Positive And Negative Syndrome Scale is a 30-item scale, which is widely used to assess the overall disease severity of schizophrenia such as psychosis-related symptoms (hallucinatory behavior, delusions, emotional withdrawal, stereotyped thinking) and general psychopathology (including ‘ poor attention ’, depression and anxiety).
95-1	17803-17806	The	_
95-2	17807-17815	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
95-3	17816-17819	And	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
95-4	17820-17828	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
95-5	17829-17837	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
95-6	17838-17843	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
95-7	17844-17846	is	_
95-8	17847-17848	a	_
95-9	17849-17856	30-item	_
95-10	17857-17862	scale	_
95-11	17863-17864	,	_
95-12	17865-17870	which	_
95-13	17871-17873	is	_
95-14	17874-17880	widely	_
95-15	17881-17885	used	_
95-16	17886-17888	to	_
95-17	17889-17895	assess	_
95-18	17896-17899	the	_
95-19	17900-17907	overall	_
95-20	17908-17915	disease	_
95-21	17916-17924	severity	_
95-22	17925-17927	of	_
95-23	17928-17941	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
95-24	17942-17946	such	_
95-25	17947-17949	as	_
95-26	17950-17967	psychosis-related	_
95-27	17968-17976	symptoms	_
95-28	17977-17978	(	_
95-29	17979-17992	hallucinatory	_
95-30	17993-18001	behavior	_
95-31	18002-18003	,	_
95-32	18004-18013	delusions	_
95-33	18014-18015	,	_
95-34	18016-18025	emotional	_
95-35	18026-18036	withdrawal	_
95-36	18037-18038	,	_
95-37	18039-18050	stereotyped	_
95-38	18051-18059	thinking	_
95-39	18060-18061	)	_
95-40	18062-18065	and	_
95-41	18066-18073	general	_
95-42	18074-18089	psychopathology	_
95-43	18090-18091	(	_
95-44	18092-18101	including	_
95-45	18102-18103	‘	_
95-46	18104-18108	poor	_
95-47	18109-18118	attention	_
95-48	18119-18120	’	_
95-49	18121-18122	,	_
95-50	18123-18133	depression	_
95-51	18134-18137	and	_
95-52	18138-18145	anxiety	_
95-53	18146-18147	)	_
95-54	18148-18149	.	_

Text=In addition, the Psychotic Symptom Rating Scale (PSYRATS), a 17-item scale, will be employed to evaluate the psychotic symptoms (hallucinations and delusions) and the Scale for the Assessment of Negative Symptoms, a 25-item scale, will be used to assess the negative symptoms in schizophrenia.
96-1	18150-18152	In	_
96-2	18153-18161	addition	_
96-3	18162-18163	,	_
96-4	18164-18167	the	_
96-5	18168-18177	Psychotic	http://maven.renci.org/NeuroBridge/neurobridge#ProdromalSymptomRatingScale
96-6	18178-18185	Symptom	http://maven.renci.org/NeuroBridge/neurobridge#ProdromalSymptomRatingScale
96-7	18186-18192	Rating	http://maven.renci.org/NeuroBridge/neurobridge#ProdromalSymptomRatingScale
96-8	18193-18198	Scale	http://maven.renci.org/NeuroBridge/neurobridge#ProdromalSymptomRatingScale
96-9	18199-18200	(	http://maven.renci.org/NeuroBridge/neurobridge#ProdromalSymptomRatingScale
96-10	18201-18208	PSYRATS	http://maven.renci.org/NeuroBridge/neurobridge#ProdromalSymptomRatingScale
96-11	18209-18210	)	http://maven.renci.org/NeuroBridge/neurobridge#ProdromalSymptomRatingScale
96-12	18211-18212	,	_
96-13	18213-18214	a	_
96-14	18215-18222	17-item	_
96-15	18223-18228	scale	_
96-16	18229-18230	,	_
96-17	18231-18235	will	_
96-18	18236-18238	be	_
96-19	18239-18247	employed	_
96-20	18248-18250	to	_
96-21	18251-18259	evaluate	_
96-22	18260-18263	the	_
96-23	18264-18273	psychotic	_
96-24	18274-18282	symptoms	_
96-25	18283-18284	(	_
96-26	18285-18299	hallucinations	_
96-27	18300-18303	and	_
96-28	18304-18313	delusions	_
96-29	18314-18315	)	_
96-30	18316-18319	and	_
96-31	18320-18323	the	_
96-32	18324-18329	Scale	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
96-33	18330-18333	for	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
96-34	18334-18337	the	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
96-35	18338-18348	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
96-36	18349-18351	of	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
96-37	18352-18360	Negative	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
96-38	18361-18369	Symptoms	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
96-39	18370-18371	,	_
96-40	18372-18373	a	_
96-41	18374-18381	25-item	_
96-42	18382-18387	scale	_
96-43	18388-18389	,	_
96-44	18390-18394	will	_
96-45	18395-18397	be	_
96-46	18398-18402	used	_
96-47	18403-18405	to	_
96-48	18406-18412	assess	_
96-49	18413-18416	the	_
96-50	18417-18425	negative	_
96-51	18426-18434	symptoms	_
96-52	18435-18437	in	_
96-53	18438-18451	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
96-54	18452-18453	.	_

Text=Comorbid depressive symptoms will be investigated with the Beck Depression Inventory, a 13-item, self-report rating inventory and the Calgary Depression Scale for Schizophrenia, a 9-item structured interview scale.
97-1	18454-18462	Comorbid	_
97-2	18463-18473	depressive	_
97-3	18474-18482	symptoms	_
97-4	18483-18487	will	_
97-5	18488-18490	be	_
97-6	18491-18503	investigated	_
97-7	18504-18508	with	_
97-8	18509-18512	the	_
97-9	18513-18517	Beck	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
97-10	18518-18528	Depression	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
97-11	18529-18538	Inventory	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
97-12	18539-18540	,	_
97-13	18541-18542	a	_
97-14	18543-18550	13-item	_
97-15	18551-18552	,	_
97-16	18553-18564	self-report	_
97-17	18565-18571	rating	http://maven.renci.org/NeuroBridge/neurobridge#RatingScale
97-18	18572-18581	inventory	_
97-19	18582-18585	and	_
97-20	18586-18589	the	_
97-21	18590-18597	Calgary	http://maven.renci.org/NeuroBridge/neurobridge#CalgaryDepressionScale
97-22	18598-18608	Depression	http://maven.renci.org/NeuroBridge/neurobridge#CalgaryDepressionScale
97-23	18609-18614	Scale	http://maven.renci.org/NeuroBridge/neurobridge#CalgaryDepressionScale
97-24	18615-18618	for	http://maven.renci.org/NeuroBridge/neurobridge#CalgaryDepressionScale
97-25	18619-18632	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#CalgaryDepressionScale
97-26	18633-18634	,	_
97-27	18635-18636	a	_
97-28	18637-18643	9-item	_
97-29	18644-18654	structured	_
97-30	18655-18664	interview	_
97-31	18665-18670	scale	_
97-32	18671-18672	.	_

Text=Finally, the Short Form (36) Health Survey, a 36-item scale, will be used to obtain a measure of the health-associated quality of life such as physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions.
98-1	18673-18680	Finally	_
98-2	18681-18682	,	_
98-3	18683-18686	the	_
98-4	18687-18692	Short	_
98-5	18693-18697	Form	_
98-6	18698-18699	(	_
98-7	18700-18702	36	_
98-8	18703-18704	)	_
98-9	18705-18711	Health	_
98-10	18712-18718	Survey	_
98-11	18719-18720	,	_
98-12	18721-18722	a	_
98-13	18723-18730	36-item	_
98-14	18731-18736	scale	_
98-15	18737-18738	,	_
98-16	18739-18743	will	_
98-17	18744-18746	be	_
98-18	18747-18751	used	_
98-19	18752-18754	to	_
98-20	18755-18761	obtain	_
98-21	18762-18763	a	_
98-22	18764-18771	measure	_
98-23	18772-18774	of	_
98-24	18775-18778	the	_
98-25	18779-18796	health-associated	_
98-26	18797-18804	quality	_
98-27	18805-18807	of	_
98-28	18808-18812	life	_
98-29	18813-18817	such	_
98-30	18818-18820	as	_
98-31	18821-18829	physical	_
98-32	18830-18841	functioning	_
98-33	18842-18843	,	_
98-34	18844-18850	bodily	_
98-35	18851-18855	pain	_
98-36	18856-18857	,	_
98-37	18858-18862	role	_
98-38	18863-18874	limitations	_
98-39	18875-18878	due	_
98-40	18879-18881	to	_
98-41	18882-18890	physical	_
98-42	18891-18897	health	_
98-43	18898-18906	problems	_
98-44	18907-18908	,	_
98-45	18909-18913	role	_
98-46	18914-18925	limitations	_
98-47	18926-18929	due	_
98-48	18930-18932	to	_
98-49	18933-18941	personal	_
98-50	18942-18944	or	_
98-51	18945-18954	emotional	_
98-52	18955-18963	problems	_
98-53	18964-18965	,	_
98-54	18966-18975	emotional	_
98-55	18976-18986	well-being	_
98-56	18987-18988	,	_
98-57	18989-18995	social	_
98-58	18996-19007	functioning	_
98-59	19008-19009	,	_
98-60	19010-19024	energy/fatigue	_
98-61	19025-19026	,	_
98-62	19027-19030	and	_
98-63	19031-19038	general	_
98-64	19039-19045	health	_
98-65	19046-19057	perceptions	_
98-66	19058-19059	.	_

Text=All of the above clinical scales will be recorded at baseline (W0) and at several stages following the end of the rTMS treatment (W3, W7, and W15).
99-1	19060-19063	All	_
99-2	19064-19066	of	_
99-3	19067-19070	the	_
99-4	19071-19076	above	_
99-5	19077-19085	clinical	_
99-6	19086-19092	scales	_
99-7	19093-19097	will	_
99-8	19098-19100	be	_
99-9	19101-19109	recorded	_
99-10	19110-19112	at	_
99-11	19113-19121	baseline	_
99-12	19122-19123	(	_
99-13	19124-19126	W0	_
99-14	19127-19128	)	_
99-15	19129-19132	and	_
99-16	19133-19135	at	_
99-17	19136-19143	several	_
99-18	19144-19150	stages	_
99-19	19151-19160	following	_
99-20	19161-19164	the	_
99-21	19165-19168	end	_
99-22	19169-19171	of	_
99-23	19172-19175	the	_
99-24	19176-19180	rTMS	_
99-25	19181-19190	treatment	_
99-26	19191-19192	(	_
99-27	19193-19195	W3	_
99-28	19196-19197	,	_
99-29	19198-19200	W7	_
99-30	19201-19202	,	_
99-31	19203-19206	and	_
99-32	19207-19210	W15	_
99-33	19211-19212	)	_
99-34	19213-19214	.	_

Text=More precisely, clinical assessments at W3 will be mainly performed on Tuesday or Wednesday.
100-1	19215-19219	More	_
100-2	19220-19229	precisely	_
100-3	19230-19231	,	_
100-4	19232-19240	clinical	_
100-5	19241-19252	assessments	_
100-6	19253-19255	at	_
100-7	19256-19258	W3	_
100-8	19259-19263	will	_
100-9	19264-19266	be	_
100-10	19267-19273	mainly	_
100-11	19274-19283	performed	_
100-12	19284-19286	on	_
100-13	19287-19294	Tuesday	_
100-14	19295-19297	or	_
100-15	19298-19307	Wednesday	_
100-16	19308-19309	.	_

Text=It will be used to follow symptomatology of schizophrenia across this study and to investigate the impact of rTMS treatment on such symptoms, in particular AVH.
101-1	19310-19312	It	_
101-2	19313-19317	will	_
101-3	19318-19320	be	_
101-4	19321-19325	used	_
101-5	19326-19328	to	_
101-6	19329-19335	follow	_
101-7	19336-19350	symptomatology	_
101-8	19351-19353	of	_
101-9	19354-19367	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
101-10	19368-19374	across	_
101-11	19375-19379	this	_
101-12	19380-19385	study	_
101-13	19386-19389	and	_
101-14	19390-19392	to	_
101-15	19393-19404	investigate	_
101-16	19405-19408	the	_
101-17	19409-19415	impact	_
101-18	19416-19418	of	_
101-19	19419-19423	rTMS	_
101-20	19424-19433	treatment	_
101-21	19434-19436	on	_
101-22	19437-19441	such	_
101-23	19442-19450	symptoms	_
101-24	19451-19452	,	_
101-25	19453-19455	in	_
101-26	19456-19466	particular	_
101-27	19467-19470	AVH	_
101-28	19471-19472	.	_

Text=Moreover, baseline AVH severity levels could also constitute a marker of the rTMS response in schizophrenia patients.
102-1	19473-19481	Moreover	_
102-2	19482-19483	,	_
102-3	19484-19492	baseline	_
102-4	19493-19496	AVH	_
102-5	19497-19505	severity	_
102-6	19506-19512	levels	_
102-7	19513-19518	could	_
102-8	19519-19523	also	_
102-9	19524-19534	constitute	_
102-10	19535-19536	a	_
102-11	19537-19543	marker	_
102-12	19544-19546	of	_
102-13	19547-19550	the	_
102-14	19551-19555	rTMS	_
102-15	19556-19564	response	_
102-16	19565-19567	in	_
102-17	19568-19581	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
102-18	19582-19590	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
102-19	19591-19592	.	_

Text=Neuropsychological assessments A neuropsychological assessment evaluating performance on several cognitive domains (more specifically, executive function, mental flexibility, inhibition, verbal fluency, memory, and writing abilities) will be carried out on each participant.
103-1	19593-19611	Neuropsychological	_
103-2	19612-19623	assessments	_
103-3	19624-19625	A	_
103-4	19626-19644	neuropsychological	_
103-5	19645-19655	assessment	_
103-6	19656-19666	evaluating	_
103-7	19667-19678	performance	_
103-8	19679-19681	on	_
103-9	19682-19689	several	_
103-10	19690-19699	cognitive	_
103-11	19700-19707	domains	_
103-12	19708-19709	(	_
103-13	19710-19714	more	_
103-14	19715-19727	specifically	_
103-15	19728-19729	,	_
103-16	19730-19739	executive	_
103-17	19740-19748	function	_
103-18	19749-19750	,	_
103-19	19751-19757	mental	_
103-20	19758-19769	flexibility	_
103-21	19770-19771	,	_
103-22	19772-19782	inhibition	_
103-23	19783-19784	,	_
103-24	19785-19791	verbal	_
103-25	19792-19799	fluency	_
103-26	19800-19801	,	_
103-27	19802-19808	memory	_
103-28	19809-19810	,	_
103-29	19811-19814	and	_
103-30	19815-19822	writing	_
103-31	19823-19832	abilities	_
103-32	19833-19834	)	_
103-33	19835-19839	will	_
103-34	19840-19842	be	_
103-35	19843-19850	carried	_
103-36	19851-19854	out	_
103-37	19855-19857	on	_
103-38	19858-19862	each	_
103-39	19863-19874	participant	_
103-40	19875-19876	.	_

Text=These data recorded at baseline (W0) will be used to evaluate cognitive impairment and identify potential neuropsychological markers associated with rTMS response.
104-1	19877-19882	These	_
104-2	19883-19887	data	_
104-3	19888-19896	recorded	_
104-4	19897-19899	at	_
104-5	19900-19908	baseline	_
104-6	19909-19910	(	_
104-7	19911-19913	W0	_
104-8	19914-19915	)	_
104-9	19916-19920	will	_
104-10	19921-19923	be	_
104-11	19924-19928	used	_
104-12	19929-19931	to	_
104-13	19932-19940	evaluate	_
104-14	19941-19950	cognitive	_
104-15	19951-19961	impairment	_
104-16	19962-19965	and	_
104-17	19966-19974	identify	_
104-18	19975-19984	potential	_
104-19	19985-20003	neuropsychological	_
104-20	20004-20011	markers	_
104-21	20012-20022	associated	_
104-22	20023-20027	with	_
104-23	20028-20032	rTMS	_
104-24	20033-20041	response	_
104-25	20042-20043	.	_

Text=Carried out in the post rTMS period, this assessment will also allow study of the impact of multiday rTMS regime on cognitive function.
105-1	20044-20051	Carried	_
105-2	20052-20055	out	_
105-3	20056-20058	in	_
105-4	20059-20062	the	_
105-5	20063-20067	post	_
105-6	20068-20072	rTMS	_
105-7	20073-20079	period	_
105-8	20080-20081	,	_
105-9	20082-20086	this	_
105-10	20087-20097	assessment	_
105-11	20098-20102	will	_
105-12	20103-20107	also	_
105-13	20108-20113	allow	_
105-14	20114-20119	study	_
105-15	20120-20122	of	_
105-16	20123-20126	the	_
105-17	20127-20133	impact	_
105-18	20134-20136	of	_
105-19	20137-20145	multiday	_
105-20	20146-20150	rTMS	_
105-21	20151-20157	regime	_
105-22	20158-20160	on	_
105-23	20161-20170	cognitive	_
105-24	20171-20179	function	_
105-25	20180-20181	.	_

Text=The assessment will be performed prior (W0) and, most importantly, at several intervals following the end of the rTMS regime (W3, W7, and W15).
106-1	20182-20185	The	_
106-2	20186-20196	assessment	_
106-3	20197-20201	will	_
106-4	20202-20204	be	_
106-5	20205-20214	performed	_
106-6	20215-20220	prior	_
106-7	20221-20222	(	_
106-8	20223-20225	W0	_
106-9	20226-20227	)	_
106-10	20228-20231	and	_
106-11	20232-20233	,	_
106-12	20234-20238	most	_
106-13	20239-20250	importantly	_
106-14	20251-20252	,	_
106-15	20253-20255	at	_
106-16	20256-20263	several	_
106-17	20264-20273	intervals	_
106-18	20274-20283	following	_
106-19	20284-20287	the	_
106-20	20288-20291	end	_
106-21	20292-20294	of	_
106-22	20295-20298	the	_
106-23	20299-20303	rTMS	_
106-24	20304-20310	regime	_
106-25	20311-20312	(	_
106-26	20313-20315	W3	_
106-27	20316-20317	,	_
106-28	20318-20320	W7	_
106-29	20321-20322	,	_
106-30	20323-20326	and	_
106-31	20327-20330	W15	_
106-32	20331-20332	)	_
106-33	20333-20334	.	_

Text=It will include the following tasks: the Trail Making Test A and B, the Stroop test, the Hanoi Tower, the Wisconsin Card Sorting Test, a Verbal Fluency task, the California Verbal Learning test, the Digit Span and Visual Memory tests, an autobiographical memory task, and a dictation writing task.
107-1	20335-20337	It	_
107-2	20338-20342	will	_
107-3	20343-20350	include	_
107-4	20351-20354	the	_
107-5	20355-20364	following	_
107-6	20365-20370	tasks	_
107-7	20371-20372	:	_
107-8	20373-20376	the	_
107-9	20377-20382	Trail	http://maven.renci.org/NeuroBridge/neurobridge#ExtrapyramidalSymptomRating
107-10	20383-20389	Making	http://maven.renci.org/NeuroBridge/neurobridge#ExtrapyramidalSymptomRating
107-11	20390-20394	Test	http://maven.renci.org/NeuroBridge/neurobridge#ExtrapyramidalSymptomRating
107-12	20395-20396	A	http://maven.renci.org/NeuroBridge/neurobridge#ExtrapyramidalSymptomRating
107-13	20397-20400	and	http://maven.renci.org/NeuroBridge/neurobridge#ExtrapyramidalSymptomRating
107-14	20401-20402	B	http://maven.renci.org/NeuroBridge/neurobridge#ExtrapyramidalSymptomRating
107-15	20403-20404	,	_
107-16	20405-20408	the	_
107-17	20409-20415	Stroop	http://maven.renci.org/NeuroBridge/neurobridge#GlucoseToleranceTest
107-18	20416-20420	test	http://maven.renci.org/NeuroBridge/neurobridge#GlucoseToleranceTest
107-19	20421-20422	,	_
107-20	20423-20426	the	_
107-21	20427-20432	Hanoi	_
107-22	20433-20438	Tower	_
107-23	20439-20440	,	_
107-24	20441-20444	the	_
107-25	20445-20454	Wisconsin	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale
107-26	20455-20459	Card	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale
107-27	20460-20467	Sorting	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale
107-28	20468-20472	Test	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale
107-29	20473-20474	,	_
107-30	20475-20476	a	_
107-31	20477-20483	Verbal	http://maven.renci.org/NeuroBridge/neurobridge#VerbalFluencyTask
107-32	20484-20491	Fluency	http://maven.renci.org/NeuroBridge/neurobridge#VerbalFluencyTask
107-33	20492-20496	task	http://maven.renci.org/NeuroBridge/neurobridge#VerbalFluencyTask
107-34	20497-20498	,	_
107-35	20499-20502	the	_
107-36	20503-20513	California	http://maven.renci.org/NeuroBridge/neurobridge#II
107-37	20514-20520	Verbal	http://maven.renci.org/NeuroBridge/neurobridge#II
107-38	20521-20529	Learning	http://maven.renci.org/NeuroBridge/neurobridge#II
107-39	20530-20534	test	http://maven.renci.org/NeuroBridge/neurobridge#II
107-40	20535-20536	,	_
107-41	20537-20540	the	_
107-42	20541-20546	Digit	http://maven.renci.org/NeuroBridge/neurobridge#NeurocognitiveTest
107-43	20547-20551	Span	http://maven.renci.org/NeuroBridge/neurobridge#NeurocognitiveTest
107-44	20552-20555	and	http://maven.renci.org/NeuroBridge/neurobridge#NeurocognitiveTest
107-45	20556-20562	Visual	http://maven.renci.org/NeuroBridge/neurobridge#NeurocognitiveTest
107-46	20563-20569	Memory	http://maven.renci.org/NeuroBridge/neurobridge#NeurocognitiveTest
107-47	20570-20575	tests	http://maven.renci.org/NeuroBridge/neurobridge#NeurocognitiveTest
107-48	20576-20577	,	_
107-49	20578-20580	an	_
107-50	20581-20597	autobiographical	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask
107-51	20598-20604	memory	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask
107-52	20605-20609	task	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask
107-53	20610-20611	,	_
107-54	20612-20615	and	_
107-55	20616-20617	a	_
107-56	20618-20627	dictation	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
107-57	20628-20635	writing	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
107-58	20636-20640	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
107-59	20641-20642	.	_

Text=Neurophysiological assessments Before and after rTMS treatment, cortical excitability measures will be assessed for each patient using a standard 70 mm figure-of-eight coil (MCF-B65 Butterfly Coil, MagVenture A/S, Farum, Denmark) attached to a MagPro R30 stimulator with MagOption (Medtronic A/S, Copenhagen, Denmark).
108-1	20643-20661	Neurophysiological	_
108-2	20662-20673	assessments	_
108-3	20674-20680	Before	_
108-4	20681-20684	and	_
108-5	20685-20690	after	_
108-6	20691-20695	rTMS	_
108-7	20696-20705	treatment	_
108-8	20706-20707	,	_
108-9	20708-20716	cortical	_
108-10	20717-20729	excitability	_
108-11	20730-20738	measures	_
108-12	20739-20743	will	_
108-13	20744-20746	be	_
108-14	20747-20755	assessed	_
108-15	20756-20759	for	_
108-16	20760-20764	each	_
108-17	20765-20772	patient	_
108-18	20773-20778	using	_
108-19	20779-20780	a	_
108-20	20781-20789	standard	_
108-21	20790-20792	70	_
108-22	20793-20795	mm	_
108-23	20796-20811	figure-of-eight	_
108-24	20812-20816	coil	_
108-25	20817-20818	(	_
108-26	20819-20826	MCF-B65	_
108-27	20827-20836	Butterfly	_
108-28	20837-20841	Coil	_
108-29	20842-20843	,	_
108-30	20844-20854	MagVenture	_
108-31	20855-20858	A/S	_
108-32	20859-20860	,	_
108-33	20861-20866	Farum	_
108-34	20867-20868	,	_
108-35	20869-20876	Denmark	_
108-36	20877-20878	)	_
108-37	20879-20887	attached	_
108-38	20888-20890	to	_
108-39	20891-20892	a	_
108-40	20893-20899	MagPro	_
108-41	20900-20903	R30	_
108-42	20904-20914	stimulator	_
108-43	20915-20919	with	_
108-44	20920-20929	MagOption	_
108-45	20930-20931	(	_
108-46	20932-20941	Medtronic	_
108-47	20942-20945	A/S	_
108-48	20946-20947	,	_
108-49	20948-20958	Copenhagen	_
108-50	20959-20960	,	_
108-51	20961-20968	Denmark	_
108-52	20969-20970	)	_
108-53	20971-20972	.	_

Text=The MT will be assessed using the TMS Motor Threshold Assessment Tool (MTAT 2.0, http: //www.clinicalresearcher.org/software.htm).
109-1	20973-20976	The	_
109-2	20977-20979	MT	_
109-3	20980-20984	will	_
109-4	20985-20987	be	_
109-5	20988-20996	assessed	_
109-6	20997-21002	using	_
109-7	21003-21006	the	_
109-8	21007-21010	TMS	http://maven.renci.org/NeuroBridge/neurobridge#MotorSkillDisorder
109-9	21011-21016	Motor	http://maven.renci.org/NeuroBridge/neurobridge#MotorSkillDisorder
109-10	21017-21026	Threshold	http://maven.renci.org/NeuroBridge/neurobridge#MotorSkillDisorder
109-11	21027-21037	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#MotorSkillDisorder
109-12	21038-21042	Tool	_
109-13	21043-21044	(	_
109-14	21045-21049	MTAT	_
109-15	21050-21053	2.0	_
109-16	21054-21055	,	_
109-17	21056-21060	http	_
109-18	21061-21062	:	_
109-19	21063-21104	//www.clinicalresearcher.org/software.htm	_
109-20	21105-21106	)	_
109-21	21107-21108	.	_

Text=Self-adhesive, solid gel-coated disposable Ag/AgCl surface electrodes placed on the first dorsal interosseous hand muscle will be employed to record these measures.
110-1	21109-21122	Self-adhesive	_
110-2	21123-21124	,	_
110-3	21125-21130	solid	_
110-4	21131-21141	gel-coated	_
110-5	21142-21152	disposable	_
110-6	21153-21160	Ag/AgCl	_
110-7	21161-21168	surface	_
110-8	21169-21179	electrodes	_
110-9	21180-21186	placed	_
110-10	21187-21189	on	_
110-11	21190-21193	the	_
110-12	21194-21199	first	_
110-13	21200-21206	dorsal	_
110-14	21207-21219	interosseous	_
110-15	21220-21224	hand	_
110-16	21225-21231	muscle	_
110-17	21232-21236	will	_
110-18	21237-21239	be	_
110-19	21240-21248	employed	_
110-20	21249-21251	to	_
110-21	21252-21258	record	_
110-22	21259-21264	these	_
110-23	21265-21273	measures	_
110-24	21274-21275	.	_

Text=Peak-to-peak MEP amplitudes will be recorded at 120% of the individual MT.
111-1	21276-21288	Peak-to-peak	_
111-2	21289-21292	MEP	_
111-3	21293-21303	amplitudes	_
111-4	21304-21308	will	_
111-5	21309-21311	be	_
111-6	21312-21320	recorded	_
111-7	21321-21323	at	_
111-8	21324-21327	120	_
111-9	21328-21329	%	_
111-10	21330-21332	of	_
111-11	21333-21336	the	_
111-12	21337-21347	individual	_
111-13	21348-21350	MT	_
111-14	21351-21352	.	_

Text=Moreover, several neuroexcitability abnormalities have been described in schizophrenia patients, essentially in cortical inhibition.
112-1	21353-21361	Moreover	_
112-2	21362-21363	,	_
112-3	21364-21371	several	_
112-4	21372-21389	neuroexcitability	_
112-5	21390-21403	abnormalities	_
112-6	21404-21408	have	_
112-7	21409-21413	been	_
112-8	21414-21423	described	_
112-9	21424-21426	in	_
112-10	21427-21440	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
112-11	21441-21449	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
112-12	21450-21451	,	_
112-13	21452-21463	essentially	_
112-14	21464-21466	in	_
112-15	21467-21475	cortical	_
112-16	21476-21486	inhibition	_
112-17	21487-21488	.	_

Text=A deficit of intracortical inhibition (ICI) is the most robust finding in this patient population, whereas deficits of the cortical silent period (CSP) and MT have been reported inconsistently.
113-1	21489-21490	A	_
113-2	21491-21498	deficit	_
113-3	21499-21501	of	_
113-4	21502-21515	intracortical	_
113-5	21516-21526	inhibition	_
113-6	21527-21528	(	_
113-7	21529-21532	ICI	_
113-8	21533-21534	)	_
113-9	21535-21537	is	_
113-10	21538-21541	the	_
113-11	21542-21546	most	_
113-12	21547-21553	robust	_
113-13	21554-21561	finding	_
113-14	21562-21564	in	_
113-15	21565-21569	this	_
113-16	21570-21577	patient	_
113-17	21578-21588	population	_
113-18	21589-21590	,	_
113-19	21591-21598	whereas	_
113-20	21599-21607	deficits	_
113-21	21608-21610	of	_
113-22	21611-21614	the	_
113-23	21615-21623	cortical	_
113-24	21624-21630	silent	_
113-25	21631-21637	period	_
113-26	21638-21639	(	_
113-27	21640-21643	CSP	_
113-28	21644-21645	)	_
113-29	21646-21649	and	_
113-30	21650-21652	MT	_
113-31	21653-21657	have	_
113-32	21658-21662	been	_
113-33	21663-21671	reported	_
113-34	21672-21686	inconsistently	_
113-35	21687-21688	.	_

Text=In our protocol, the CSP, ICI, and intracortical facilitation (ICF) will also be recorded to monitor potential motor intracortical changes following the rTMS treatment over the left TPJ.
114-1	21689-21691	In	_
114-2	21692-21695	our	_
114-3	21696-21704	protocol	_
114-4	21705-21706	,	_
114-5	21707-21710	the	_
114-6	21711-21714	CSP	_
114-7	21715-21716	,	_
114-8	21717-21720	ICI	_
114-9	21721-21722	,	_
114-10	21723-21726	and	_
114-11	21727-21740	intracortical	_
114-12	21741-21753	facilitation	_
114-13	21754-21755	(	_
114-14	21756-21759	ICF	_
114-15	21760-21761	)	_
114-16	21762-21766	will	_
114-17	21767-21771	also	_
114-18	21772-21774	be	_
114-19	21775-21783	recorded	_
114-20	21784-21786	to	_
114-21	21787-21794	monitor	_
114-22	21795-21804	potential	_
114-23	21805-21810	motor	_
114-24	21811-21824	intracortical	_
114-25	21825-21832	changes	_
114-26	21833-21842	following	_
114-27	21843-21846	the	_
114-28	21847-21851	rTMS	_
114-29	21852-21861	treatment	_
114-30	21862-21866	over	_
114-31	21867-21870	the	_
114-32	21871-21875	left	_
114-33	21876-21879	TPJ	_
114-34	21880-21881	.	_

Text=To this regard, a recent clinical case reported indirect signs of clinical improvement and motor excitability changes via CSP in a pontine stroke patient after rTMS treatment delivered over the left TPJ to treat their AVH.
115-1	21882-21884	To	_
115-2	21885-21889	this	_
115-3	21890-21896	regard	_
115-4	21897-21898	,	_
115-5	21899-21900	a	_
115-6	21901-21907	recent	_
115-7	21908-21916	clinical	_
115-8	21917-21921	case	_
115-9	21922-21930	reported	_
115-10	21931-21939	indirect	_
115-11	21940-21945	signs	_
115-12	21946-21948	of	_
115-13	21949-21957	clinical	_
115-14	21958-21969	improvement	_
115-15	21970-21973	and	_
115-16	21974-21979	motor	_
115-17	21980-21992	excitability	_
115-18	21993-22000	changes	_
115-19	22001-22004	via	_
115-20	22005-22008	CSP	_
115-21	22009-22011	in	_
115-22	22012-22013	a	_
115-23	22014-22021	pontine	_
115-24	22022-22028	stroke	_
115-25	22029-22036	patient	_
115-26	22037-22042	after	_
115-27	22043-22047	rTMS	_
115-28	22048-22057	treatment	_
115-29	22058-22067	delivered	_
115-30	22068-22072	over	_
115-31	22073-22076	the	_
115-32	22077-22081	left	_
115-33	22082-22085	TPJ	_
115-34	22086-22088	to	_
115-35	22089-22094	treat	_
115-36	22095-22100	their	_
115-37	22101-22104	AVH	_
115-38	22105-22106	.	_

Text=The CSP will be evoked by applying TMS intensity at 120% of the individual MT while patients will perform a hand isometric contraction of approximately 50% of their maximum force.
116-1	22107-22110	The	_
116-2	22111-22114	CSP	_
116-3	22115-22119	will	_
116-4	22120-22122	be	_
116-5	22123-22129	evoked	_
116-6	22130-22132	by	_
116-7	22133-22141	applying	_
116-8	22142-22145	TMS	_
116-9	22146-22155	intensity	_
116-10	22156-22158	at	_
116-11	22159-22162	120	_
116-12	22163-22164	%	_
116-13	22165-22167	of	_
116-14	22168-22171	the	_
116-15	22172-22182	individual	_
116-16	22183-22185	MT	_
116-17	22186-22191	while	_
116-18	22192-22200	patients	_
116-19	22201-22205	will	_
116-20	22206-22213	perform	_
116-21	22214-22215	a	_
116-22	22216-22220	hand	_
116-23	22221-22230	isometric	_
116-24	22231-22242	contraction	_
116-25	22243-22245	of	_
116-26	22246-22259	approximately	_
116-27	22260-22262	50	_
116-28	22263-22264	%	_
116-29	22265-22267	of	_
116-30	22268-22273	their	_
116-31	22274-22281	maximum	_
116-32	22282-22287	force	_
116-33	22288-22289	.	_

Text=The duration of the CSP will be measured from the end of MEP until the re-occurrence of EMG activity.
117-1	22290-22293	The	_
117-2	22294-22302	duration	_
117-3	22303-22305	of	_
117-4	22306-22309	the	_
117-5	22310-22313	CSP	_
117-6	22314-22318	will	_
117-7	22319-22321	be	_
117-8	22322-22330	measured	_
117-9	22331-22335	from	_
117-10	22336-22339	the	_
117-11	22340-22343	end	_
117-12	22344-22346	of	_
117-13	22347-22350	MEP	_
117-14	22351-22356	until	_
117-15	22357-22360	the	_
117-16	22361-22374	re-occurrence	_
117-17	22375-22377	of	_
117-18	22378-22381	EMG	_
117-19	22382-22390	activity	_
117-20	22391-22392	.	_

Text=ICI and ICF will be determined using a paired-pulse paradigm.
118-1	22393-22396	ICI	_
118-2	22397-22400	and	_
118-3	22401-22404	ICF	_
118-4	22405-22409	will	_
118-5	22410-22412	be	_
118-6	22413-22423	determined	_
118-7	22424-22429	using	_
118-8	22430-22431	a	_
118-9	22432-22444	paired-pulse	_
118-10	22445-22453	paradigm	_
118-11	22454-22455	.	_

Text=The conditioning subthreshold stimulus, which will be set at 80% of MT, will be preceded by a suprathreshold stimulus test at 120% of the MT.
119-1	22456-22459	The	_
119-2	22460-22472	conditioning	_
119-3	22473-22485	subthreshold	_
119-4	22486-22494	stimulus	_
119-5	22495-22496	,	_
119-6	22497-22502	which	_
119-7	22503-22507	will	_
119-8	22508-22510	be	_
119-9	22511-22514	set	_
119-10	22515-22517	at	_
119-11	22518-22520	80	_
119-12	22521-22522	%	_
119-13	22523-22525	of	_
119-14	22526-22528	MT	_
119-15	22529-22530	,	_
119-16	22531-22535	will	_
119-17	22536-22538	be	_
119-18	22539-22547	preceded	_
119-19	22548-22550	by	_
119-20	22551-22552	a	_
119-21	22553-22567	suprathreshold	_
119-22	22568-22576	stimulus	_
119-23	22577-22581	test	_
119-24	22582-22584	at	_
119-25	22585-22588	120	_
119-26	22589-22590	%	_
119-27	22591-22593	of	_
119-28	22594-22597	the	_
119-29	22598-22600	MT	_
119-30	22601-22602	.	_

Text=Interstimulus intervals will be set at 2 and 4 ms for ICI and at 10 and 15 ms for ICF.
120-1	22603-22616	Interstimulus	_
120-2	22617-22626	intervals	_
120-3	22627-22631	will	_
120-4	22632-22634	be	_
120-5	22635-22638	set	_
120-6	22639-22641	at	_
120-7	22642-22643	2	_
120-8	22644-22647	and	_
120-9	22648-22649	4	_
120-10	22650-22652	ms	_
120-11	22653-22656	for	_
120-12	22657-22660	ICI	_
120-13	22661-22664	and	_
120-14	22665-22667	at	_
120-15	22668-22670	10	_
120-16	22671-22674	and	_
120-17	22675-22677	15	_
120-18	22678-22680	ms	_
120-19	22681-22684	for	_
120-20	22685-22688	ICF	_
120-21	22689-22690	.	_

Text=The EMG activity will be recorded by a computer using System PLUS EVOLUTION software (version 1.04, Micromed, Mâcon, France).
121-1	22691-22694	The	_
121-2	22695-22698	EMG	_
121-3	22699-22707	activity	_
121-4	22708-22712	will	_
121-5	22713-22715	be	_
121-6	22716-22724	recorded	_
121-7	22725-22727	by	_
121-8	22728-22729	a	_
121-9	22730-22738	computer	_
121-10	22739-22744	using	_
121-11	22745-22751	System	_
121-12	22752-22756	PLUS	_
121-13	22757-22766	EVOLUTION	_
121-14	22767-22775	software	_
121-15	22776-22777	(	_
121-16	22778-22785	version	_
121-17	22786-22790	1.04	_
121-18	22791-22792	,	_
121-19	22793-22801	Micromed	_
121-20	22802-22803	,	_
121-21	22804-22809	Mâcon	_
121-22	22810-22811	,	_
121-23	22812-22818	France	_
121-24	22819-22820	)	_
121-25	22821-22822	.	_

Text=The MEPs amplitude at 120% of the MT as well as CSP, ICI, and ICF will be obtained prior (W0) and following the rTMS treatment (W3, W7 and W15) and will be used to estimate individual levels of motor cortical excitability between ‘ responder ’ and ‘ non-responder ’ patients, monitoring potential changes of such across treatment and during follow-up.
122-1	22823-22826	The	_
122-2	22827-22831	MEPs	_
122-3	22832-22841	amplitude	_
122-4	22842-22844	at	_
122-5	22845-22848	120	_
122-6	22849-22850	%	_
122-7	22851-22853	of	_
122-8	22854-22857	the	_
122-9	22858-22860	MT	_
122-10	22861-22863	as	_
122-11	22864-22868	well	_
122-12	22869-22871	as	_
122-13	22872-22875	CSP	_
122-14	22876-22877	,	_
122-15	22878-22881	ICI	_
122-16	22882-22883	,	_
122-17	22884-22887	and	_
122-18	22888-22891	ICF	_
122-19	22892-22896	will	_
122-20	22897-22899	be	_
122-21	22900-22908	obtained	_
122-22	22909-22914	prior	_
122-23	22915-22916	(	_
122-24	22917-22919	W0	_
122-25	22920-22921	)	_
122-26	22922-22925	and	_
122-27	22926-22935	following	_
122-28	22936-22939	the	_
122-29	22940-22944	rTMS	_
122-30	22945-22954	treatment	_
122-31	22955-22956	(	_
122-32	22957-22959	W3	_
122-33	22960-22961	,	_
122-34	22962-22964	W7	_
122-35	22965-22968	and	_
122-36	22969-22972	W15	_
122-37	22973-22974	)	_
122-38	22975-22978	and	_
122-39	22979-22983	will	_
122-40	22984-22986	be	_
122-41	22987-22991	used	_
122-42	22992-22994	to	_
122-43	22995-23003	estimate	_
122-44	23004-23014	individual	_
122-45	23015-23021	levels	_
122-46	23022-23024	of	_
122-47	23025-23030	motor	_
122-48	23031-23039	cortical	_
122-49	23040-23052	excitability	_
122-50	23053-23060	between	_
122-51	23061-23062	‘	_
122-52	23063-23072	responder	_
122-53	23073-23074	’	_
122-54	23075-23078	and	_
122-55	23079-23080	‘	_
122-56	23081-23094	non-responder	_
122-57	23095-23096	’	_
122-58	23097-23105	patients	_
122-59	23106-23107	,	_
122-60	23108-23118	monitoring	_
122-61	23119-23128	potential	_
122-62	23129-23136	changes	_
122-63	23137-23139	of	_
122-64	23140-23144	such	_
122-65	23145-23151	across	_
122-66	23152-23161	treatment	_
122-67	23162-23165	and	_
122-68	23166-23172	during	_
122-69	23173-23182	follow-up	_
122-70	23183-23184	.	_

Text=Electrophysiological measures comparing pre versus post rTMS between ‘ responders ’ and ‘ non-responders ’ could constitute a potential explanatory marker informing on rTMS mechanism of action.
123-1	23185-23205	Electrophysiological	_
123-2	23206-23214	measures	_
123-3	23215-23224	comparing	_
123-4	23225-23228	pre	_
123-5	23229-23235	versus	_
123-6	23236-23240	post	_
123-7	23241-23245	rTMS	_
123-8	23246-23253	between	_
123-9	23254-23255	‘	_
123-10	23256-23266	responders	_
123-11	23267-23268	’	_
123-12	23269-23272	and	_
123-13	23273-23274	‘	_
123-14	23275-23289	non-responders	_
123-15	23290-23291	’	_
123-16	23292-23297	could	_
123-17	23298-23308	constitute	_
123-18	23309-23310	a	_
123-19	23311-23320	potential	_
123-20	23321-23332	explanatory	_
123-21	23333-23339	marker	_
123-22	23340-23349	informing	_
123-23	23350-23352	on	_
123-24	23353-23357	rTMS	_
123-25	23358-23367	mechanism	_
123-26	23368-23370	of	_
123-27	23371-23377	action	_
123-28	23378-23379	.	_

Text=Biological measures from blood samples Brain-derived neurotrophic factor (BDNF) is a neurotrophin that plays a key role in neuronal survival and synaptic plasticity (i.e.
124-1	23380-23390	Biological	_
124-2	23391-23399	measures	_
124-3	23400-23404	from	_
124-4	23405-23410	blood	_
124-5	23411-23418	samples	_
124-6	23419-23432	Brain-derived	_
124-7	23433-23445	neurotrophic	_
124-8	23446-23452	factor	_
124-9	23453-23454	(	_
124-10	23455-23459	BDNF	_
124-11	23460-23461	)	_
124-12	23462-23464	is	_
124-13	23465-23466	a	_
124-14	23467-23479	neurotrophin	_
124-15	23480-23484	that	_
124-16	23485-23490	plays	_
124-17	23491-23492	a	_
124-18	23493-23496	key	_
124-19	23497-23501	role	_
124-20	23502-23504	in	_
124-21	23505-23513	neuronal	_
124-22	23514-23522	survival	_
124-23	23523-23526	and	_
124-24	23527-23535	synaptic	_
124-25	23536-23546	plasticity	_
124-26	23547-23548	(	_
124-27	23549-23552	i.e	_
124-28	23553-23554	.	_

Text=morphological and physiological changes of synapses induced by neuronal activity changes).
125-1	23555-23568	morphological	_
125-2	23569-23572	and	_
125-3	23573-23586	physiological	_
125-4	23587-23594	changes	_
125-5	23595-23597	of	_
125-6	23598-23606	synapses	_
125-7	23607-23614	induced	_
125-8	23615-23617	by	_
125-9	23618-23626	neuronal	_
125-10	23627-23635	activity	_
125-11	23636-23643	changes	_
125-12	23644-23645	)	_
125-13	23646-23647	.	_

Text=BDNF levels may reflect a decrease or increase of brain activity and provide a potential explanatory marker of rTMS effects.
126-1	23648-23652	BDNF	_
126-2	23653-23659	levels	_
126-3	23660-23663	may	_
126-4	23664-23671	reflect	_
126-5	23672-23673	a	_
126-6	23674-23682	decrease	_
126-7	23683-23685	or	_
126-8	23686-23694	increase	_
126-9	23695-23697	of	_
126-10	23698-23703	brain	_
126-11	23704-23712	activity	_
126-12	23713-23716	and	_
126-13	23717-23724	provide	_
126-14	23725-23726	a	_
126-15	23727-23736	potential	_
126-16	23737-23748	explanatory	_
126-17	23749-23755	marker	_
126-18	23756-23758	of	_
126-19	23759-23763	rTMS	_
126-20	23764-23771	effects	_
126-21	23772-23773	.	_

Text=Serum BDNF levels will be measured and compared between ‘ responder ’ versus ‘ non-responder ’ patient groups and also between active rTMS versus sham rTMS stimulated groups of patients.
127-1	23774-23779	Serum	_
127-2	23780-23784	BDNF	_
127-3	23785-23791	levels	_
127-4	23792-23796	will	_
127-5	23797-23799	be	_
127-6	23800-23808	measured	_
127-7	23809-23812	and	_
127-8	23813-23821	compared	_
127-9	23822-23829	between	_
127-10	23830-23831	‘	_
127-11	23832-23841	responder	_
127-12	23842-23843	’	_
127-13	23844-23850	versus	_
127-14	23851-23852	‘	_
127-15	23853-23866	non-responder	_
127-16	23867-23868	’	_
127-17	23869-23876	patient	_
127-18	23877-23883	groups	_
127-19	23884-23887	and	_
127-20	23888-23892	also	_
127-21	23893-23900	between	_
127-22	23901-23907	active	_
127-23	23908-23912	rTMS	_
127-24	23913-23919	versus	_
127-25	23920-23924	sham	_
127-26	23925-23929	rTMS	_
127-27	23930-23940	stimulated	_
127-28	23941-23947	groups	_
127-29	23948-23950	of	_
127-30	23951-23959	patients	_
127-31	23960-23961	.	_

Text=This will allow investigation of rTMS-induced brain plasticity changes.
128-1	23962-23966	This	_
128-2	23967-23971	will	_
128-3	23972-23977	allow	_
128-4	23978-23991	investigation	_
128-5	23992-23994	of	_
128-6	23995-24007	rTMS-induced	_
128-7	24008-24013	brain	_
128-8	24014-24024	plasticity	_
128-9	24025-24032	changes	_
128-10	24033-24034	.	_

Text=To this end, blood samples will be collected from all patients in the morning (before 10:00 a.m.) at baseline (W0) and after the end of the regime (W3, W7, and W15) in a 3.5 mL serum separator tube (SST™ II Advance, BD Vacutainer®, New Jersey, USA).
129-1	24035-24037	To	_
129-2	24038-24042	this	_
129-3	24043-24046	end	_
129-4	24047-24048	,	_
129-5	24049-24054	blood	_
129-6	24055-24062	samples	_
129-7	24063-24067	will	_
129-8	24068-24070	be	_
129-9	24071-24080	collected	_
129-10	24081-24085	from	_
129-11	24086-24089	all	_
129-12	24090-24098	patients	_
129-13	24099-24101	in	_
129-14	24102-24105	the	_
129-15	24106-24113	morning	_
129-16	24114-24115	(	_
129-17	24116-24122	before	_
129-18	24123-24128	10:00	_
129-19	24129-24133	a.m.	_
129-20	24134-24135	)	_
129-21	24136-24138	at	_
129-22	24139-24147	baseline	_
129-23	24148-24149	(	_
129-24	24150-24152	W0	_
129-25	24153-24154	)	_
129-26	24155-24158	and	_
129-27	24159-24164	after	_
129-28	24165-24168	the	_
129-29	24169-24172	end	_
129-30	24173-24175	of	_
129-31	24176-24179	the	_
129-32	24180-24186	regime	_
129-33	24187-24188	(	_
129-34	24189-24191	W3	_
129-35	24192-24193	,	_
129-36	24194-24196	W7	_
129-37	24197-24198	,	_
129-38	24199-24202	and	_
129-39	24203-24206	W15	_
129-40	24207-24208	)	_
129-41	24209-24211	in	_
129-42	24212-24213	a	_
129-43	24214-24217	3.5	_
129-44	24218-24220	mL	_
129-45	24221-24226	serum	_
129-46	24227-24236	separator	_
129-47	24237-24241	tube	_
129-48	24242-24243	(	_
129-49	24244-24248	SST™	_
129-50	24249-24251	II	_
129-51	24252-24259	Advance	_
129-52	24260-24261	,	_
129-53	24262-24264	BD	_
129-54	24265-24276	Vacutainer®	_
129-55	24277-24278	,	_
129-56	24279-24282	New	_
129-57	24283-24289	Jersey	_
129-58	24290-24291	,	_
129-59	24292-24295	USA	_
129-60	24296-24297	)	_
129-61	24298-24299	.	_

Text=Blood samples will be stored at room temperature for 20 min, then centrifuged at 3500 rpm at 4 °C for 20 min.
130-1	24300-24305	Blood	_
130-2	24306-24313	samples	_
130-3	24314-24318	will	_
130-4	24319-24321	be	_
130-5	24322-24328	stored	_
130-6	24329-24331	at	_
130-7	24332-24336	room	_
130-8	24337-24348	temperature	_
130-9	24349-24352	for	_
130-10	24353-24355	20	_
130-11	24356-24359	min	_
130-12	24360-24361	,	_
130-13	24362-24366	then	_
130-14	24367-24378	centrifuged	_
130-15	24379-24381	at	_
130-16	24382-24386	3500	_
130-17	24387-24390	rpm	_
130-18	24391-24393	at	_
130-19	24394-24395	4	_
130-20	24396-24398	°C	_
130-21	24399-24402	for	_
130-22	24403-24405	20	_
130-23	24406-24409	min	_
130-24	24410-24411	.	_

Text=Serum will be separated from blood and kept in a refrigerator at − 30 °C prior to analyses.
131-1	24412-24417	Serum	_
131-2	24418-24422	will	_
131-3	24423-24425	be	_
131-4	24426-24435	separated	_
131-5	24436-24440	from	_
131-6	24441-24446	blood	_
131-7	24447-24450	and	_
131-8	24451-24455	kept	_
131-9	24456-24458	in	_
131-10	24459-24460	a	_
131-11	24461-24473	refrigerator	_
131-12	24474-24476	at	_
131-13	24477-24478	−	_
131-14	24479-24481	30	_
131-15	24482-24484	°C	_
131-16	24485-24490	prior	_
131-17	24491-24493	to	_
131-18	24494-24502	analyses	_
131-19	24503-24504	.	_

Text=Serum optical density will be measured at 450 nm using a microplate reader (EZ Read 400, Biochrom, Cambridge, UK).
132-1	24505-24510	Serum	_
132-2	24511-24518	optical	_
132-3	24519-24526	density	_
132-4	24527-24531	will	_
132-5	24532-24534	be	_
132-6	24535-24543	measured	_
132-7	24544-24546	at	_
132-8	24547-24550	450	_
132-9	24551-24553	nm	_
132-10	24554-24559	using	_
132-11	24560-24561	a	_
132-12	24562-24572	microplate	_
132-13	24573-24579	reader	_
132-14	24580-24581	(	_
132-15	24582-24584	EZ	_
132-16	24585-24589	Read	_
132-17	24590-24593	400	_
132-18	24594-24595	,	_
132-19	24596-24604	Biochrom	_
132-20	24605-24606	,	_
132-21	24607-24616	Cambridge	_
132-22	24617-24618	,	_
132-23	24619-24621	UK	_
132-24	24622-24623	)	_
132-25	24624-24625	.	_

Text=BDNF concentrations will be determined by comparing the optical density to a standard curve.
133-1	24626-24630	BDNF	_
133-2	24631-24645	concentrations	_
133-3	24646-24650	will	_
133-4	24651-24653	be	_
133-5	24654-24664	determined	_
133-6	24665-24667	by	_
133-7	24668-24677	comparing	_
133-8	24678-24681	the	_
133-9	24682-24689	optical	_
133-10	24690-24697	density	_
133-11	24698-24700	to	_
133-12	24701-24702	a	_
133-13	24703-24711	standard	_
133-14	24712-24717	curve	_
133-15	24718-24719	.	_

Text=Participant timeline The week prior to the onset of the 10-day rTMS treatment, clinical scales, neuropsychological tests, structural and functional MRI recordings, neurophysiological motor excitability evaluations, and biological markers from blood serum samples will be obtained.
134-1	24720-24731	Participant	_
134-2	24732-24740	timeline	_
134-3	24741-24744	The	_
134-4	24745-24749	week	_
134-5	24750-24755	prior	_
134-6	24756-24758	to	_
134-7	24759-24762	the	_
134-8	24763-24768	onset	_
134-9	24769-24771	of	_
134-10	24772-24775	the	_
134-11	24776-24782	10-day	_
134-12	24783-24787	rTMS	http://maven.renci.org/NeuroBridge/neurobridge#TreatmentResponseProgressScale
134-13	24788-24797	treatment	http://maven.renci.org/NeuroBridge/neurobridge#TreatmentResponseProgressScale
134-14	24798-24799	,	_
134-15	24800-24808	clinical	_
134-16	24809-24815	scales	_
134-17	24816-24817	,	_
134-18	24818-24836	neuropsychological	_
134-19	24837-24842	tests	_
134-20	24843-24844	,	_
134-21	24845-24855	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
134-22	24856-24859	and	_
134-23	24860-24870	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
134-24	24871-24874	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
134-25	24875-24885	recordings	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
134-26	24886-24887	,	_
134-27	24888-24906	neurophysiological	_
134-28	24907-24912	motor	_
134-29	24913-24925	excitability	_
134-30	24926-24937	evaluations	_
134-31	24938-24939	,	_
134-32	24940-24943	and	_
134-33	24944-24954	biological	_
134-34	24955-24962	markers	_
134-35	24963-24967	from	_
134-36	24968-24973	blood	_
134-37	24974-24979	serum	_
134-38	24980-24987	samples	_
134-39	24988-24992	will	_
134-40	24993-24995	be	_
134-41	24996-25004	obtained	_
134-42	25005-25006	.	_

Text=Once baseline recordings are completed, the rTMS treatment will start.
135-1	25007-25011	Once	_
135-2	25012-25020	baseline	_
135-3	25021-25031	recordings	_
135-4	25032-25035	are	_
135-5	25036-25045	completed	_
135-6	25046-25047	,	_
135-7	25048-25051	the	_
135-8	25052-25056	rTMS	_
135-9	25057-25066	treatment	_
135-10	25067-25071	will	_
135-11	25072-25077	start	_
135-12	25078-25079	.	_

Text=Each patient will receive a total of 20 sessions of 1 Hz rTMS (1200 pulses/session, two sessions/day from Monday to Friday, over two consecutive weeks), delivered on the left TPJ region.
136-1	25080-25084	Each	_
136-2	25085-25092	patient	_
136-3	25093-25097	will	_
136-4	25098-25105	receive	_
136-5	25106-25107	a	_
136-6	25108-25113	total	_
136-7	25114-25116	of	_
136-8	25117-25119	20	_
136-9	25120-25128	sessions	_
136-10	25129-25131	of	_
136-11	25132-25133	1	_
136-12	25134-25136	Hz	_
136-13	25137-25141	rTMS	_
136-14	25142-25143	(	_
136-15	25144-25148	1200	_
136-16	25149-25163	pulses/session	_
136-17	25164-25165	,	_
136-18	25166-25169	two	_
136-19	25170-25182	sessions/day	_
136-20	25183-25187	from	_
136-21	25188-25194	Monday	_
136-22	25195-25197	to	_
136-23	25198-25204	Friday	_
136-24	25205-25206	,	_
136-25	25207-25211	over	_
136-26	25212-25215	two	_
136-27	25216-25227	consecutive	_
136-28	25228-25233	weeks	_
136-29	25234-25235	)	_
136-30	25236-25237	,	_
136-31	25238-25247	delivered	_
136-32	25248-25250	on	_
136-33	25251-25254	the	_
136-34	25255-25259	left	_
136-35	25260-25263	TPJ	_
136-36	25264-25270	region	_
136-37	25271-25272	.	_

Text=Once the rTMS treatment is completed, many of the same clinical, neuropsychological, neuroimaging, and neurophysiological measures determined during the baseline prior to rTMS regime onset will be recorded again to evaluate the impact of stimulation (Fig.
137-1	25273-25277	Once	_
137-2	25278-25281	the	_
137-3	25282-25286	rTMS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
137-4	25287-25296	treatment	_
137-5	25297-25299	is	_
137-6	25300-25309	completed	_
137-7	25310-25311	,	_
137-8	25312-25316	many	_
137-9	25317-25319	of	_
137-10	25320-25323	the	_
137-11	25324-25328	same	_
137-12	25329-25337	clinical	_
137-13	25338-25339	,	_
137-14	25340-25358	neuropsychological	_
137-15	25359-25360	,	_
137-16	25361-25373	neuroimaging	_
137-17	25374-25375	,	_
137-18	25376-25379	and	_
137-19	25380-25398	neurophysiological	_
137-20	25399-25407	measures	_
137-21	25408-25418	determined	_
137-22	25419-25425	during	_
137-23	25426-25429	the	_
137-24	25430-25438	baseline	_
137-25	25439-25444	prior	_
137-26	25445-25447	to	_
137-27	25448-25452	rTMS	_
137-28	25453-25459	regime	_
137-29	25460-25465	onset	_
137-30	25466-25470	will	_
137-31	25471-25473	be	_
137-32	25474-25482	recorded	_
137-33	25483-25488	again	_
137-34	25489-25491	to	_
137-35	25492-25500	evaluate	_
137-36	25501-25504	the	_
137-37	25505-25511	impact	_
137-38	25512-25514	of	_
137-39	25515-25526	stimulation	_
137-40	25527-25528	(	_
137-41	25529-25532	Fig	_
137-42	25533-25534	.	_

Text=1).
138-1	25535-25536	1	_
138-2	25537-25538	)	_
138-3	25539-25540	.	_

Text=Data collection and management A CRF will be used to collect the data for each participant.
139-1	25541-25545	Data	_
139-2	25546-25556	collection	_
139-3	25557-25560	and	_
139-4	25561-25571	management	_
139-5	25572-25573	A	_
139-6	25574-25577	CRF	_
139-7	25578-25582	will	_
139-8	25583-25585	be	_
139-9	25586-25590	used	_
139-10	25591-25593	to	_
139-11	25594-25601	collect	_
139-12	25602-25605	the	_
139-13	25606-25610	data	_
139-14	25611-25614	for	_
139-15	25615-25619	each	_
139-16	25620-25631	participant	_
139-17	25632-25633	.	_

Text=To preserve patient anonymity, an identification code is allocated during the enrollment phase allowing patient identification on the CRF.
140-1	25634-25636	To	_
140-2	25637-25645	preserve	_
140-3	25646-25653	patient	_
140-4	25654-25663	anonymity	_
140-5	25664-25665	,	_
140-6	25666-25668	an	_
140-7	25669-25683	identification	_
140-8	25684-25688	code	_
140-9	25689-25691	is	_
140-10	25692-25701	allocated	_
140-11	25702-25708	during	_
140-12	25709-25712	the	_
140-13	25713-25723	enrollment	_
140-14	25724-25729	phase	_
140-15	25730-25738	allowing	_
140-16	25739-25746	patient	_
140-17	25747-25761	identification	_
140-18	25762-25764	on	_
140-19	25765-25768	the	_
140-20	25769-25772	CRF	_
140-21	25773-25774	.	_

Text=Throughout this trial, CRFs will be reviewed to ensure complete and accurate collection of data following each assessment.
141-1	25775-25785	Throughout	_
141-2	25786-25790	this	_
141-3	25791-25796	trial	_
141-4	25797-25798	,	_
141-5	25799-25803	CRFs	_
141-6	25804-25808	will	_
141-7	25809-25811	be	_
141-8	25812-25820	reviewed	_
141-9	25821-25823	to	_
141-10	25824-25830	ensure	_
141-11	25831-25839	complete	_
141-12	25840-25843	and	_
141-13	25844-25852	accurate	_
141-14	25853-25863	collection	_
141-15	25864-25866	of	_
141-16	25867-25871	data	_
141-17	25872-25881	following	_
141-18	25882-25886	each	_
141-19	25887-25897	assessment	_
141-20	25898-25899	.	_

Text=CRFs will be stored in a locked cupboard for data security.
142-1	25900-25904	CRFs	_
142-2	25905-25909	will	_
142-3	25910-25912	be	_
142-4	25913-25919	stored	_
142-5	25920-25922	in	_
142-6	25923-25924	a	_
142-7	25925-25931	locked	_
142-8	25932-25940	cupboard	_
142-9	25941-25944	for	_
142-10	25945-25949	data	_
142-11	25950-25958	security	_
142-12	25959-25960	.	_

Text=MRI data will be stored on a computer secured by a password and will be identified with the patient ’ s identification code to preserve anonymity.
143-1	25961-25964	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
143-2	25965-25969	data	_
143-3	25970-25974	will	_
143-4	25975-25977	be	_
143-5	25978-25984	stored	_
143-6	25985-25987	on	_
143-7	25988-25989	a	_
143-8	25990-25998	computer	_
143-9	25999-26006	secured	_
143-10	26007-26009	by	_
143-11	26010-26011	a	_
143-12	26012-26020	password	_
143-13	26021-26024	and	_
143-14	26025-26029	will	_
143-15	26030-26032	be	_
143-16	26033-26043	identified	_
143-17	26044-26048	with	_
143-18	26049-26052	the	_
143-19	26053-26060	patient	_
143-20	26061-26062	’	_
143-21	26063-26064	s	_
143-22	26065-26079	identification	_
143-23	26080-26084	code	_
143-24	26085-26087	to	_
143-25	26088-26096	preserve	_
143-26	26097-26106	anonymity	_
143-27	26107-26108	.	_

Text=Statistical analysis Sample size The aim of this trial is to investigate the difference in brain functional and structural connectivity in schizophrenia patients receiving an active rTMS treatment and clinically responding to it or not as assessed by an amelioration of their AVH symptoms.
144-1	26109-26120	Statistical	_
144-2	26121-26129	analysis	_
144-3	26130-26136	Sample	_
144-4	26137-26141	size	_
144-5	26142-26145	The	_
144-6	26146-26149	aim	_
144-7	26150-26152	of	_
144-8	26153-26157	this	_
144-9	26158-26163	trial	_
144-10	26164-26166	is	_
144-11	26167-26169	to	_
144-12	26170-26181	investigate	_
144-13	26182-26185	the	_
144-14	26186-26196	difference	_
144-15	26197-26199	in	_
144-16	26200-26205	brain	_
144-17	26206-26216	functional	_
144-18	26217-26220	and	_
144-19	26221-26231	structural	_
144-20	26232-26244	connectivity	_
144-21	26245-26247	in	_
144-22	26248-26261	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
144-23	26262-26270	patients	_
144-24	26271-26280	receiving	_
144-25	26281-26283	an	_
144-26	26284-26290	active	_
144-27	26291-26295	rTMS	_
144-28	26296-26305	treatment	_
144-29	26306-26309	and	_
144-30	26310-26320	clinically	_
144-31	26321-26331	responding	_
144-32	26332-26334	to	_
144-33	26335-26337	it	_
144-34	26338-26340	or	_
144-35	26341-26344	not	_
144-36	26345-26347	as	_
144-37	26348-26356	assessed	_
144-38	26357-26359	by	_
144-39	26360-26362	an	_
144-40	26363-26375	amelioration	_
144-41	26376-26378	of	_
144-42	26379-26384	their	_
144-43	26385-26388	AVH	_
144-44	26389-26397	symptoms	_
144-45	26398-26399	.	_

Text=Therefore, the sample size was calculated to determine the number of patients to be included in the active rTMS group on the basis of the primary outcome, namely the difference in FA values at baseline between ‘ responders ’ and ‘ non-responders ’.
145-1	26400-26409	Therefore	_
145-2	26410-26411	,	_
145-3	26412-26415	the	_
145-4	26416-26422	sample	_
145-5	26423-26427	size	_
145-6	26428-26431	was	_
145-7	26432-26442	calculated	_
145-8	26443-26445	to	_
145-9	26446-26455	determine	_
145-10	26456-26459	the	_
145-11	26460-26466	number	_
145-12	26467-26469	of	_
145-13	26470-26478	patients	_
145-14	26479-26481	to	_
145-15	26482-26484	be	_
145-16	26485-26493	included	_
145-17	26494-26496	in	_
145-18	26497-26500	the	_
145-19	26501-26507	active	_
145-20	26508-26512	rTMS	_
145-21	26513-26518	group	_
145-22	26519-26521	on	_
145-23	26522-26525	the	_
145-24	26526-26531	basis	_
145-25	26532-26534	of	_
145-26	26535-26538	the	_
145-27	26539-26546	primary	_
145-28	26547-26554	outcome	_
145-29	26555-26556	,	_
145-30	26557-26563	namely	_
145-31	26564-26567	the	_
145-32	26568-26578	difference	_
145-33	26579-26581	in	_
145-34	26582-26584	FA	_
145-35	26585-26591	values	_
145-36	26592-26594	at	_
145-37	26595-26603	baseline	_
145-38	26604-26611	between	_
145-39	26612-26613	‘	_
145-40	26614-26624	responders	_
145-41	26625-26626	’	_
145-42	26627-26630	and	_
145-43	26631-26632	‘	_
145-44	26633-26647	non-responders	_
145-45	26648-26649	’	_
145-46	26650-26651	.	_

Text=Unfortunately, no study provides a significant difference of rs-fMRI measures or FA values for a given tract (such as the left arcuate fasciculus) before and following a clinically effective versus a non-clinically effective rTMS treatment in schizophrenia patients, which would allow us to accurately estimate the adequate sample size for our trial.
146-1	26652-26665	Unfortunately	_
146-2	26666-26667	,	_
146-3	26668-26670	no	_
146-4	26671-26676	study	_
146-5	26677-26685	provides	_
146-6	26686-26687	a	_
146-7	26688-26699	significant	_
146-8	26700-26710	difference	_
146-9	26711-26713	of	_
146-10	26714-26721	rs-fMRI	_
146-11	26722-26730	measures	_
146-12	26731-26733	or	_
146-13	26734-26736	FA	_
146-14	26737-26743	values	_
146-15	26744-26747	for	_
146-16	26748-26749	a	_
146-17	26750-26755	given	_
146-18	26756-26761	tract	_
146-19	26762-26763	(	_
146-20	26764-26768	such	_
146-21	26769-26771	as	_
146-22	26772-26775	the	_
146-23	26776-26780	left	_
146-24	26781-26788	arcuate	_
146-25	26789-26799	fasciculus	_
146-26	26800-26801	)	_
146-27	26802-26808	before	_
146-28	26809-26812	and	_
146-29	26813-26822	following	_
146-30	26823-26824	a	_
146-31	26825-26835	clinically	_
146-32	26836-26845	effective	_
146-33	26846-26852	versus	_
146-34	26853-26854	a	_
146-35	26855-26869	non-clinically	_
146-36	26870-26879	effective	_
146-37	26880-26884	rTMS	_
146-38	26885-26894	treatment	_
146-39	26895-26897	in	_
146-40	26898-26911	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
146-41	26912-26920	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
146-42	26921-26922	,	_
146-43	26923-26928	which	_
146-44	26929-26934	would	_
146-45	26935-26940	allow	_
146-46	26941-26943	us	_
146-47	26944-26946	to	_
146-48	26947-26957	accurately	_
146-49	26958-26966	estimate	_
146-50	26967-26970	the	_
146-51	26971-26979	adequate	_
146-52	26980-26986	sample	_
146-53	26987-26991	size	_
146-54	26992-26995	for	_
146-55	26996-26999	our	_
146-56	27000-27005	trial	_
146-57	27006-27007	.	_

Text=Nonetheless, FA values are highly reproducible and have a reliable estimation of variance.
147-1	27008-27019	Nonetheless	_
147-2	27020-27021	,	_
147-3	27022-27024	FA	_
147-4	27025-27031	values	_
147-5	27032-27035	are	_
147-6	27036-27042	highly	_
147-7	27043-27055	reproducible	_
147-8	27056-27059	and	_
147-9	27060-27064	have	_
147-10	27065-27066	a	_
147-11	27067-27075	reliable	_
147-12	27076-27086	estimation	_
147-13	27087-27089	of	_
147-14	27090-27098	variance	_
147-15	27099-27100	.	_

Text=Therefore, we focused on FA values to determine sample size.
148-1	27101-27110	Therefore	_
148-2	27111-27112	,	_
148-3	27113-27115	we	_
148-4	27116-27123	focused	_
148-5	27124-27126	on	_
148-6	27127-27129	FA	_
148-7	27130-27136	values	_
148-8	27137-27139	to	_
148-9	27140-27149	determine	_
148-10	27150-27156	sample	_
148-11	27157-27161	size	_
148-12	27162-27163	.	_

Text=Therefore, on the basis of a significant difference in the FA values between schizophrenia patients and healthy subjects for the left arcuate fasciculus and assuming an α risk of 0.05 and a 1-β power of 0.80, we estimated the need to include 32 patients for the active rTMS group.
149-1	27164-27173	Therefore	_
149-2	27174-27175	,	_
149-3	27176-27178	on	_
149-4	27179-27182	the	_
149-5	27183-27188	basis	_
149-6	27189-27191	of	_
149-7	27192-27193	a	_
149-8	27194-27205	significant	_
149-9	27206-27216	difference	_
149-10	27217-27219	in	_
149-11	27220-27223	the	_
149-12	27224-27226	FA	_
149-13	27227-27233	values	_
149-14	27234-27241	between	_
149-15	27242-27255	schizophrenia	_
149-16	27256-27264	patients	_
149-17	27265-27268	and	_
149-18	27269-27276	healthy	_
149-19	27277-27285	subjects	_
149-20	27286-27289	for	_
149-21	27290-27293	the	_
149-22	27294-27298	left	_
149-23	27299-27306	arcuate	_
149-24	27307-27317	fasciculus	_
149-25	27318-27321	and	_
149-26	27322-27330	assuming	_
149-27	27331-27333	an	_
149-28	27334-27335	α	_
149-29	27336-27340	risk	_
149-30	27341-27343	of	_
149-31	27344-27348	0.05	_
149-32	27349-27352	and	_
149-33	27353-27354	a	_
149-34	27355-27358	1-β	_
149-35	27359-27364	power	_
149-36	27365-27367	of	_
149-37	27368-27372	0.80	_
149-38	27373-27374	,	_
149-39	27375-27377	we	_
149-40	27378-27387	estimated	_
149-41	27388-27391	the	_
149-42	27392-27396	need	_
149-43	27397-27399	to	_
149-44	27400-27407	include	_
149-45	27408-27410	32	_
149-46	27411-27419	patients	_
149-47	27420-27423	for	_
149-48	27424-27427	the	_
149-49	27428-27434	active	_
149-50	27435-27439	rTMS	_
149-51	27440-27445	group	_
149-52	27446-27447	.	_

Text=To overcome an estimated 10% drop-out, we increased our recruitment needs for active rTMS group to 35 patients.
150-1	27448-27450	To	_
150-2	27451-27459	overcome	_
150-3	27460-27462	an	_
150-4	27463-27472	estimated	_
150-5	27473-27475	10	_
150-6	27476-27477	%	_
150-7	27478-27486	drop-out	_
150-8	27487-27488	,	_
150-9	27489-27491	we	_
150-10	27492-27501	increased	_
150-11	27502-27505	our	_
150-12	27506-27517	recruitment	_
150-13	27518-27523	needs	_
150-14	27524-27527	for	_
150-15	27528-27534	active	_
150-16	27535-27539	rTMS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
150-17	27540-27545	group	_
150-18	27546-27548	to	_
150-19	27549-27551	35	_
150-20	27552-27560	patients	_
150-21	27561-27562	.	_

Text=Given a proportion of ‘ responders ’ and ‘ non-responders ’ to rTMS treatment as the one we propose for AVH in schizophrenia estimated at 40% and 60%, respectively, we will divide our cohort into 14 ‘ responders ’ and 21 ‘ non-responder ’ patients.
151-1	27563-27568	Given	_
151-2	27569-27570	a	_
151-3	27571-27581	proportion	_
151-4	27582-27584	of	_
151-5	27585-27586	‘	_
151-6	27587-27597	responders	_
151-7	27598-27599	’	_
151-8	27600-27603	and	_
151-9	27604-27605	‘	_
151-10	27606-27620	non-responders	_
151-11	27621-27622	’	_
151-12	27623-27625	to	_
151-13	27626-27630	rTMS	_
151-14	27631-27640	treatment	_
151-15	27641-27643	as	_
151-16	27644-27647	the	_
151-17	27648-27651	one	_
151-18	27652-27654	we	_
151-19	27655-27662	propose	_
151-20	27663-27666	for	_
151-21	27667-27670	AVH	_
151-22	27671-27673	in	_
151-23	27674-27687	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
151-24	27688-27697	estimated	_
151-25	27698-27700	at	_
151-26	27701-27703	40	_
151-27	27704-27705	%	_
151-28	27706-27709	and	_
151-29	27710-27712	60	_
151-30	27713-27714	%	_
151-31	27715-27716	,	_
151-32	27717-27729	respectively	_
151-33	27730-27731	,	_
151-34	27732-27734	we	_
151-35	27735-27739	will	_
151-36	27740-27746	divide	_
151-37	27747-27750	our	_
151-38	27751-27757	cohort	_
151-39	27758-27762	into	_
151-40	27763-27765	14	_
151-41	27766-27767	‘	_
151-42	27768-27778	responders	_
151-43	27779-27780	’	_
151-44	27781-27784	and	_
151-45	27785-27787	21	_
151-46	27788-27789	‘	_
151-47	27790-27803	non-responder	_
151-48	27804-27805	’	_
151-49	27806-27814	patients	_
151-50	27815-27816	.	_

Text=According to a prior study, a minimum of 14 participants per group (‘ responders ’ or ‘ non-responders ’) has been deemed sufficient to conduct statistical analysis in neuroimaging and detect a significant effect of rTMS on brain structural connectivity.
152-1	27817-27826	According	_
152-2	27827-27829	to	_
152-3	27830-27831	a	_
152-4	27832-27837	prior	_
152-5	27838-27843	study	_
152-6	27844-27845	,	_
152-7	27846-27847	a	_
152-8	27848-27855	minimum	_
152-9	27856-27858	of	_
152-10	27859-27861	14	_
152-11	27862-27874	participants	_
152-12	27875-27878	per	_
152-13	27879-27884	group	_
152-14	27885-27886	(	_
152-15	27887-27888	‘	_
152-16	27889-27899	responders	_
152-17	27900-27901	’	_
152-18	27902-27904	or	_
152-19	27905-27906	‘	_
152-20	27907-27921	non-responders	_
152-21	27922-27923	’	_
152-22	27924-27925	)	_
152-23	27926-27929	has	_
152-24	27930-27934	been	_
152-25	27935-27941	deemed	_
152-26	27942-27952	sufficient	_
152-27	27953-27955	to	_
152-28	27956-27963	conduct	_
152-29	27964-27975	statistical	_
152-30	27976-27984	analysis	_
152-31	27985-27987	in	_
152-32	27988-28000	neuroimaging	_
152-33	28001-28004	and	_
152-34	28005-28011	detect	_
152-35	28012-28013	a	_
152-36	28014-28025	significant	_
152-37	28026-28032	effect	_
152-38	28033-28035	of	_
152-39	28036-28040	rTMS	_
152-40	28041-28043	on	_
152-41	28044-28049	brain	_
152-42	28050-28060	structural	_
152-43	28061-28073	connectivity	_
152-44	28074-28075	.	_

Text=Moreover, a sham rTMS group of 10 patients will be followed in parallel to control for the placebo rTMS effect on AVH.
153-1	28076-28084	Moreover	_
153-2	28085-28086	,	_
153-3	28087-28088	a	_
153-4	28089-28093	sham	_
153-5	28094-28098	rTMS	_
153-6	28099-28104	group	_
153-7	28105-28107	of	_
153-8	28108-28110	10	_
153-9	28111-28119	patients	_
153-10	28120-28124	will	_
153-11	28125-28127	be	_
153-12	28128-28136	followed	_
153-13	28137-28139	in	_
153-14	28140-28148	parallel	_
153-15	28149-28151	to	_
153-16	28152-28159	control	_
153-17	28160-28163	for	_
153-18	28164-28167	the	_
153-19	28168-28175	placebo	_
153-20	28176-28180	rTMS	_
153-21	28181-28187	effect	_
153-22	28188-28190	on	_
153-23	28191-28194	AVH	_
153-24	28195-28196	.	_

Text=As a result, the total number of participants required for the study is of 45 patients.
154-1	28197-28199	As	_
154-2	28200-28201	a	_
154-3	28202-28208	result	_
154-4	28209-28210	,	_
154-5	28211-28214	the	_
154-6	28215-28220	total	_
154-7	28221-28227	number	_
154-8	28228-28230	of	_
154-9	28231-28243	participants	_
154-10	28244-28252	required	_
154-11	28253-28256	for	_
154-12	28257-28260	the	_
154-13	28261-28266	study	_
154-14	28267-28269	is	_
154-15	28270-28272	of	_
154-16	28273-28275	45	_
154-17	28276-28284	patients	_
154-18	28285-28286	.	_

Text=Data analysis In order to meet the objectives of this trial, structural and functional connectivity data will be processed in two different ways.
155-1	28287-28291	Data	_
155-2	28292-28300	analysis	_
155-3	28301-28303	In	_
155-4	28304-28309	order	_
155-5	28310-28312	to	_
155-6	28313-28317	meet	_
155-7	28318-28321	the	_
155-8	28322-28332	objectives	_
155-9	28333-28335	of	_
155-10	28336-28340	this	_
155-11	28341-28346	trial	_
155-12	28347-28348	,	_
155-13	28349-28359	structural	_
155-14	28360-28363	and	_
155-15	28364-28374	functional	_
155-16	28375-28387	connectivity	_
155-17	28388-28392	data	_
155-18	28393-28397	will	_
155-19	28398-28400	be	_
155-20	28401-28410	processed	_
155-21	28411-28413	in	_
155-22	28414-28417	two	_
155-23	28418-28427	different	_
155-24	28428-28432	ways	_
155-25	28433-28434	.	_

Text=First, we will compare measures, obtained at baseline (W0), between ‘ responder ’ and ‘ non-responder ’ patients submitted to active rTMS to identify potential brain biomarkers associated with rTMS response.
156-1	28435-28440	First	_
156-2	28441-28442	,	_
156-3	28443-28445	we	_
156-4	28446-28450	will	_
156-5	28451-28458	compare	_
156-6	28459-28467	measures	_
156-7	28468-28469	,	_
156-8	28470-28478	obtained	_
156-9	28479-28481	at	_
156-10	28482-28490	baseline	_
156-11	28491-28492	(	_
156-12	28493-28495	W0	_
156-13	28496-28497	)	_
156-14	28498-28499	,	_
156-15	28500-28507	between	_
156-16	28508-28509	‘	_
156-17	28510-28519	responder	_
156-18	28520-28521	’	_
156-19	28522-28525	and	_
156-20	28526-28527	‘	_
156-21	28528-28541	non-responder	_
156-22	28542-28543	’	_
156-23	28544-28552	patients	_
156-24	28553-28562	submitted	_
156-25	28563-28565	to	_
156-26	28566-28572	active	_
156-27	28573-28577	rTMS	_
156-28	28578-28580	to	_
156-29	28581-28589	identify	_
156-30	28590-28599	potential	_
156-31	28600-28605	brain	_
156-32	28606-28616	biomarkers	_
156-33	28617-28627	associated	_
156-34	28628-28632	with	_
156-35	28633-28637	rTMS	_
156-36	28638-28646	response	_
156-37	28647-28648	.	_

Text=Secondly, we will compare these same data, before versus after active rTMS, between groups of ‘ responders ’ and ‘ non-responders ’ to determine explanatory markers of active rTMS-induced AVH improvement.
157-1	28649-28657	Secondly	_
157-2	28658-28659	,	_
157-3	28660-28662	we	_
157-4	28663-28667	will	_
157-5	28668-28675	compare	_
157-6	28676-28681	these	_
157-7	28682-28686	same	_
157-8	28687-28691	data	_
157-9	28692-28693	,	_
157-10	28694-28700	before	_
157-11	28701-28707	versus	_
157-12	28708-28713	after	_
157-13	28714-28720	active	_
157-14	28721-28725	rTMS	_
157-15	28726-28727	,	_
157-16	28728-28735	between	_
157-17	28736-28742	groups	_
157-18	28743-28745	of	_
157-19	28746-28747	‘	_
157-20	28748-28758	responders	_
157-21	28759-28760	’	_
157-22	28761-28764	and	_
157-23	28765-28766	‘	_
157-24	28767-28781	non-responders	_
157-25	28782-28783	’	_
157-26	28784-28786	to	_
157-27	28787-28796	determine	_
157-28	28797-28808	explanatory	_
157-29	28809-28816	markers	_
157-30	28817-28819	of	_
157-31	28820-28826	active	_
157-32	28827-28839	rTMS-induced	_
157-33	28840-28843	AVH	_
157-34	28844-28855	improvement	_
157-35	28856-28857	.	_

Text=For both steps, we sought to show a significant difference between ‘ responders ’ and ‘ non-responders ’.
158-1	28858-28861	For	_
158-2	28862-28866	both	_
158-3	28867-28872	steps	_
158-4	28873-28874	,	_
158-5	28875-28877	we	_
158-6	28878-28884	sought	_
158-7	28885-28887	to	_
158-8	28888-28892	show	_
158-9	28893-28894	a	_
158-10	28895-28906	significant	_
158-11	28907-28917	difference	_
158-12	28918-28925	between	_
158-13	28926-28927	‘	_
158-14	28928-28938	responders	_
158-15	28939-28940	’	_
158-16	28941-28944	and	_
158-17	28945-28946	‘	_
158-18	28947-28961	non-responders	_
158-19	28962-28963	’	_
158-20	28964-28965	.	_

Text=Thirdly, additional exploratory analysis will be performed on clinical, neurophysiological, neuropsychological, and biological measures.
159-1	28966-28973	Thirdly	_
159-2	28974-28975	,	_
159-3	28976-28986	additional	_
159-4	28987-28998	exploratory	_
159-5	28999-29007	analysis	_
159-6	29008-29012	will	_
159-7	29013-29015	be	_
159-8	29016-29025	performed	_
159-9	29026-29028	on	_
159-10	29029-29037	clinical	_
159-11	29038-29039	,	_
159-12	29040-29058	neurophysiological	_
159-13	29059-29060	,	_
159-14	29061-29079	neuropsychological	_
159-15	29080-29081	,	_
159-16	29082-29085	and	_
159-17	29086-29096	biological	_
159-18	29097-29105	measures	_
159-19	29106-29107	.	_

Text=MRI data analysis Regions of interest (ROIs) Two spherical ROIs corresponding to the rTMS target (left TPJ) and its homotopic region in the right hemisphere (right TPJ) will be generated using the MarsBaR toolbox (http: //marsbar.sourceforge.net/).
160-1	29108-29111	MRI	_
160-2	29112-29116	data	_
160-3	29117-29125	analysis	_
160-4	29126-29133	Regions	_
160-5	29134-29136	of	_
160-6	29137-29145	interest	_
160-7	29146-29147	(	_
160-8	29148-29152	ROIs	_
160-9	29153-29154	)	_
160-10	29155-29158	Two	_
160-11	29159-29168	spherical	_
160-12	29169-29173	ROIs	_
160-13	29174-29187	corresponding	_
160-14	29188-29190	to	_
160-15	29191-29194	the	_
160-16	29195-29199	rTMS	_
160-17	29200-29206	target	_
160-18	29207-29208	(	_
160-19	29209-29213	left	_
160-20	29214-29217	TPJ	_
160-21	29218-29219	)	_
160-22	29220-29223	and	_
160-23	29224-29227	its	_
160-24	29228-29237	homotopic	_
160-25	29238-29244	region	_
160-26	29245-29247	in	_
160-27	29248-29251	the	_
160-28	29252-29257	right	_
160-29	29258-29268	hemisphere	_
160-30	29269-29270	(	_
160-31	29271-29276	right	_
160-32	29277-29280	TPJ	_
160-33	29281-29282	)	_
160-34	29283-29287	will	_
160-35	29288-29290	be	_
160-36	29291-29300	generated	_
160-37	29301-29306	using	_
160-38	29307-29310	the	_
160-39	29311-29318	MarsBaR	_
160-40	29319-29326	toolbox	_
160-41	29327-29328	(	_
160-42	29329-29333	http	_
160-43	29334-29335	:	_
160-44	29336-29362	//marsbar.sourceforge.net/	_
160-45	29363-29364	)	_
160-46	29365-29366	.	_

Text=Each sphere of a 5 mm radius will be centered at x = − 55, y = − 41, and y = 11 for the left TPJ, and at x = 55, y = − 41, and y = 11 for the right TPJ.
161-1	29367-29371	Each	_
161-2	29372-29378	sphere	_
161-3	29379-29381	of	_
161-4	29382-29383	a	_
161-5	29384-29385	5	_
161-6	29386-29388	mm	_
161-7	29389-29395	radius	_
161-8	29396-29400	will	_
161-9	29401-29403	be	_
161-10	29404-29412	centered	_
161-11	29413-29415	at	_
161-12	29416-29417	x	_
161-13	29418-29419	=	_
161-14	29420-29421	−	_
161-15	29422-29424	55	_
161-16	29425-29426	,	_
161-17	29427-29428	y	_
161-18	29429-29430	=	_
161-19	29431-29432	−	_
161-20	29433-29435	41	_
161-21	29436-29437	,	_
161-22	29438-29441	and	_
161-23	29442-29443	y	_
161-24	29444-29445	=	_
161-25	29446-29448	11	_
161-26	29449-29452	for	_
161-27	29453-29456	the	_
161-28	29457-29461	left	_
161-29	29462-29465	TPJ	_
161-30	29466-29467	,	_
161-31	29468-29471	and	_
161-32	29472-29474	at	_
161-33	29475-29476	x	_
161-34	29477-29478	=	_
161-35	29479-29481	55	_
161-36	29482-29483	,	_
161-37	29484-29485	y	_
161-38	29486-29487	=	_
161-39	29488-29489	−	_
161-40	29490-29492	41	_
161-41	29493-29494	,	_
161-42	29495-29498	and	_
161-43	29499-29500	y	_
161-44	29501-29502	=	_
161-45	29503-29505	11	_
161-46	29506-29509	for	_
161-47	29510-29513	the	_
161-48	29514-29519	right	_
161-49	29520-29523	TPJ	_
161-50	29524-29525	.	_

Text=MNI atlases will be used to define ROIs containing the nodes of the DMN and the language network.
162-1	29526-29529	MNI	_
162-2	29530-29537	atlases	_
162-3	29538-29542	will	_
162-4	29543-29545	be	_
162-5	29546-29550	used	_
162-6	29551-29553	to	_
162-7	29554-29560	define	_
162-8	29561-29565	ROIs	_
162-9	29566-29576	containing	_
162-10	29577-29580	the	_
162-11	29581-29586	nodes	_
162-12	29587-29589	of	_
162-13	29590-29593	the	_
162-14	29594-29597	DMN	_
162-15	29598-29601	and	_
162-16	29602-29605	the	_
162-17	29606-29614	language	_
162-18	29615-29622	network	_
162-19	29623-29624	.	_

Text=The masks of the left and right frontal inferior gyri and posterior cingulate cortex will be extracted from the WFU PickAtlas (http: //fmri.wfubmc.edu/software/PickAtlas).
163-1	29625-29628	The	_
163-2	29629-29634	masks	_
163-3	29635-29637	of	_
163-4	29638-29641	the	_
163-5	29642-29646	left	_
163-6	29647-29650	and	_
163-7	29651-29656	right	_
163-8	29657-29664	frontal	_
163-9	29665-29673	inferior	_
163-10	29674-29678	gyri	_
163-11	29679-29682	and	_
163-12	29683-29692	posterior	_
163-13	29693-29702	cingulate	_
163-14	29703-29709	cortex	_
163-15	29710-29714	will	_
163-16	29715-29717	be	_
163-17	29718-29727	extracted	_
163-18	29728-29732	from	_
163-19	29733-29736	the	_
163-20	29737-29740	WFU	_
163-21	29741-29750	PickAtlas	_
163-22	29751-29752	(	_
163-23	29753-29757	http	_
163-24	29758-29759	:	_
163-25	29760-29796	//fmri.wfubmc.edu/software/PickAtlas	_
163-26	29797-29798	)	_
163-27	29799-29800	.	_

Text=A mask of the corpus callosum will be manually drawn on a T1-weighted MNI template using the Functional Magnetic Resonance Imaging of the Brain (FMRIB) Software Library (FSL 5.0.9, http: //www.fmrib.ox.ac.uk/fsl/).
164-1	29801-29802	A	_
164-2	29803-29807	mask	_
164-3	29808-29810	of	_
164-4	29811-29814	the	_
164-5	29815-29821	corpus	_
164-6	29822-29830	callosum	_
164-7	29831-29835	will	_
164-8	29836-29838	be	_
164-9	29839-29847	manually	_
164-10	29848-29853	drawn	_
164-11	29854-29856	on	_
164-12	29857-29858	a	_
164-13	29859-29870	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
164-14	29871-29874	MNI	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
164-15	29875-29883	template	_
164-16	29884-29889	using	_
164-17	29890-29893	the	_
164-18	29894-29904	Functional	_
164-19	29905-29913	Magnetic	_
164-20	29914-29923	Resonance	_
164-21	29924-29931	Imaging	_
164-22	29932-29934	of	_
164-23	29935-29938	the	_
164-24	29939-29944	Brain	_
164-25	29945-29946	(	_
164-26	29947-29952	FMRIB	_
164-27	29953-29954	)	_
164-28	29955-29963	Software	_
164-29	29964-29971	Library	_
164-30	29972-29973	(	_
164-31	29974-29977	FSL	_
164-32	29978-29983	5.0.9	_
164-33	29984-29985	,	_
164-34	29986-29990	http	_
164-35	29991-29992	:	_
164-36	29993-30018	//www.fmrib.ox.ac.uk/fsl/	_
164-37	30019-30020	)	_
164-38	30021-30022	.	_

Text=For tractography analyses, the same ROI will be de-normalized from the MNI space to the individual space using the inverse transformation obtained from the VBM8 toolbox.
165-1	30023-30026	For	_
165-2	30027-30039	tractography	_
165-3	30040-30048	analyses	_
165-4	30049-30050	,	_
165-5	30051-30054	the	_
165-6	30055-30059	same	_
165-7	30060-30063	ROI	_
165-8	30064-30068	will	_
165-9	30069-30071	be	_
165-10	30072-30085	de-normalized	_
165-11	30086-30090	from	_
165-12	30091-30094	the	_
165-13	30095-30098	MNI	_
165-14	30099-30104	space	_
165-15	30105-30107	to	_
165-16	30108-30111	the	_
165-17	30112-30122	individual	_
165-18	30123-30128	space	_
165-19	30129-30134	using	_
165-20	30135-30138	the	_
165-21	30139-30146	inverse	_
165-22	30147-30161	transformation	_
165-23	30162-30170	obtained	_
165-24	30171-30175	from	_
165-25	30176-30179	the	_
165-26	30180-30184	VBM8	_
165-27	30185-30192	toolbox	_
165-28	30193-30194	.	_

Text=Structural connectivity analysis Diffusion images will be preprocessed using FSL software and then processed for probabilistic diffusion tractography with MRtrix3 software (http: //www.mrtrix.org/).
166-1	30195-30205	Structural	_
166-2	30206-30218	connectivity	_
166-3	30219-30227	analysis	_
166-4	30228-30237	Diffusion	_
166-5	30238-30244	images	_
166-6	30245-30249	will	_
166-7	30250-30252	be	_
166-8	30253-30265	preprocessed	_
166-9	30266-30271	using	_
166-10	30272-30275	FSL	_
166-11	30276-30284	software	_
166-12	30285-30288	and	_
166-13	30289-30293	then	_
166-14	30294-30303	processed	_
166-15	30304-30307	for	_
166-16	30308-30321	probabilistic	_
166-17	30322-30331	diffusion	_
166-18	30332-30344	tractography	_
166-19	30345-30349	with	_
166-20	30350-30357	MRtrix3	_
166-21	30358-30366	software	_
166-22	30367-30368	(	_
166-23	30369-30373	http	_
166-24	30374-30375	:	_
166-25	30376-30393	//www.mrtrix.org/	_
166-26	30394-30395	)	_
166-27	30396-30397	.	_

Text=Diffusion volumes will be corrected for motion and geometric distortions induced by eddy currents.
167-1	30398-30407	Diffusion	_
167-2	30408-30415	volumes	_
167-3	30416-30420	will	_
167-4	30421-30423	be	_
167-5	30424-30433	corrected	_
167-6	30434-30437	for	_
167-7	30438-30444	motion	_
167-8	30445-30448	and	_
167-9	30449-30458	geometric	_
167-10	30459-30470	distortions	_
167-11	30471-30478	induced	_
167-12	30479-30481	by	_
167-13	30482-30486	eddy	_
167-14	30487-30495	currents	_
167-15	30496-30497	.	_

Text=The constrained spherical deconvolution method will be used to estimate the fiber orientation distribution function (ODF) in MRtrix3.
168-1	30498-30501	The	_
168-2	30502-30513	constrained	_
168-3	30514-30523	spherical	_
168-4	30524-30537	deconvolution	_
168-5	30538-30544	method	_
168-6	30545-30549	will	_
168-7	30550-30552	be	_
168-8	30553-30557	used	_
168-9	30558-30560	to	_
168-10	30561-30569	estimate	_
168-11	30570-30573	the	_
168-12	30574-30579	fiber	_
168-13	30580-30591	orientation	_
168-14	30592-30604	distribution	_
168-15	30605-30613	function	_
168-16	30614-30615	(	_
168-17	30616-30619	ODF	_
168-18	30620-30621	)	_
168-19	30622-30624	in	_
168-20	30625-30632	MRtrix3	_
168-21	30633-30634	.	_

Text=In the native space of each subject, a seed-to-target analysis will be performed to reconstruct the tracts of interest included in the DMN and the language network (arcuate fasciculus, corpus callosum).
169-1	30635-30637	In	_
169-2	30638-30641	the	_
169-3	30642-30648	native	_
169-4	30649-30654	space	_
169-5	30655-30657	of	_
169-6	30658-30662	each	_
169-7	30663-30670	subject	_
169-8	30671-30672	,	_
169-9	30673-30674	a	_
169-10	30675-30689	seed-to-target	_
169-11	30690-30698	analysis	_
169-12	30699-30703	will	_
169-13	30704-30706	be	_
169-14	30707-30716	performed	_
169-15	30717-30719	to	_
169-16	30720-30731	reconstruct	_
169-17	30732-30735	the	_
169-18	30736-30742	tracts	_
169-19	30743-30745	of	_
169-20	30746-30754	interest	_
169-21	30755-30763	included	_
169-22	30764-30766	in	_
169-23	30767-30770	the	_
169-24	30771-30774	DMN	_
169-25	30775-30778	and	_
169-26	30779-30782	the	_
169-27	30783-30791	language	_
169-28	30792-30799	network	_
169-29	30800-30801	(	_
169-30	30802-30809	arcuate	_
169-31	30810-30820	fasciculus	_
169-32	30821-30822	,	_
169-33	30823-30829	corpus	_
169-34	30830-30838	callosum	_
169-35	30839-30840	)	_
169-36	30841-30842	.	_

Text=Fiber-tracking maps will be created for each subject by using FSL software (data preprocessing) and MRtrix3 software (diffusion images).
170-1	30843-30857	Fiber-tracking	_
170-2	30858-30862	maps	_
170-3	30863-30867	will	_
170-4	30868-30870	be	_
170-5	30871-30878	created	_
170-6	30879-30882	for	_
170-7	30883-30887	each	_
170-8	30888-30895	subject	_
170-9	30896-30898	by	_
170-10	30899-30904	using	_
170-11	30905-30908	FSL	_
170-12	30909-30917	software	_
170-13	30918-30919	(	_
170-14	30920-30924	data	_
170-15	30925-30938	preprocessing	_
170-16	30939-30940	)	_
170-17	30941-30944	and	_
170-18	30945-30952	MRtrix3	_
170-19	30953-30961	software	_
170-20	30962-30963	(	_
170-21	30964-30973	diffusion	_
170-22	30974-30980	images	_
170-23	30981-30982	)	_
170-24	30983-30984	.	_

Text=Using a voxel-wise model of diffusion (the Q-ball model), the maximum-likelihood solution for fiber orientation within each voxel will be represented by an ODF on the location of the fiber trajectory.
171-1	30985-30990	Using	_
171-2	30991-30992	a	_
171-3	30993-31003	voxel-wise	_
171-4	31004-31009	model	_
171-5	31010-31012	of	_
171-6	31013-31022	diffusion	_
171-7	31023-31024	(	_
171-8	31025-31028	the	_
171-9	31029-31035	Q-ball	_
171-10	31036-31041	model	_
171-11	31042-31043	)	_
171-12	31044-31045	,	_
171-13	31046-31049	the	_
171-14	31050-31068	maximum-likelihood	_
171-15	31069-31077	solution	_
171-16	31078-31081	for	_
171-17	31082-31087	fiber	_
171-18	31088-31099	orientation	_
171-19	31100-31106	within	_
171-20	31107-31111	each	_
171-21	31112-31117	voxel	_
171-22	31118-31122	will	_
171-23	31123-31125	be	_
171-24	31126-31137	represented	_
171-25	31138-31140	by	_
171-26	31141-31143	an	_
171-27	31144-31147	ODF	_
171-28	31148-31150	on	_
171-29	31151-31154	the	_
171-30	31155-31163	location	_
171-31	31164-31166	of	_
171-32	31167-31170	the	_
171-33	31171-31176	fiber	_
171-34	31177-31187	trajectory	_
171-35	31188-31189	.	_

Text=The ODF characterizes the orientation dependency of the diffusion probability density function of water molecules in several possible directions for each voxel.
172-1	31190-31193	The	_
172-2	31194-31197	ODF	_
172-3	31198-31211	characterizes	_
172-4	31212-31215	the	_
172-5	31216-31227	orientation	_
172-6	31228-31238	dependency	_
172-7	31239-31241	of	_
172-8	31242-31245	the	_
172-9	31246-31255	diffusion	_
172-10	31256-31267	probability	_
172-11	31268-31275	density	_
172-12	31276-31284	function	_
172-13	31285-31287	of	_
172-14	31288-31293	water	_
172-15	31294-31303	molecules	_
172-16	31304-31306	in	_
172-17	31307-31314	several	_
172-18	31315-31323	possible	_
172-19	31324-31334	directions	_
172-20	31335-31338	for	_
172-21	31339-31343	each	_
172-22	31344-31349	voxel	_
172-23	31350-31351	.	_

Text=This model can be used to track complex fiber configurations.
173-1	31352-31356	This	_
173-2	31357-31362	model	_
173-3	31363-31366	can	_
173-4	31367-31369	be	_
173-5	31370-31374	used	_
173-6	31375-31377	to	_
173-7	31378-31383	track	_
173-8	31384-31391	complex	_
173-9	31392-31397	fiber	_
173-10	31398-31412	configurations	_
173-11	31413-31414	.	_

Text=The ODF information obtained from constrained spherical deconvolution will be used with a suitable fiber-tracking algorithm to infer connectivity of crossing fibers.
174-1	31415-31418	The	_
174-2	31419-31422	ODF	_
174-3	31423-31434	information	_
174-4	31435-31443	obtained	_
174-5	31444-31448	from	_
174-6	31449-31460	constrained	_
174-7	31461-31470	spherical	_
174-8	31471-31484	deconvolution	_
174-9	31485-31489	will	_
174-10	31490-31492	be	_
174-11	31493-31497	used	_
174-12	31498-31502	with	_
174-13	31503-31504	a	_
174-14	31505-31513	suitable	_
174-15	31514-31528	fiber-tracking	_
174-16	31529-31538	algorithm	_
174-17	31539-31541	to	_
174-18	31542-31547	infer	_
174-19	31548-31560	connectivity	_
174-20	31561-31563	of	_
174-21	31564-31572	crossing	_
174-22	31573-31579	fibers	_
174-23	31580-31581	.	_

Text=We will use a probabilistic streamline algorithm with the entire ODF as a probability density function (ODF threshold = 0.1; step size = 0.5 mm x voxelsize; radius of curvature = 1 mm; up-sampling of DWIs, data to 1 mm).
175-1	31582-31584	We	_
175-2	31585-31589	will	_
175-3	31590-31593	use	_
175-4	31594-31595	a	_
175-5	31596-31609	probabilistic	_
175-6	31610-31620	streamline	_
175-7	31621-31630	algorithm	_
175-8	31631-31635	with	_
175-9	31636-31639	the	_
175-10	31640-31646	entire	_
175-11	31647-31650	ODF	_
175-12	31651-31653	as	_
175-13	31654-31655	a	_
175-14	31656-31667	probability	_
175-15	31668-31675	density	_
175-16	31676-31684	function	_
175-17	31685-31686	(	_
175-18	31687-31690	ODF	_
175-19	31691-31700	threshold	_
175-20	31701-31702	=	_
175-21	31703-31706	0.1	_
175-22	31707-31708	;	_
175-23	31709-31713	step	_
175-24	31714-31718	size	_
175-25	31719-31720	=	_
175-26	31721-31724	0.5	_
175-27	31725-31727	mm	_
175-28	31728-31729	x	_
175-29	31730-31739	voxelsize	_
175-30	31740-31741	;	_
175-31	31742-31748	radius	_
175-32	31749-31751	of	_
175-33	31752-31761	curvature	_
175-34	31762-31763	=	_
175-35	31764-31765	1	_
175-36	31766-31768	mm	_
175-37	31769-31770	;	_
175-38	31771-31782	up-sampling	_
175-39	31783-31785	of	_
175-40	31786-31790	DWIs	_
175-41	31791-31792	,	_
175-42	31793-31797	data	_
175-43	31798-31800	to	_
175-44	31801-31802	1	_
175-45	31803-31805	mm	_
175-46	31806-31807	)	_
175-47	31808-31809	.	_

Text=In the native individual space, we will perform a seed-to-target analysis from ROIs of the networks of interest (see Region of interest section).
176-1	31810-31812	In	_
176-2	31813-31816	the	_
176-3	31817-31823	native	_
176-4	31824-31834	individual	_
176-5	31835-31840	space	_
176-6	31841-31842	,	_
176-7	31843-31845	we	_
176-8	31846-31850	will	_
176-9	31851-31858	perform	_
176-10	31859-31860	a	_
176-11	31861-31875	seed-to-target	_
176-12	31876-31884	analysis	_
176-13	31885-31889	from	_
176-14	31890-31894	ROIs	_
176-15	31895-31897	of	_
176-16	31898-31901	the	_
176-17	31902-31910	networks	_
176-18	31911-31913	of	_
176-19	31914-31922	interest	_
176-20	31923-31924	(	_
176-21	31925-31928	see	_
176-22	31929-31935	Region	_
176-23	31936-31938	of	_
176-24	31939-31947	interest	_
176-25	31948-31955	section	_
176-26	31956-31957	)	_
176-27	31958-31959	.	_

Text=These regions will include the bilateral TPJ, the inferior frontal gyri and the corpus callosum.
177-1	31960-31965	These	_
177-2	31966-31973	regions	_
177-3	31974-31978	will	_
177-4	31979-31986	include	_
177-5	31987-31990	the	_
177-6	31991-32000	bilateral	_
177-7	32001-32004	TPJ	_
177-8	32005-32006	,	_
177-9	32007-32010	the	_
177-10	32011-32019	inferior	_
177-11	32020-32027	frontal	_
177-12	32028-32032	gyri	_
177-13	32033-32036	and	_
177-14	32037-32040	the	_
177-15	32041-32047	corpus	_
177-16	32048-32056	callosum	_
177-17	32057-32058	.	_

Text=We will use the following probabilistic tractography algorithm: the number of fibers (streamlines) connecting a seed voxel to a target voxel will be calculated by sampling 1 million draws for each fiber connecting the seed to the target.
178-1	32059-32061	We	_
178-2	32062-32066	will	_
178-3	32067-32070	use	_
178-4	32071-32074	the	_
178-5	32075-32084	following	_
178-6	32085-32098	probabilistic	_
178-7	32099-32111	tractography	_
178-8	32112-32121	algorithm	_
178-9	32122-32123	:	_
178-10	32124-32127	the	_
178-11	32128-32134	number	_
178-12	32135-32137	of	_
178-13	32138-32144	fibers	_
178-14	32145-32146	(	_
178-15	32147-32158	streamlines	_
178-16	32159-32160	)	_
178-17	32161-32171	connecting	_
178-18	32172-32173	a	_
178-19	32174-32178	seed	_
178-20	32179-32184	voxel	_
178-21	32185-32187	to	_
178-22	32188-32189	a	_
178-23	32190-32196	target	_
178-24	32197-32202	voxel	_
178-25	32203-32207	will	_
178-26	32208-32210	be	_
178-27	32211-32221	calculated	_
178-28	32222-32224	by	_
178-29	32225-32233	sampling	_
178-30	32234-32235	1	_
178-31	32236-32243	million	_
178-32	32244-32249	draws	_
178-33	32250-32253	for	_
178-34	32254-32258	each	_
178-35	32259-32264	fiber	_
178-36	32265-32275	connecting	_
178-37	32276-32279	the	_
178-38	32280-32284	seed	_
178-39	32285-32287	to	_
178-40	32288-32291	the	_
178-41	32292-32298	target	_
178-42	32299-32300	.	_

Text=The pair-wise connections of the DMN and the language networks will be reconstructed for each subject.
179-1	32301-32304	The	_
179-2	32305-32314	pair-wise	_
179-3	32315-32326	connections	_
179-4	32327-32329	of	_
179-5	32330-32333	the	_
179-6	32334-32337	DMN	_
179-7	32338-32341	and	_
179-8	32342-32345	the	_
179-9	32346-32354	language	_
179-10	32355-32363	networks	_
179-11	32364-32368	will	_
179-12	32369-32371	be	_
179-13	32372-32385	reconstructed	_
179-14	32386-32389	for	_
179-15	32390-32394	each	_
179-16	32395-32402	subject	_
179-17	32403-32404	.	_

Text=Once tracts are reconstructed, one complementary measure will be considered.
180-1	32405-32409	Once	_
180-2	32410-32416	tracts	_
180-3	32417-32420	are	_
180-4	32421-32434	reconstructed	_
180-5	32435-32436	,	_
180-6	32437-32440	one	_
180-7	32441-32454	complementary	_
180-8	32455-32462	measure	_
180-9	32463-32467	will	_
180-10	32468-32470	be	_
180-11	32471-32481	considered	_
180-12	32482-32483	.	_

Text=FA values will be measured along the tracts of interest.
181-1	32484-32486	FA	_
181-2	32487-32493	values	_
181-3	32494-32498	will	_
181-4	32499-32501	be	_
181-5	32502-32510	measured	_
181-6	32511-32516	along	_
181-7	32517-32520	the	_
181-8	32521-32527	tracts	_
181-9	32528-32530	of	_
181-10	32531-32539	interest	_
181-11	32540-32541	.	_

Text=Along-tract measures of FA will be obtained on the basis of B-spline resampling of the fibers and averaging the FA values for each individual fiber on a given location (elastic model with 30 points in space at analogous anatomical locations in each individual).
182-1	32542-32553	Along-tract	_
182-2	32554-32562	measures	_
182-3	32563-32565	of	_
182-4	32566-32568	FA	_
182-5	32569-32573	will	_
182-6	32574-32576	be	_
182-7	32577-32585	obtained	_
182-8	32586-32588	on	_
182-9	32589-32592	the	_
182-10	32593-32598	basis	_
182-11	32599-32601	of	_
182-12	32602-32610	B-spline	_
182-13	32611-32621	resampling	_
182-14	32622-32624	of	_
182-15	32625-32628	the	_
182-16	32629-32635	fibers	_
182-17	32636-32639	and	_
182-18	32640-32649	averaging	_
182-19	32650-32653	the	_
182-20	32654-32656	FA	_
182-21	32657-32663	values	_
182-22	32664-32667	for	_
182-23	32668-32672	each	_
182-24	32673-32683	individual	_
182-25	32684-32689	fiber	_
182-26	32690-32692	on	_
182-27	32693-32694	a	_
182-28	32695-32700	given	_
182-29	32701-32709	location	_
182-30	32710-32711	(	_
182-31	32712-32719	elastic	_
182-32	32720-32725	model	_
182-33	32726-32730	with	_
182-34	32731-32733	30	_
182-35	32734-32740	points	_
182-36	32741-32743	in	_
182-37	32744-32749	space	_
182-38	32750-32752	at	_
182-39	32753-32762	analogous	_
182-40	32763-32773	anatomical	_
182-41	32774-32783	locations	_
182-42	32784-32786	in	_
182-43	32787-32791	each	_
182-44	32792-32802	individual	_
182-45	32803-32804	)	_
182-46	32805-32806	.	_

Text=For instance, for the language network, the posterior location will be defined on the ROI of the TPJ, whereas the anterior location will be defined as the level of the ROI of the Broca areas.
183-1	32807-32810	For	_
183-2	32811-32819	instance	_
183-3	32820-32821	,	_
183-4	32822-32825	for	_
183-5	32826-32829	the	_
183-6	32830-32838	language	_
183-7	32839-32846	network	_
183-8	32847-32848	,	_
183-9	32849-32852	the	_
183-10	32853-32862	posterior	_
183-11	32863-32871	location	_
183-12	32872-32876	will	_
183-13	32877-32879	be	_
183-14	32880-32887	defined	_
183-15	32888-32890	on	_
183-16	32891-32894	the	_
183-17	32895-32898	ROI	_
183-18	32899-32901	of	_
183-19	32902-32905	the	_
183-20	32906-32909	TPJ	_
183-21	32910-32911	,	_
183-22	32912-32919	whereas	_
183-23	32920-32923	the	_
183-24	32924-32932	anterior	_
183-25	32933-32941	location	_
183-26	32942-32946	will	_
183-27	32947-32949	be	_
183-28	32950-32957	defined	_
183-29	32958-32960	as	_
183-30	32961-32964	the	_
183-31	32965-32970	level	_
183-32	32971-32973	of	_
183-33	32974-32977	the	_
183-34	32978-32981	ROI	_
183-35	32982-32984	of	_
183-36	32985-32988	the	_
183-37	32989-32994	Broca	_
183-38	32995-33000	areas	_
183-39	33001-33002	.	_

Text=Mean FA values will be calculated at each point of the mean fiber along the y axis to check for local differences at specific points of the tract.
184-1	33003-33007	Mean	_
184-2	33008-33010	FA	_
184-3	33011-33017	values	_
184-4	33018-33022	will	_
184-5	33023-33025	be	_
184-6	33026-33036	calculated	_
184-7	33037-33039	at	_
184-8	33040-33044	each	_
184-9	33045-33050	point	_
184-10	33051-33053	of	_
184-11	33054-33057	the	_
184-12	33058-33062	mean	_
184-13	33063-33068	fiber	_
184-14	33069-33074	along	_
184-15	33075-33078	the	_
184-16	33079-33080	y	_
184-17	33081-33085	axis	_
184-18	33086-33088	to	_
184-19	33089-33094	check	_
184-20	33095-33098	for	_
184-21	33099-33104	local	_
184-22	33105-33116	differences	_
184-23	33117-33119	at	_
184-24	33120-33128	specific	_
184-25	33129-33135	points	_
184-26	33136-33138	of	_
184-27	33139-33142	the	_
184-28	33143-33148	tract	_
184-29	33149-33150	.	_

Text=A linear mixed-effects model will be applied serially for each tract and permutation methods will be performed to adjust the p values and control the Type 1 error.
185-1	33151-33152	A	_
185-2	33153-33159	linear	_
185-3	33160-33173	mixed-effects	_
185-4	33174-33179	model	_
185-5	33180-33184	will	_
185-6	33185-33187	be	_
185-7	33188-33195	applied	_
185-8	33196-33204	serially	_
185-9	33205-33208	for	_
185-10	33209-33213	each	_
185-11	33214-33219	tract	_
185-12	33220-33223	and	_
185-13	33224-33235	permutation	_
185-14	33236-33243	methods	_
185-15	33244-33248	will	_
185-16	33249-33251	be	_
185-17	33252-33261	performed	_
185-18	33262-33264	to	_
185-19	33265-33271	adjust	_
185-20	33272-33275	the	_
185-21	33276-33277	p	_
185-22	33278-33284	values	_
185-23	33285-33288	and	_
185-24	33289-33296	control	_
185-25	33297-33300	the	_
185-26	33301-33305	Type	_
185-27	33306-33307	1	_
185-28	33308-33313	error	_
185-29	33314-33315	.	_

Text=Resting-state functional connectivity analysis Statistical parametric mapping software (SPM8, Wellcome Department of Cognitive Neurology, London, UK) will be used for image processing (http: //www.fil.ion.ucl.ac.uk/spm/).
186-1	33316-33329	Resting-state	_
186-2	33330-33340	functional	_
186-3	33341-33353	connectivity	_
186-4	33354-33362	analysis	_
186-5	33363-33374	Statistical	_
186-6	33375-33385	parametric	_
186-7	33386-33393	mapping	_
186-8	33394-33402	software	_
186-9	33403-33404	(	_
186-10	33405-33409	SPM8	_
186-11	33410-33411	,	_
186-12	33412-33420	Wellcome	_
186-13	33421-33431	Department	_
186-14	33432-33434	of	_
186-15	33435-33444	Cognitive	_
186-16	33445-33454	Neurology	_
186-17	33455-33456	,	_
186-18	33457-33463	London	_
186-19	33464-33465	,	_
186-20	33466-33468	UK	_
186-21	33469-33470	)	_
186-22	33471-33475	will	_
186-23	33476-33478	be	_
186-24	33479-33483	used	_
186-25	33484-33487	for	_
186-26	33488-33493	image	_
186-27	33494-33504	processing	_
186-28	33505-33506	(	_
186-29	33507-33511	http	_
186-30	33512-33513	:	_
186-31	33514-33542	//www.fil.ion.ucl.ac.uk/spm/	_
186-32	33543-33544	)	_
186-33	33545-33546	.	_

Text=The functional images will be interpolated in time to correct for phase advance during volume acquisition, and will be realigned with the first image of each session.
187-1	33547-33550	The	_
187-2	33551-33561	functional	_
187-3	33562-33568	images	_
187-4	33569-33573	will	_
187-5	33574-33576	be	_
187-6	33577-33589	interpolated	_
187-7	33590-33592	in	_
187-8	33593-33597	time	_
187-9	33598-33600	to	_
187-10	33601-33608	correct	_
187-11	33609-33612	for	_
187-12	33613-33618	phase	_
187-13	33619-33626	advance	_
187-14	33627-33633	during	_
187-15	33634-33640	volume	_
187-16	33641-33652	acquisition	_
187-17	33653-33654	,	_
187-18	33655-33658	and	_
187-19	33659-33663	will	_
187-20	33664-33666	be	_
187-21	33667-33676	realigned	_
187-22	33677-33681	with	_
187-23	33682-33685	the	_
187-24	33686-33691	first	_
187-25	33692-33697	image	_
187-26	33698-33700	of	_
187-27	33701-33705	each	_
187-28	33706-33713	session	_
187-29	33714-33715	.	_

Text=The anatomical image and the realigned functional images of each subject will then be normalized to a common standard space by using the MNI template (DARTEL).
188-1	33716-33719	The	_
188-2	33720-33730	anatomical	_
188-3	33731-33736	image	_
188-4	33737-33740	and	_
188-5	33741-33744	the	_
188-6	33745-33754	realigned	_
188-7	33755-33765	functional	_
188-8	33766-33772	images	_
188-9	33773-33775	of	_
188-10	33776-33780	each	_
188-11	33781-33788	subject	_
188-12	33789-33793	will	_
188-13	33794-33798	then	_
188-14	33799-33801	be	_
188-15	33802-33812	normalized	_
188-16	33813-33815	to	_
188-17	33816-33817	a	_
188-18	33818-33824	common	_
188-19	33825-33833	standard	_
188-20	33834-33839	space	_
188-21	33840-33842	by	_
188-22	33843-33848	using	_
188-23	33849-33852	the	_
188-24	33853-33856	MNI	_
188-25	33857-33865	template	_
188-26	33866-33867	(	_
188-27	33868-33874	DARTEL	_
188-28	33875-33876	)	_
188-29	33877-33878	.	_

Text=The functional data will be spatially smoothed with a 4-mm full-width at half-maximum Gaussian filter and temporally filtered (0.01–0.08 Hz) with a 128-s period high-pass filter.
189-1	33879-33882	The	_
189-2	33883-33893	functional	_
189-3	33894-33898	data	_
189-4	33899-33903	will	_
189-5	33904-33906	be	_
189-6	33907-33916	spatially	_
189-7	33917-33925	smoothed	_
189-8	33926-33930	with	_
189-9	33931-33932	a	_
189-10	33933-33937	4-mm	_
189-11	33938-33948	full-width	_
189-12	33949-33951	at	_
189-13	33952-33964	half-maximum	_
189-14	33965-33973	Gaussian	_
189-15	33974-33980	filter	_
189-16	33981-33984	and	_
189-17	33985-33995	temporally	_
189-18	33996-34004	filtered	_
189-19	34005-34006	(	_
189-20	34007-34016	0.01–0.08	_
189-21	34017-34019	Hz	_
189-22	34020-34021	)	_
189-23	34022-34026	with	_
189-24	34027-34028	a	_
189-25	34029-34034	128-s	_
189-26	34035-34041	period	_
189-27	34042-34051	high-pass	_
189-28	34052-34058	filter	_
189-29	34059-34060	.	_

Text=Functional connectivity analysis will be performed.
190-1	34061-34071	Functional	_
190-2	34072-34084	connectivity	_
190-3	34085-34093	analysis	_
190-4	34094-34098	will	_
190-5	34099-34101	be	_
190-6	34102-34111	performed	_
190-7	34112-34113	.	_

Text=The correlations in spontaneous BOLD fluctuations reflect the inter-regional correlations in neuronal variability.
191-1	34114-34117	The	_
191-2	34118-34130	correlations	_
191-3	34131-34133	in	_
191-4	34134-34145	spontaneous	_
191-5	34146-34150	BOLD	_
191-6	34151-34163	fluctuations	_
191-7	34164-34171	reflect	_
191-8	34172-34175	the	_
191-9	34176-34190	inter-regional	_
191-10	34191-34203	correlations	_
191-11	34204-34206	in	_
191-12	34207-34215	neuronal	_
191-13	34216-34227	variability	_
191-14	34228-34229	.	_

Text=The averaged time course will be obtained from a previously defined ROI (posterior cingulate cortex for the DMN, TPJ for the language network).
192-1	34230-34233	The	_
192-2	34234-34242	averaged	_
192-3	34243-34247	time	_
192-4	34248-34254	course	_
192-5	34255-34259	will	_
192-6	34260-34262	be	_
192-7	34263-34271	obtained	_
192-8	34272-34276	from	_
192-9	34277-34278	a	_
192-10	34279-34289	previously	_
192-11	34290-34297	defined	_
192-12	34298-34301	ROI	_
192-13	34302-34303	(	_
192-14	34304-34313	posterior	_
192-15	34314-34323	cingulate	_
192-16	34324-34330	cortex	_
192-17	34331-34334	for	_
192-18	34335-34338	the	_
192-19	34339-34342	DMN	_
192-20	34343-34344	,	_
192-21	34345-34348	TPJ	_
192-22	34349-34352	for	_
192-23	34353-34356	the	_
192-24	34357-34365	language	_
192-25	34366-34373	network	_
192-26	34374-34375	)	_
192-27	34376-34377	.	_

Text=The correlation analysis will be performed in a voxel-wise way to generate the functional connectivity map.
193-1	34378-34381	The	_
193-2	34382-34393	correlation	_
193-3	34394-34402	analysis	_
193-4	34403-34407	will	_
193-5	34408-34410	be	_
193-6	34411-34420	performed	_
193-7	34421-34423	in	_
193-8	34424-34425	a	_
193-9	34426-34436	voxel-wise	_
193-10	34437-34440	way	_
193-11	34441-34443	to	_
193-12	34444-34452	generate	_
193-13	34453-34456	the	_
193-14	34457-34467	functional	_
193-15	34468-34480	connectivity	_
193-16	34481-34484	map	_
193-17	34485-34486	.	_

Text=The correlation coefficient map will be converted into a z map by Fisher ’ s r-to-z transform to improve the normality (Data Processing Assistant for Resting-State fMRI, http: //www.restfmri.net).
194-1	34487-34490	The	_
194-2	34491-34502	correlation	_
194-3	34503-34514	coefficient	_
194-4	34515-34518	map	_
194-5	34519-34523	will	_
194-6	34524-34526	be	_
194-7	34527-34536	converted	_
194-8	34537-34541	into	_
194-9	34542-34543	a	_
194-10	34544-34545	z	_
194-11	34546-34549	map	_
194-12	34550-34552	by	_
194-13	34553-34559	Fisher	_
194-14	34560-34561	’	_
194-15	34562-34563	s	_
194-16	34564-34570	r-to-z	_
194-17	34571-34580	transform	_
194-18	34581-34583	to	_
194-19	34584-34591	improve	_
194-20	34592-34595	the	_
194-21	34596-34605	normality	_
194-22	34606-34607	(	_
194-23	34608-34612	Data	_
194-24	34613-34623	Processing	_
194-25	34624-34633	Assistant	_
194-26	34634-34637	for	_
194-27	34638-34651	Resting-State	_
194-28	34652-34656	fMRI	_
194-29	34657-34658	,	_
194-30	34659-34663	http	_
194-31	34664-34665	:	_
194-32	34666-34684	//www.restfmri.net	_
194-33	34685-34686	)	_
194-34	34687-34688	.	_

Text=For each network of interest (DMN, language network), the second level analysis will be performed using a two-tailed, two-sample t test on the z-score maps to show group differences on connections of the DMN and language networks.
195-1	34689-34692	For	_
195-2	34693-34697	each	_
195-3	34698-34705	network	_
195-4	34706-34708	of	_
195-5	34709-34717	interest	_
195-6	34718-34719	(	_
195-7	34720-34723	DMN	_
195-8	34724-34725	,	_
195-9	34726-34734	language	_
195-10	34735-34742	network	_
195-11	34743-34744	)	_
195-12	34745-34746	,	_
195-13	34747-34750	the	_
195-14	34751-34757	second	_
195-15	34758-34763	level	_
195-16	34764-34772	analysis	_
195-17	34773-34777	will	_
195-18	34778-34780	be	_
195-19	34781-34790	performed	_
195-20	34791-34796	using	_
195-21	34797-34798	a	_
195-22	34799-34809	two-tailed	_
195-23	34810-34811	,	_
195-24	34812-34822	two-sample	_
195-25	34823-34824	t	_
195-26	34825-34829	test	_
195-27	34830-34832	on	_
195-28	34833-34836	the	_
195-29	34837-34844	z-score	_
195-30	34845-34849	maps	_
195-31	34850-34852	to	_
195-32	34853-34857	show	_
195-33	34858-34863	group	_
195-34	34864-34875	differences	_
195-35	34876-34878	on	_
195-36	34879-34890	connections	_
195-37	34891-34893	of	_
195-38	34894-34897	the	_
195-39	34898-34901	DMN	_
195-40	34902-34905	and	_
195-41	34906-34914	language	_
195-42	34915-34923	networks	_
195-43	34924-34925	.	_

Text=Effective connectivity analysis will be performed using DCM with the DCM10 routine implemented in Statistical Parametric Mapping software 12.
196-1	34926-34935	Effective	_
196-2	34936-34948	connectivity	_
196-3	34949-34957	analysis	_
196-4	34958-34962	will	_
196-5	34963-34965	be	_
196-6	34966-34975	performed	_
196-7	34976-34981	using	_
196-8	34982-34985	DCM	_
196-9	34986-34990	with	_
196-10	34991-34994	the	_
196-11	34995-35000	DCM10	_
196-12	35001-35008	routine	_
196-13	35009-35020	implemented	_
196-14	35021-35023	in	_
196-15	35024-35035	Statistical	_
196-16	35036-35046	Parametric	_
196-17	35047-35054	Mapping	_
196-18	35055-35063	software	_
196-19	35064-35066	12	_
196-20	35067-35068	.	_

Text=The first eigenvectors will be extracted from the ROIs representing the DMN and language networks (see ‘ Regions of interest ’ section).
197-1	35069-35072	The	_
197-2	35073-35078	first	_
197-3	35079-35091	eigenvectors	_
197-4	35092-35096	will	_
197-5	35097-35099	be	_
197-6	35100-35109	extracted	_
197-7	35110-35114	from	_
197-8	35115-35118	the	_
197-9	35119-35123	ROIs	_
197-10	35124-35136	representing	_
197-11	35137-35140	the	_
197-12	35141-35144	DMN	_
197-13	35145-35148	and	_
197-14	35149-35157	language	_
197-15	35158-35166	networks	_
197-16	35167-35168	(	_
197-17	35169-35172	see	_
197-18	35173-35174	‘	_
197-19	35175-35182	Regions	_
197-20	35183-35185	of	_
197-21	35186-35194	interest	_
197-22	35195-35196	’	_
197-23	35197-35204	section	_
197-24	35205-35206	)	_
197-25	35207-35208	.	_

Text=The a priori models will be based on anatomical connections, considering a fully connected model of the DMN and language network.
198-1	35209-35212	The	_
198-2	35213-35214	a	_
198-3	35215-35221	priori	_
198-4	35222-35228	models	_
198-5	35229-35233	will	_
198-6	35234-35236	be	_
198-7	35237-35242	based	_
198-8	35243-35245	on	_
198-9	35246-35256	anatomical	_
198-10	35257-35268	connections	_
198-11	35269-35270	,	_
198-12	35271-35282	considering	_
198-13	35283-35284	a	_
198-14	35285-35290	fully	_
198-15	35291-35300	connected	_
198-16	35301-35306	model	_
198-17	35307-35309	of	_
198-18	35310-35313	the	_
198-19	35314-35317	DMN	_
198-20	35318-35321	and	_
198-21	35322-35330	language	_
198-22	35331-35338	network	_
198-23	35339-35340	.	_

Text=Intrinsic connectivity will be defined as the endogenous connectivity parameter without driving input.
199-1	35341-35350	Intrinsic	_
199-2	35351-35363	connectivity	_
199-3	35364-35368	will	_
199-4	35369-35371	be	_
199-5	35372-35379	defined	_
199-6	35380-35382	as	_
199-7	35383-35386	the	_
199-8	35387-35397	endogenous	_
199-9	35398-35410	connectivity	_
199-10	35411-35420	parameter	_
199-11	35421-35428	without	_
199-12	35429-35436	driving	_
199-13	35437-35442	input	_
199-14	35443-35444	.	_

Text=The intrinsic connectivity values will be obtained for each subject in the best model of each network that will be considered for group analysis.
200-1	35445-35448	The	_
200-2	35449-35458	intrinsic	_
200-3	35459-35471	connectivity	_
200-4	35472-35478	values	_
200-5	35479-35483	will	_
200-6	35484-35486	be	_
200-7	35487-35495	obtained	_
200-8	35496-35499	for	_
200-9	35500-35504	each	_
200-10	35505-35512	subject	_
200-11	35513-35515	in	_
200-12	35516-35519	the	_
200-13	35520-35524	best	_
200-14	35525-35530	model	_
200-15	35531-35533	of	_
200-16	35534-35538	each	_
200-17	35539-35546	network	_
200-18	35547-35551	that	_
200-19	35552-35556	will	_
200-20	35557-35559	be	_
200-21	35560-35570	considered	_
200-22	35571-35574	for	_
200-23	35575-35580	group	_
200-24	35581-35589	analysis	_
200-25	35590-35591	.	_

Text=Bayesian model selection will be used to determine the best model between unilateral and bilateral connections.
201-1	35592-35600	Bayesian	_
201-2	35601-35606	model	_
201-3	35607-35616	selection	_
201-4	35617-35621	will	_
201-5	35622-35624	be	_
201-6	35625-35629	used	_
201-7	35630-35632	to	_
201-8	35633-35642	determine	_
201-9	35643-35646	the	_
201-10	35647-35651	best	_
201-11	35652-35657	model	_
201-12	35658-35665	between	_
201-13	35666-35676	unilateral	_
201-14	35677-35680	and	_
201-15	35681-35690	bilateral	_
201-16	35691-35702	connections	_
201-17	35703-35704	.	_

Text=Expected posterior model probabilities and exceedance probabilities will be computed.
202-1	35705-35713	Expected	_
202-2	35714-35723	posterior	_
202-3	35724-35729	model	_
202-4	35730-35743	probabilities	_
202-5	35744-35747	and	_
202-6	35748-35758	exceedance	_
202-7	35759-35772	probabilities	_
202-8	35773-35777	will	_
202-9	35778-35780	be	_
202-10	35781-35789	computed	_
202-11	35790-35791	.	_

Text=The group analysis on the DCM parameters will only include the model that will best fit the data.
203-1	35792-35795	The	_
203-2	35796-35801	group	_
203-3	35802-35810	analysis	_
203-4	35811-35813	on	_
203-5	35814-35817	the	_
203-6	35818-35821	DCM	_
203-7	35822-35832	parameters	_
203-8	35833-35837	will	_
203-9	35838-35842	only	_
203-10	35843-35850	include	_
203-11	35851-35854	the	_
203-12	35855-35860	model	_
203-13	35861-35865	that	_
203-14	35866-35870	will	_
203-15	35871-35875	best	_
203-16	35876-35879	fit	_
203-17	35880-35883	the	_
203-18	35884-35888	data	_
203-19	35889-35890	.	_

Text=Within each group, one sample t test will be conducted to examine whether the parameters of the model that best fits the data will have significant non-zero values.
204-1	35891-35897	Within	_
204-2	35898-35902	each	_
204-3	35903-35908	group	_
204-4	35909-35910	,	_
204-5	35911-35914	one	_
204-6	35915-35921	sample	_
204-7	35922-35923	t	_
204-8	35924-35928	test	_
204-9	35929-35933	will	_
204-10	35934-35936	be	_
204-11	35937-35946	conducted	_
204-12	35947-35949	to	_
204-13	35950-35957	examine	_
204-14	35958-35965	whether	_
204-15	35966-35969	the	_
204-16	35970-35980	parameters	_
204-17	35981-35983	of	_
204-18	35984-35987	the	_
204-19	35988-35993	model	_
204-20	35994-35998	that	_
204-21	35999-36003	best	_
204-22	36004-36008	fits	_
204-23	36009-36012	the	_
204-24	36013-36017	data	_
204-25	36018-36022	will	_
204-26	36023-36027	have	_
204-27	36028-36039	significant	_
204-28	36040-36048	non-zero	_
204-29	36049-36055	values	_
204-30	36056-36057	.	_

Text=Two-sample t tests will be used to identify group differences in intrinsic connectivity on each connection.
205-1	36058-36068	Two-sample	_
205-2	36069-36070	t	_
205-3	36071-36076	tests	_
205-4	36077-36081	will	_
205-5	36082-36084	be	_
205-6	36085-36089	used	_
205-7	36090-36092	to	_
205-8	36093-36101	identify	_
205-9	36102-36107	group	_
205-10	36108-36119	differences	_
205-11	36120-36122	in	_
205-12	36123-36132	intrinsic	_
205-13	36133-36145	connectivity	_
205-14	36146-36148	on	_
205-15	36149-36153	each	_
205-16	36154-36164	connection	_
205-17	36165-36166	.	_

Text=The same will be performed for the DMN to examine whether rTMS has a specific effect on the language network or a more global effect on attentional mechanisms.
206-1	36167-36170	The	_
206-2	36171-36175	same	_
206-3	36176-36180	will	_
206-4	36181-36183	be	_
206-5	36184-36193	performed	_
206-6	36194-36197	for	_
206-7	36198-36201	the	_
206-8	36202-36205	DMN	_
206-9	36206-36208	to	_
206-10	36209-36216	examine	_
206-11	36217-36224	whether	_
206-12	36225-36229	rTMS	_
206-13	36230-36233	has	_
206-14	36234-36235	a	_
206-15	36236-36244	specific	_
206-16	36245-36251	effect	_
206-17	36252-36254	on	_
206-18	36255-36258	the	_
206-19	36259-36267	language	_
206-20	36268-36275	network	_
206-21	36276-36278	or	_
206-22	36279-36280	a	_
206-23	36281-36285	more	_
206-24	36286-36292	global	_
206-25	36293-36299	effect	_
206-26	36300-36302	on	_
206-27	36303-36314	attentional	_
206-28	36315-36325	mechanisms	_
206-29	36326-36327	.	_

Text=Demographic, clinical, neurophysiological, neuropsychological and biological data analysis Socio-demographic data will be compared between the active rTMS and the sham rTMS groups, and also between the ‘ responder ’ and ‘ non-responder ’ groups, using a two-sample t test (Student ’ s t test) or a χ2 test.
207-1	36328-36339	Demographic	_
207-2	36340-36341	,	_
207-3	36342-36350	clinical	_
207-4	36351-36352	,	_
207-5	36353-36371	neurophysiological	_
207-6	36372-36373	,	_
207-7	36374-36392	neuropsychological	_
207-8	36393-36396	and	_
207-9	36397-36407	biological	_
207-10	36408-36412	data	_
207-11	36413-36421	analysis	_
207-12	36422-36439	Socio-demographic	_
207-13	36440-36444	data	_
207-14	36445-36449	will	_
207-15	36450-36452	be	_
207-16	36453-36461	compared	_
207-17	36462-36469	between	_
207-18	36470-36473	the	_
207-19	36474-36480	active	_
207-20	36481-36485	rTMS	_
207-21	36486-36489	and	_
207-22	36490-36493	the	_
207-23	36494-36498	sham	_
207-24	36499-36503	rTMS	_
207-25	36504-36510	groups	_
207-26	36511-36512	,	_
207-27	36513-36516	and	_
207-28	36517-36521	also	_
207-29	36522-36529	between	_
207-30	36530-36533	the	_
207-31	36534-36535	‘	_
207-32	36536-36545	responder	_
207-33	36546-36547	’	_
207-34	36548-36551	and	_
207-35	36552-36553	‘	_
207-36	36554-36567	non-responder	_
207-37	36568-36569	’	_
207-38	36570-36576	groups	_
207-39	36577-36578	,	_
207-40	36579-36584	using	_
207-41	36585-36586	a	_
207-42	36587-36597	two-sample	_
207-43	36598-36599	t	_
207-44	36600-36604	test	_
207-45	36605-36606	(	_
207-46	36607-36614	Student	_
207-47	36615-36616	’	_
207-48	36617-36618	s	_
207-49	36619-36620	t	_
207-50	36621-36625	test	_
207-51	36626-36627	)	_
207-52	36628-36630	or	_
207-53	36631-36632	a	_
207-54	36633-36635	χ2	_
207-55	36636-36640	test	_
207-56	36641-36642	.	_

Text=To control for the rTMS treatment efficacy, a repeated-measures analysis of variance (ANOVA) will be performed on AHRS with time (before/after rTMS) as the within-subject factor and group (active rTMS/sham rTMS) as the between-group factor (based on the per-protocol principles).
208-1	36643-36645	To	_
208-2	36646-36653	control	_
208-3	36654-36657	for	_
208-4	36658-36661	the	_
208-5	36662-36666	rTMS	_
208-6	36667-36676	treatment	_
208-7	36677-36685	efficacy	_
208-8	36686-36687	,	_
208-9	36688-36689	a	_
208-10	36690-36707	repeated-measures	_
208-11	36708-36716	analysis	_
208-12	36717-36719	of	_
208-13	36720-36728	variance	_
208-14	36729-36730	(	_
208-15	36731-36736	ANOVA	_
208-16	36737-36738	)	_
208-17	36739-36743	will	_
208-18	36744-36746	be	_
208-19	36747-36756	performed	_
208-20	36757-36759	on	_
208-21	36760-36764	AHRS	_
208-22	36765-36769	with	_
208-23	36770-36774	time	_
208-24	36775-36776	(	_
208-25	36777-36789	before/after	_
208-26	36790-36794	rTMS	_
208-27	36795-36796	)	_
208-28	36797-36799	as	_
208-29	36800-36803	the	_
208-30	36804-36818	within-subject	_
208-31	36819-36825	factor	_
208-32	36826-36829	and	_
208-33	36830-36835	group	_
208-34	36836-36837	(	_
208-35	36838-36844	active	_
208-36	36845-36854	rTMS/sham	_
208-37	36855-36859	rTMS	_
208-38	36860-36861	)	_
208-39	36862-36864	as	_
208-40	36865-36868	the	_
208-41	36869-36882	between-group	_
208-42	36883-36889	factor	_
208-43	36890-36891	(	_
208-44	36892-36897	based	_
208-45	36898-36900	on	_
208-46	36901-36904	the	_
208-47	36905-36917	per-protocol	_
208-48	36918-36928	principles	_
208-49	36929-36930	)	_
208-50	36931-36932	.	_

Text=The same strategy will be followed for clinical, neurophysiological, neuropsychological, and biological data.
209-1	36933-36936	The	_
209-2	36937-36941	same	_
209-3	36942-36950	strategy	_
209-4	36951-36955	will	_
209-5	36956-36958	be	_
209-6	36959-36967	followed	_
209-7	36968-36971	for	_
209-8	36972-36980	clinical	_
209-9	36981-36982	,	_
209-10	36983-37001	neurophysiological	_
209-11	37002-37003	,	_
209-12	37004-37022	neuropsychological	_
209-13	37023-37024	,	_
209-14	37025-37028	and	_
209-15	37029-37039	biological	_
209-16	37040-37044	data	_
209-17	37045-37046	.	_

Text=Post-hoc pair-wise comparisons will be performed using a two-sample t test (Student ’ s t test) or χ2 test.
210-1	37047-37055	Post-hoc	_
210-2	37056-37065	pair-wise	_
210-3	37066-37077	comparisons	_
210-4	37078-37082	will	_
210-5	37083-37085	be	_
210-6	37086-37095	performed	_
210-7	37096-37101	using	_
210-8	37102-37103	a	_
210-9	37104-37114	two-sample	_
210-10	37115-37116	t	_
210-11	37117-37121	test	_
210-12	37122-37123	(	_
210-13	37124-37131	Student	_
210-14	37132-37133	’	_
210-15	37134-37135	s	_
210-16	37136-37137	t	_
210-17	37138-37142	test	_
210-18	37143-37144	)	_
210-19	37145-37147	or	_
210-20	37148-37150	χ2	_
210-21	37151-37155	test	_
210-22	37156-37157	.	_

Text=Bonferroni correction will be applied as a multiple comparison adjustment to reduce the chances of a false positive result.
211-1	37158-37168	Bonferroni	_
211-2	37169-37179	correction	_
211-3	37180-37184	will	_
211-4	37185-37187	be	_
211-5	37188-37195	applied	_
211-6	37196-37198	as	_
211-7	37199-37200	a	_
211-8	37201-37209	multiple	_
211-9	37210-37220	comparison	_
211-10	37221-37231	adjustment	_
211-11	37232-37234	to	_
211-12	37235-37241	reduce	_
211-13	37242-37245	the	_
211-14	37246-37253	chances	_
211-15	37254-37256	of	_
211-16	37257-37258	a	_
211-17	37259-37264	false	_
211-18	37265-37273	positive	_
211-19	37274-37280	result	_
211-20	37281-37282	.	_

Text=Normality of data distribution (Shapiro–Wilk ’ s test) and equality of variances (Levene ’ s test) will be previously verified.
212-1	37283-37292	Normality	_
212-2	37293-37295	of	_
212-3	37296-37300	data	_
212-4	37301-37313	distribution	_
212-5	37314-37315	(	_
212-6	37316-37328	Shapiro–Wilk	_
212-7	37329-37330	’	_
212-8	37331-37332	s	_
212-9	37333-37337	test	_
212-10	37338-37339	)	_
212-11	37340-37343	and	_
212-12	37344-37352	equality	_
212-13	37353-37355	of	_
212-14	37356-37365	variances	_
212-15	37366-37367	(	_
212-16	37368-37374	Levene	_
212-17	37375-37376	’	_
212-18	37377-37378	s	_
212-19	37379-37383	test	_
212-20	37384-37385	)	_
212-21	37386-37390	will	_
212-22	37391-37393	be	_
212-23	37394-37404	previously	_
212-24	37405-37413	verified	_
212-25	37414-37415	.	_

Text=All data will be presented as mean ± standard deviation.
213-1	37416-37419	All	_
213-2	37420-37424	data	_
213-3	37425-37429	will	_
213-4	37430-37432	be	_
213-5	37433-37442	presented	_
213-6	37443-37445	as	_
213-7	37446-37450	mean	_
213-8	37451-37452	±	_
213-9	37453-37461	standard	_
213-10	37462-37471	deviation	_
213-11	37472-37473	.	_

Text=For all tests, statistical significance will be set as p ≤ 0.05.
214-1	37474-37477	For	_
214-2	37478-37481	all	_
214-3	37482-37487	tests	_
214-4	37488-37489	,	_
214-5	37490-37501	statistical	_
214-6	37502-37514	significance	_
214-7	37515-37519	will	_
214-8	37520-37522	be	_
214-9	37523-37526	set	_
214-10	37527-37529	as	_
214-11	37530-37531	p	_
214-12	37532-37533	≤	_
214-13	37534-37538	0.05	_
214-14	37539-37540	.	_

